0001425450-24-000033.txt : 20240507 0001425450-24-000033.hdr.sgml : 20240507 20240507171849 ACCESSION NUMBER: 0001425450-24-000033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORTHOPEDIATRICS CORP CENTRAL INDEX KEY: 0001425450 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 261761833 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38242 FILM NUMBER: 24923275 BUSINESS ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 BUSINESS PHONE: 574-268-6379 MAIL ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 10-Q 1 kids-20240331.htm 10-Q kids-20240331
2024Q1FALSE0001425450--12-31http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://www.orthopediatrics.com/20240331#AssetsNoncurrentExcludingPropertyPlantAndEquipmenthttp://www.orthopediatrics.com/20240331#AssetsNoncurrentExcludingPropertyPlantAndEquipmenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:shareskids:individualxbrli:purekids:tranchekids:segmentkids:supplier00014254502024-01-012024-03-3100014254502024-05-0300014254502024-03-3100014254502023-12-310001425450us-gaap:NonrelatedPartyMember2024-03-310001425450us-gaap:NonrelatedPartyMember2023-12-310001425450us-gaap:RelatedPartyMember2024-03-310001425450us-gaap:RelatedPartyMember2023-12-3100014254502023-01-012023-03-310001425450us-gaap:CommonStockMember2023-12-310001425450us-gaap:AdditionalPaidInCapitalMember2023-12-310001425450us-gaap:RetainedEarningsMember2023-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001425450us-gaap:RetainedEarningsMember2024-01-012024-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001425450us-gaap:CommonStockMember2024-01-012024-03-310001425450us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001425450us-gaap:CommonStockMember2024-03-310001425450us-gaap:AdditionalPaidInCapitalMember2024-03-310001425450us-gaap:RetainedEarningsMember2024-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001425450us-gaap:CommonStockMember2022-12-310001425450us-gaap:AdditionalPaidInCapitalMember2022-12-310001425450us-gaap:RetainedEarningsMember2022-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100014254502022-12-310001425450us-gaap:RetainedEarningsMember2023-01-012023-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001425450us-gaap:CommonStockMember2023-01-012023-03-310001425450us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001425450us-gaap:CommonStockMember2023-03-310001425450us-gaap:AdditionalPaidInCapitalMember2023-03-310001425450us-gaap:RetainedEarningsMember2023-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100014254502023-03-310001425450srt:ScenarioPreviouslyReportedMember2023-01-012023-03-310001425450srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2023-01-012023-03-310001425450kids:BostonBraceInternationalInc.Member2024-01-052024-01-050001425450us-gaap:RestrictedStockMemberkids:BostonBraceInternationalInc.Member2024-01-052024-01-050001425450kids:BostonBraceInternationalInc.Member2024-01-050001425450us-gaap:RestrictedStockMemberkids:BostonBraceInternationalInc.Member2024-01-050001425450us-gaap:TrademarksAndTradeNamesMemberkids:BostonBraceInternationalInc.Member2024-01-050001425450us-gaap:CustomerRelationshipsMemberkids:BostonBraceInternationalInc.Member2024-01-050001425450us-gaap:CustomerRelationshipsMemberkids:BostonBraceInternationalInc.Member2024-01-052024-01-050001425450kids:RhinoPediatricOrthopedicDesignsIncMember2023-07-012023-07-010001425450kids:RhinoPediatricOrthopedicDesignsIncMemberus-gaap:CommonStockMember2023-07-012023-07-010001425450kids:RhinoPediatricOrthopedicDesignsIncMemberus-gaap:CommonStockMember2023-07-010001425450kids:MedtechConceptsLLCMember2023-05-012023-05-010001425450us-gaap:CommonStockMemberkids:MedtechConceptsLLCMember2023-05-012023-05-010001425450us-gaap:CommonStockMemberkids:MedtechConceptsLLCMember2023-05-010001425450kids:MedtechConceptsLLCMember2023-05-010001425450us-gaap:CarryingReportedAmountFairValueDisclosureMemberkids:MedtechConceptsLLCMember2023-05-012023-05-010001425450us-gaap:TrademarksMemberkids:MedtechConceptsLLCMember2023-05-012023-05-010001425450kids:MedtechConceptsLLCMemberus-gaap:IntellectualPropertyMember2023-05-012023-05-010001425450kids:MedtechConceptsLLCMemberus-gaap:IntellectualPropertyMember2023-05-010001425450us-gaap:PatentsMember2024-03-310001425450kids:IntellectualPropertyAndCapitalizedSoftwareMember2024-03-310001425450us-gaap:CustomerRelationshipsMember2024-03-310001425450us-gaap:LicensingAgreementsMember2024-03-310001425450us-gaap:PatentsMember2023-12-310001425450kids:IntellectualPropertyAndCapitalizedSoftwareMember2023-12-310001425450us-gaap:CustomerRelationshipsMember2023-12-310001425450us-gaap:LicensingAgreementsMember2023-12-310001425450us-gaap:TrademarksMember2024-03-310001425450us-gaap:TrademarksMember2023-12-310001425450us-gaap:TrademarksMemberkids:ApiFixLtdMember2023-01-012023-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-03-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2024-03-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2024-03-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-03-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001425450us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2023-12-310001425450us-gaap:RevolvingCreditFacilityMemberkids:TermLoanMember2024-03-310001425450us-gaap:RevolvingCreditFacilityMemberkids:TermLoanMember2023-12-310001425450us-gaap:MortgagesMember2024-03-310001425450us-gaap:MortgagesMember2023-12-310001425450kids:AcquisitionNotesMemberus-gaap:NotesPayableOtherPayablesMember2024-03-310001425450kids:AcquisitionNotesMemberus-gaap:NotesPayableOtherPayablesMember2023-12-310001425450us-gaap:RevolvingCreditFacilityMemberkids:SecurityAndGuarantyAgreementMember2023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:SecurityAndGuarantyAgreementMember2023-12-292023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:TermLoanMember2023-12-292023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMember2023-12-292023-12-290001425450us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMemberkids:OptionOneMember2023-12-292023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMemberkids:OptionOneMember2023-12-290001425450kids:OptionTwoMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMember2023-12-292023-12-290001425450kids:OptionTwoMemberus-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMember2023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMemberkids:OptionThreeMember2023-12-292023-12-290001425450kids:OptionFourMemberus-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMember2023-12-292023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:RevolvingLoanMemberkids:OptionFiveMember2023-12-292023-12-290001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2024-03-310001425450us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-132022-06-130001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-130001425450kids:ThreeMonthLIBORMemberus-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-132022-06-130001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-132022-06-130001425450us-gaap:MortgagesMember2024-01-012024-03-310001425450us-gaap:RestrictedStockMember2023-12-310001425450us-gaap:RestrictedStockMember2023-01-012023-12-310001425450us-gaap:RestrictedStockUnitsRSUMember2023-12-310001425450us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001425450us-gaap:RestrictedStockMember2024-01-012024-03-310001425450us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001425450us-gaap:RestrictedStockMember2024-03-310001425450us-gaap:RestrictedStockUnitsRSUMember2024-03-310001425450us-gaap:RestrictedStockMember2023-01-012023-03-310001425450country:US2024-01-012024-03-310001425450country:US2023-01-012023-03-310001425450us-gaap:NonUsMember2024-01-012024-03-310001425450us-gaap:NonUsMember2023-01-012023-03-310001425450kids:TraumaAndDeformityMember2024-01-012024-03-310001425450kids:TraumaAndDeformityMember2023-01-012023-03-310001425450kids:SpineMember2024-01-012024-03-310001425450kids:SpineMember2023-01-012023-03-310001425450kids:SportsMedicineAndOtherMember2024-01-012024-03-310001425450kids:SportsMedicineAndOtherMember2023-01-012023-03-310001425450srt:AffiliatedEntityMember2024-01-012024-03-310001425450kids:SupplierMemberkids:StructureMedicalLLCMember2024-01-012024-03-310001425450kids:SupplierMemberkids:StructureMedicalLLCMember2023-01-012023-03-310001425450kids:MDOrthopaedicsMember2024-01-012024-03-310001425450kids:BostonOPMember2024-03-310001425450kids:VilexAndOrthexMember2019-06-012019-06-300001425450srt:AffiliatedEntityMemberkids:TeamNoteBMemberkids:SquadronCapitalLLCMember2019-12-312019-12-310001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2021-07-202021-07-200001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2024-01-012024-03-310001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2023-01-012023-03-310001425450srt:MinimumMember2024-01-012024-03-310001425450srt:MaximumMember2024-01-012024-03-310001425450us-gaap:SubsequentEventMemberkids:ApiFixLtdMember2024-04-012024-04-010001425450us-gaap:SubsequentEventMemberkids:ApiFixLtdMember2024-04-010001425450us-gaap:SubsequentEventMemberkids:MedtechMember2024-04-012024-04-010001425450us-gaap:SubsequentEventMemberkids:MedtechMember2024-04-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-38242
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
Delaware
26-1761833
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
2850 Frontier Drive
Warsaw, IN 46582
(574) 268-6379
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market
________________________________________________________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ¨
Indicate by check mark whether t he registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☒
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐    No ☒

As of May 3, 2024, the registrant had 23,828,882 outstanding shares of common stock, $0.00025 par value per share.




OrthoPediatrics Corp.
Form 10-Q
For the Quarterly Period Ended March 31, 2024

TABLE OF CONTENTS
Page No.
PART I. FINANCIAL INFORMATION
Item 1
Item 2
Item 3
Item 4
PART II. OTHER INFORMATION
Item 1
Item 1A
Item 2
Item 3
Item 4
Item 5
Item 6







NOTE REGARDING FORWARD-LOOKING STATEMENTS

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will" or "would," or the negative of these terms or other terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to:

•our ability to achieve or sustain profitability in the future;

•our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations;

•our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively;

•our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability;

•our ability to comply with extensive government regulation and oversight both in the United States and abroad;

•our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and

•our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others.

We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 8, 2024 and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.
3

PART I. FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS
ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In Thousands, Except Share Data)
March 31, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$21,602 $31,055 
Restricted cash1,962 1,972 
Short-term investments26,141 49,251 
Accounts receivable - trade, net of allowances of $1,195 and $1,373, respectively
36,275 34,617 
Inventories, net112,689 105,851 
Prepaid expenses and other current assets5,056 3,750 
Total current assets203,725 226,496 
Property and equipment, net48,721 41,048 
Other assets:
Amortizable intangible assets, net70,382 69,275 
Goodwill91,481 83,699 
Other intangible assets18,792 15,287 
Other non-current assets4,084 2,940 
Total other assets184,739 171,201 
Total assets$437,185 $438,745 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade$19,736 $12,649 
Accrued compensation and benefits9,772 11,325 
Current portion of long-term debt with affiliate154 152 
Current portion of acquisition installment payable10,368 10,149 
Other current liabilities5,790 7,391 
Total current liabilities45,820 41,666 
Long-term liabilities:
Long-term debt, net of current portion9,579 9,297 
Long-term debt with affiliate, net of current portion572 611 
Acquisition installment payable, net of current portion3,613 3,551 
Deferred income taxes5,202 5,483 
Other long-term liabilities1,815 1,112 
Total long-term liabilities20,781 20,054 
Total liabilities66,601 61,720 
Stockholders' equity:
Common stock, $0.00025 par value; 50,000,000 shares authorized; 23,540,411 shares and 23,378,408 shares issued as of March 31, 2024 and December 31, 2023, respectively
6 6 
Additional paid-in capital583,086 580,287 
Accumulated deficit(205,547)(197,742)
Accumulated other comprehensive loss(6,961)(5,526)
Total stockholders' equity370,584 377,025 
Total liabilities and stockholders' equity$437,185 $438,745 

See notes to condensed consolidated financial statements.
4

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)
Three Months Ended March 31,
20242023
Net revenue$44,685 $31,588 
Cost of revenue12,511 8,027 
Gross profit32,174 23,561 
Operating expenses:
Sales and marketing14,169 12,549 
General and administrative24,730 17,157 
Research and development2,998 2,446 
Total operating expenses41,897 32,152 
Operating loss(9,723)(8,591)
Other expense (income):
Interest expense (income), net637 (210)
Fair value adjustment of contingent consideration— (670)
Other income, net(24)(331)
Total other expense (income), net613 (1,211)
Loss before income taxes$(10,336)$(7,380)
Provision for income taxes (benefit)(2,531)(574)
Net loss$(7,805)$(6,806)
Weighted average shares outstanding
Basic and diluted22,820,779 22,506,024 
Net loss per share
Basic and diluted$(0.34)$(0.30)

See notes to condensed consolidated financial statements.
5

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited) (In Thousands)

Three Months Ended March 31,
20242023
Net loss$(7,805)$(6,806)
Other comprehensive loss:
Foreign currency translation adjustment(1,426)(962)
Unrealized gain (loss) on short-term investments109 617 
Adjustment for realized (gain) loss on securities(118)(301)
Other comprehensive loss, net of tax(1,435)(646)
Comprehensive loss$(9,240)$(7,452)

See notes to condensed consolidated financial statements.
6

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Three Months Ended March 31, 2024
Accumulated
AdditionalOtherTotal
Common StockPaid-inAccumulatedComprehensiveStockholders'
SharesValueCapitalDeficitLossEquity
Balance at January 1, 202423,378,408 $6 $580,287 $(197,742)$(5,526)$377,025 
Net loss— — — (7,805)— (7,805)
Other comprehensive loss— — — — (1,435)(1,435)
Restricted stock162,003 — 2,799 — — 2,799 
Balance at March 31, 202423,540,411 $6 $583,086 $(205,547)$(6,961)$370,584 

See notes to condensed consolidated financial statements.
7

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Three Months Ended March 31, 2023
Accumulated
AdditionalOtherTotal
Common StockPaid-inAccumulatedComprehensiveStockholders'
SharesValueCapitalDeficitLossEquity
Balance at January 1, 202322,877,962 $6 $560,810 $(176,768)$(5,400)$378,648 
Net loss— — — (6,806)— (6,806)
Other comprehensive loss— — — — (646)(646)
Restricted stock264,156 — 1,959 — — 1,959 
Balance at March 31, 202323,142,118 $6 $562,769 $(183,574)$(6,046)$373,155 

See notes to condensed consolidated financial statements.
8

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands)
Three Months Ended
March 31,
20242023
OPERATING ACTIVITIES
Net loss$(7,805)$(6,806)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization5,028 3,848 
Stock-based compensation2,799 2,113 
Fair value adjustment of contingent consideration— (670)
Accretion of acquisition installment payable281 381 
Deferred income taxes(2,445)(574)
Changes in certain operating assets and liabilities:
Accounts receivable - trade1,155 (2,002)
Inventories, net(6,631)(5,979)
Prepaid expenses and other current assets(953)(33)
Accounts payable - trade6,562 5,541 
Accrued expenses and other liabilities(5,049)(1,571)
Other368 (709)
Net cash used in operating activities(6,690)(6,461)
INVESTING ACTIVITIES
Acquisition of Boston O&P, net of cash acquired(20,693)— 
Sale of short-term marketable securities23,474 37,250 
Purchases of property and equipment(6,460)(4,940)
Net cash (used in) provided by investing activities(3,679)32,310 
FINANCING ACTIVITIES
Payments on acquisition note(538)— 
Payments on mortgage notes(35)(36)
Net cash used in financing activities(573)(36)
Effect of exchange rate changes on cash, cash equivalents and restricted cash1,479 (138)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH(9,463)25,675 
Cash, cash equivalents and restricted cash, beginning of year$33,027 $10,462 
Cash, cash equivalents and restricted cash, end of period$23,564 $36,137 
SUPPLEMENTAL DISCLOSURES
Cash paid for interest$223 $11 
Transfer of instruments between property and equipment and inventory$117 $332 
See notes to condensed consolidated financial statements.
9

ORTHOPEDIATRICS CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(Dollars In Thousands, Except Share and Per Share data)
NOTE 1 – BUSINESS

OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLoc Duo®, Pediatric Nailing Platform | Femur, Devise Rail, Orthex®, The Fassier-Duval Telescopic Intramedullary System®, SLIMTM Nail, The GAP NailTM, The Free Gliding SCFE Screw SystemTM, GIRO® Growth Modulation System, PNP Tibia System, ApiFix® Mid-C System and Mitchell Ponseti® specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation while our clubfoot orthopedic products are manufactured in-house.

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants, instruments and specialized braces to meet the needs of pediatric surgeons or orthotists and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2023 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 8, 2024. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of
10

operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $205,547 and $197,742 as of March 31, 2024 and December 31, 2023, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short-term investments, at March 31, 2024 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months.

Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.

Significant Accounting Policies

There have been no changes in the Company's significant accounting polices as disclosed in Note 2 to the audited consolidated financial statements included in the 2023 Annual Report on Form 10-K.

Reclassification

In the condensed consolidated financial statements, the Company has reclassified stock-based compensation to conform to the current period presentation. All stock-based compensation was previously recorded within general and administrative expenses, and such costs have now been allocated between general and administrative expenses, research and development expenses and sales and marketing expenses. The current presentation results in stock-based compensation expense being recorded in the same manner in which the award recipient's payroll costs are classified. This reclassification did not affect previously reported total operating expenses, loss before income taxes, or net loss in the condensed consolidated statements of operations.

The following tables present the impact of the reclassification on our condensed consolidated statements of operations:
Three Months Ended March 31, 2023
Sales and marketing (prior presentation)$12,216 
Reclassification333 
Sales and marketing (new presentation)$12,549 
Three Months Ended March 31, 2023
General and administrative (prior presentation)$17,666 
Reclassification(509)
General and administrative (new presentation)$17,157 
11

Three Months Ended March 31, 2023
Research and development (prior presentation)$2,270 
Reclassification176 
Research and development (new presentation)$2,446 

Financial Instruments and Concentration of Credit Risk

Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds.

Recent Accounting Pronouncements

In October 2023, the FASB issued ASU No. 2023-06 "Disclosure Improvements - Codification Amendments in Response to SEC's Disclosure Update and Simplification Initiative". This amendment modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. For entities subject to the SEC's existing disclosure requirements and entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. Amendments in this Update should be applied prospectively. The Company continues to analyze this ASU. The update is specific to disclosures and, therefore, is not expected to have a material impact to the condensed consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The standard requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. This authoritative guidance will be effective for us in fiscal 2024 for annual periods and in the first quarter of fiscal 2025 for interim periods, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09), which enhances the transparency and decision usefulness of income tax disclosures. The ASU is effective for public companies for fiscal years beginning on or after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures.





12

NOTE 3 - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS

Boston Brace International, Inc.

On January 5, 2024, the Company purchased all of the issued and outstanding share capital of Boston Brace International, Inc., a Massachusetts corporation ("Boston O&P"). Boston O&P has developed and manufactures pediatric orthotic and prosthetic devices, including non-surgical scoliosis treatment options, and provides related clinical services.

Under the terms of the stock purchase agreement, the Company paid to the shareholders of Boston O&P consideration of $22,000 in cash, subject to customary adjustments related to net working capital, transaction expenses, and funded indebtedness. Additionally, certain employees and executives of Boston O&P also received awards of restricted stock of the Company which will vest in three years subject to continuous service. The Restricted Stock Award Agreements were to approximately 170 individuals for an aggregate of approximately 83,000 shares representing approximately $2,500 (based on a share price of $30.12, which was the average closing price during the four-month period ending on January 4, 2024) and were granted pursuant to the Company’s 2017 Plan. The restricted stock units are not considered part of the purchase consideration.

The following table summarizes the total consideration paid for Boston O&P and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

Fair value of estimated total acquisition consideration$22,000 
Assets
Cash1,307 
Accounts receivable - trade2,876 
Inventories1,093 
Prepaid expenses and other current assets378 
Property and equipment4,360 
Amortizable intangible assets3,720 
Other intangible assets3,650 
Other non-current assets2,208 
Total assets19,592 
Liabilities
Accounts payable-trade581 
Other current liabilities2,063 
Long-term debt724 
Deferred tax liability2,268 
Other non-current liabilities1,003 
Total liabilities6,639 
Less: total net assets12,953 
Goodwill$9,047 

The fair value of identifiable intangible assets and certain long-lived assets were based on valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:
13


AmountRemaining Economic Useful Life
Trademarks / Names$3,650 Indefinite
Customer Relationships & Other 3,720 12 years
$7,370 

The following table represents the pro forma net revenue and net loss assuming the acquisition of Boston O&P occurred on January 1, 2023.
Three Months Ended March 31,
20242023
Net revenue$45,116 $38,435 
Net loss$(7,786)$(6,690)

Rhino Pediatric Orthopedic Designs, Inc.

On July 1, 2023, the Company completed an acquisition of assets, including inventory and certain intangible assets, of Rhino Pediatric Orthopedic Designs, Inc. ("Rhino"). Rhino's product portfolio included several pediatric orthopedic products in the bracing and soft goods space, including the Cruiser TM, Kicker TM, and Rhino Stomper TM. The Company paid $1,024 in total consideration for the assets which was comprised of $546 of cash, including $46 of transactions costs, and 11,133 shares of the Company’s common stock, par value $0.00025 per share, representing approximately $478 (based on closing price of $42.91 on July 1, 2023).

Medtech Concepts LLC

On May 1, 2023, the Company purchased all of the issued and outstanding membership interest of Medtech Concepts LLC, a Delaware limited liability company (“MedTech”). MedTech has developed an early-stage, pre-commercial enabling technology platform designed to increase efficiency in the perioperative environment. The solution combines hardware, software, and data analytics to help streamline operative care and support better decision making in the operating room. In the future, the Company believes this enabling technology platform will provide valuable intraoperative resources for surgeons that will improve decision making, drive operating room efficiency, and ultimately improve healthcare for children. The Company also expects that the acquisition will further support future market share gains for its implant systems, similar to what the Company has experienced with the FIREFLY® Technology and the 7D Surgical FLASHTM Navigation platform. No revenue was recorded from this platform in 2023, and the Company does not anticipate material revenue contributions from the platform in 2024.

The sellers of MedTech are being paid a purchase price of approximately $15,274 in the following manner: (i) cash in the aggregate amount of $3,000 was paid on May 1, 2023, the transaction closing date (the “Closing Date”); (ii) 43,751 unregistered shares of the Company’s common stock, par value $0.00025 per share, representing approximately $2,274 (based on a closing share price of $51.98 on May 1, 2023), were issued on the Closing Date; and (iii) an aggregate of $2,500 payable 50% in cash and 50% in shares of unregistered common stock, will be paid on each of the first four anniversaries of the Closing Date, all subject to the conditions set forth in the Membership Interest Purchase Agreement (the "Purchase Agreement"), as amended, relating to the transaction.

The Company concluded that the business acquired did not comprise an integrated set of activities that meet the definition of a business and therefore did not result in the acquisition of a business. Instead, the Company accounted for the transaction as an asset acquisition for accounting purposes.

14

Under the Purchase Agreement, a number of future payments in the form of common stock are contingent on continued service through each applicable payment anniversary date. As such, these amounts have been excluded from measuring the cost of the acquisition. The result is $4,500 of stock compensation which is being recognized on a straight-line basis over the four year service period. Future cash payments and stock issuances that are not contingent on continuous service are included in the calculation of consideration. The total consideration is $10,043 after discounting the future guaranteed fixed payments to their present value. Additionally, since this was treated as an asset acquisition, the Company included $97 of transaction costs in the total consideration. The table below reconciles the payments and issuances to total consideration transferred after discounting the future payments to present value.
ConsiderationPresent Value
Cash consideration$3,000 $3,000 
Issuance of common stock2,274 2,274 
Anniversary payments5,500 4,672 
Transaction costs97 97 
Total consideration transferred$10,871 $10,043 

As result of this asset acquisition, the Company recorded a trademark asset in the amount of $520 with an indefinite useful life and an intellectual property asset relating to software acquired of $9,523 which is being amortized over a useful life of ten years.

Kevin Unger, a member of the Company’s Board of Directors (the “Board”) through April 28, 2023, was one of the sellers in the transaction. As a result, the Board formed a special committee comprised of independent and disinterested directors (the “Special Committee”) with the exclusive authority to review, evaluate, and negotiate, or reject, the potential MedTech acquisition. The Purchase Agreement and the transactions contemplated thereby were approved by both the Special Committee and the full Board (with Mr. Unger abstaining).

NOTE 4 - GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill for the three months ended March 31, 2024 were as follows:
Total
Goodwill at January 1, 2024$83,699 
Boston O&P acquisition9,047 
Foreign currency translation impact(1,265)
Goodwill at March 31, 2024
$91,481 

Intangible Assets

As of March 31, 2024, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents11.0 years$44,969 $(11,619)$33,350 
Intellectual Property & Capitalized Software8.9 years16,027 (2,911)13,116 
Customer Relationships & Other12.1 years22,417 (3,675)18,742 
License Agreements3.6 years10,733 (5,559)5,174 
Total amortizable assets$94,146 $(23,764)$70,382 
15


As of December 31, 2023, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents11.2 years$45,646 $(11,008)$34,638 
Intellectual Property & Capitalized Software9.1 years16,026 (2,524)13,502 
Customer Relationships & Other12.4 years18,862 (3,270)15,592 
License Agreements3.8 years10,733 (5,190)5,543 
Total amortizable assets$91,267 $(21,992)$69,275 

Licenses are tied to product launches and do not begin amortizing until the product is launched to the market.

Trademarks are non-amortizing intangible assets which were $18,792 and $15,287 as of March 31, 2024 and December 31, 2023, respectively. Trademarks are recorded in Other intangible assets on the condensed consolidated balance sheets. The change in balance during the three months ended March 31, 2024 was driven by foreign currency translation adjustments and the Boston O&P acquisition.

During 2023, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the Company completed a quantitative analysis whereby we determined the fair value of the ApiFix trademark asset was below the carrying value. We recorded an impairment charge of $985 for the year ended December 31, 2023 to reduce the carrying amount of the intangible asset to its estimated fair value.

NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.

The following tables summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023.
March 31, 2024
Level 1Level 2Level 3Total
Financial Assets
Short-term investments
Certificates of Deposit$— $26,141 $— $26,141 
16

December 31, 2023
Level 1Level 2Level 3Total
Financial Assets
Short-term investments
Certificates of Deposit$— $25,792 $— $25,792 
Exchange Trade Mutual Funds$5,015 $— $— $5,015 
Treasury Bonds$18,235 $— $— $18,235 
Other$207 $— $— $207 

The Company's Level 1 assets consist of short-term, liquid investments with original maturity of three months or less at inception and other short-term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months.

The Company's Level 2 assets pertain to certain asset-backed securities, collateralized by non-mortgage-related consumer debt, or certificates of deposit. These securities are predominately priced by third parties, either by a pricing vendor or dealer with significant inputs observable in active markets.

The Company's Level 3 instruments consist of contingent consideration. The fair value of the contingent consideration liability assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as forecasted annual revenues, expected volatility and discount rates. The contingent consideration was zero as of both March 31, 2024 and December 31, 2023.

NOTE 6 - DEBT AND CREDIT ARRANGEMENTS

Long-term debt consisted of the following as of the dates indicated:
March 31, 2024December 31, 2023
Term loan and final payment$10,300 $10,300 
Mortgage payable to affiliate726 763 
Acquisition note payable261 — 
Total debt11,287 11,063 
Less: debt discount and issuance costs982 1,003 
Less: current maturities154 152 
Long-term debt, net of current maturities$10,151 $9,908 

On December 29, 2023, the Company entered into an $80 million Credit, Security and Guaranty Agreement (the “Credit Agreement”) by and among (i) the Company and other borrowers party to the Credit Agreement (collectively, the “Borrowers”), (ii) MidCap Funding IV Trust, as Agent (“Agent”), (iii) MidCap Financial Trust, as Term Loan Servicer (“Servicer”), and (iv) the financial institutions or other entities from time to time party thereto as Lenders (collectively, “Lenders”). Under the terms of the Credit Agreement, the Lenders have provided to Borrowers a term loan in an aggregate principal amount that will not exceed $30 million available in three tranches of $10 million each subject to certain draw conditions (the “Term Loan”) and a revolving loan in an aggregate principal amount that will not exceed $50 million (the “Revolving Loan”). Borrowings are available subject to certain levels of working capital for the Revolving Loan. The second tranche of the Term Loan is eligible to be drawn between July 1, 2024 through June 30, 2025. The third tranche of the Term Loan is eligible to be drawn between January 1, 2025 through June 30, 2025. The Company must meet certain cash usage requirements at the time of each draw to be eligible to access these term loans. Interest on the Term Loan will accrue at the greater of (a) One Month Term SOFR plus 6.50% or (b) 9.0% and interest on the Revolving Loan will accrue at the greater of (a) One Month Term SOFR plus 4.0% or (b) 6.50% (the “Applicable Rate”) and
17

will be payable monthly by the Borrowers. The Term Loans may be prepaid in full through December 29, 2024 with payment of a 3.00% prepayment premium, after which they may be prepaid in full through December 29, 2025 with payment of a 2.00% prepayment premium, after which they may be prepaid in full through December 29, 2026 with payment of a 1.00% prepayment premium, after which they may be prepaid in full with no prepayment premium. An additional final payment of 3.00% ("Final Payment") of the amount of the Terms Loans advanced by the Lenders will be due upon prepayment or repayment of the Terms Loans in full, and is accounted for as debt discount. The first tranche of $10 million was issued under the Term Loan upon execution. Payments of principal and all accrued but unpaid interest will be due and payable upon the earlier of: (i) December 1, 2028; (ii) the occurrence of any transaction or series of transactions pursuant to which any person or entity in the aggregate acquire(s) 35% or more of the voting capital stock of the Company; (iii) a change in the majority of the Company’s Board of Directors over a 12-month period; (iv) the Company ceases to own directly or indirectly, 100% of the capital stock of any of its subsidiaries (with the exception of any subsidiaries permitted to be dissolved, merged or otherwise disposed of by the Credit Agreement), or (v) the occurrence of a change in control, fundamental change, deemed liquidation event or terms of similar import under any document or instrument governing or relating to debt of or equity interests of the Company. The loans under the Credit Agreement are secured by a security interest in the Company’s and other Borrowers' assets. The Credit Agreement provides for customary events of default. If an event of default is not cured within the time periods specified (if any), the Lenders and Agent have the right to accelerate the Company’s payment of principal and interest in addition to other rights and remedies.

The Credit Agreement includes certain customary non-financial covenants, and also include certain financial covenants related to the Company achieving minimum revenue targets over a trailing twelve month period. The Credit Agreement was amended on May 3, 2024 to clarify the inputs into the financial covenant calculations. No other changes were made to the Credit Agreement. The Company was in compliance with all covenants under the Credit Agreement, as amended, as of March 31, 2024 and December 31, 2023.

The debt facilities available under the Credit Agreement replace the Fourth Amended and Restated Loan and Security Agreement with Squadron Capital, LLC ("Squadron"), (as amended, the “Squadron Loan Agreement”), which provided the Company with a $50 million revolving credit facility. During the year ended December 31, 2023, there was no indebtedness outstanding under the Squadron Loan Agreement and it was terminated in connection with the Credit Agreement.

Borrowings under the Squadron Loan Agreement accrued interest at an annual rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%, and the Company was permitted to make interest only payments on amounts outstanding. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company paid Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee was payable quarterly in arrears.

Borrowings under the Squadron Loan Agreement were made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note matured at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Squadron Loan Agreement were secured by substantially all of the Company's assets and were unconditionally guaranteed by each of its subsidiaries with the exception of Vilex in Tennessee, Inc. ("Vilex"). There were no traditional financial covenants associated with the Squadron Loan Agreement. However, there were negative covenants that prohibited us from, among other things,
18

transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions.

In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. At March 31, 2024, the mortgage balance was $726 of which current principal of $154 was included in the current portion of long-term debt. As of December 31, 2023, the mortgage balance was $763 of which current principal due of $152 was included in the current portion of long-term debt.

The aggregate interest expense relating to the notes payable to Squadron, the mortgage note payable to Tawani Enterprises Inc. and the term loan with MidCap was $339 and $11 for the three months ended March 31, 2024 and 2023, respectively.

NOTE 7 - INCOME TAXES

The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss).

For the three months ended March 31, 2024, the income tax benefit was $2,531 compared to $574 for the three months ended March 31, 2023. Our effective income tax rate was (24.5)% and (7.8)% for the three months ended March 31, 2024 and 2023, respectively. The higher effective rate compared to the prior period is from the remeasurement of the valuation allowance subsequent to recording the deferred tax liability as a result of the purchase accounting from the Boston O&P acquisition.

The deferred tax assets were fully offset by a valuation allowance at March 31, 2024 and December 31, 2023, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix, Ltd. ("ApiFix") and Pega Medical. See Note 3 under Item 8 in the Company's Annual Report on Form 10-K for additional information regarding the ApiFix business combination. The Company has recorded a tax benefit during the period ended March 31, 2024 for losses generated in Canada and Israel, respectively.

NOTE 8 - STOCKHOLDERS’ EQUITY

Restricted Stock

Our restricted stock activity and related information are summarized as follows:
Weighted-AverageWeighted-Average
RestrictedRemainingRestrictedRemaining
StockContractual TermsStockContractual Terms
Awards(in Years)Units(in Years)
Outstanding at January 1, 2024592,453 1.613,851 1.7
Granted165,473 7,900 
Forfeited(3,470)(100)
Vested(82,659)— 
Outstanding at March 31, 2024
671,797 1.921,651 1.9

19

At March 31, 2024, there was $16,757 of unrecognized compensation expense remaining related to our service-based restricted stock awards and restricted stock units. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.9 years or earlier upon an elimination of the restriction period as a result of a change in control event.

Stock-based compensation expense on restricted stock amounted to $2,799 and $1,959 for the three months ended March 31, 2024 and 2023, respectively.

NOTE 9 – NET LOSS PER SHARE

The following is a reconciliation of basic and diluted net loss per share:
Three Months Ended
March 31,
20242023
Net loss$(7,805)$(6,806)
Weighted average shares outstanding for basic and diluted22,820,779 22,506,024 
Net loss per share - basic and diluted$(0.34)$(0.30)

Our basic and diluted net loss per share is computed using the two-class method.  For purposes of our equity disclosures and calculation of weighted average shares for basic earnings per share calculations, the two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. 

The contingently issuable shares in the paragraph above do not include shares of our common stock associated with our obligation to issue a variable number of our common shares as a result of our recent acquisitions of Pega Medical, ApiFix or MedTech. See Note 3 for additional information regarding our commitment to issue future equity under the MedTech acquisition. Additionally, as a component of the acquisition of ApiFix, the Company is obligated to make anniversary installment payments on the second, third and fourth anniversary of the acquisition date. These payments included a minimum cash component with the remaining settled in common stock. See Note 3 under Item 8 in the Company's Annual Report on Form 10-K for additional information regarding this business combination.

NOTE 10 – BUSINESS SEGMENT

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reportable segment, which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No individual customer accounted for more than 10% of total product sales for the three months ended March 31, 2024 or 2023.
20

No individual customer accounted for more than 10% of consolidated accounts receivable as of March 31, 2024 and December 31, 2023.

Product sales by source were as follows:
Three Months Ended March 31,
Product sales by geographic location:20242023
U.S.$34,305 $23,800 
International10,380 7,788 
Total$44,685 $31,588 
Three Months Ended March 31,
Product sales by category:20242023
Trauma and deformity$33,302 $23,395 
Scoliosis10,203 7,072 
Sports medicine/other1,180 1,121 
Total$44,685 $31,588 

NOTE 11 - RELATED PARTY TRANSACTIONS

In addition to the expired debt and credit agreements and mortgage with Squadron (the Company's largest investor) and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $382 and $246 for the three months ended March 31, 2024 and 2023, respectively.

NOTE 12 - EMPLOYEE BENEFIT PLAN

We have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. Additionally, employees of MD Ortho receive contribution matches up to 3% of their salary.

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Leases

As of March 31, 2024, the Company has recorded a lease liability of $2,235 and corresponding right-of-use asset of $2,529 on its condensed consolidated balance sheet. We assumed $1,749 of operating right-of-use assets and $1,582 of total lease liabilities in connection with our acquisition of Boston O&P.

Legal Proceedings

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.



21

IMED Surgical - Software Ownership Dispute

On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron, and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company ("IMED"), in Broward County, Florida Circuit Court. In the lawsuit, IMED claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).

In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point & Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent. According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with IMED. IMED, among other things, requests that the defendants be ordered to convey and assign to IMED all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants.

On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent IMED desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, IMED initiated an arbitration proceeding; however, IMED failed to pay the fees it was required to pay for the arbitration to continue, resulting in the arbitration panel terminating the arbitration proceedings in mid-October 2022. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to IMED before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order.

On February 3, 2023, the Court partially lifted the stay in this case for the sole purpose of, as clarified by the Court's order on March 7, 2023, "permitting any party to argue any motion challenging the events that occurred which led to the arbitration panel's termination order." No filing was made in response to that order. No further filings were made in this case until October 30, 2023, when defendants filed a motion to dismiss.

On December 12, 2023, the Court ordered IMED has until March 13, 2024, to appear before the Court and show cause why this case should not be dismissed for failure to pursue arbitration consistent with the Court’s orders. On March 13, 2024, a hearing took place to discuss the status of IMED’s effort to re-initiate arbitration. Thereafter, on March 25, 2024, the court ordered, if, by April 27, 2024, IMED has not begun arbitration, resolved this case, or substantiated (in the form of an attorney and client declaration) that it has executed an agreement with a litigation funder to pay for arbitration proceedings, to pay the balance due to the subject arbitration association and to re-instate the arbitration, the Court will dismiss this case without prejudice. On April 26, 2024, IMED informed the Court it has executed an agreement with a litigation funder to pay for arbitration proceedings, to pay the balance due to the subject arbitration association, and to reinstate the arbitration, and is in the final stages of resolving the balance due to the subject arbitration association.
22


Although we believe the Company has strong defenses to the IMED lawsuit and we intend to vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.

Boston O&P Litigation

This lawsuit arises from the alleged wrongful death of a patient following his January 2016, tracheal and laryngeal resection procedure at Boston Children’s Hospital, which was performed by two physicians named as defendants in the suit. The Plaintiffs allege that as a result of the patient’s post-operative care, which included placing his neck in a position of flexion in a modified brace provided by Boston O&P, the patient was paralyzed, and years later, he died due to complications caused by his paralysis. The Company acquired all of the outstanding shares of Boston O&P on January 5, 2024 as described more fully under Note 3 - Business Combinations and Asset Acquisitions.

The lawsuit commenced in December 2018, in Suffolk Superior Court in Boston, Massachusetts. The Plaintiffs assert counts of negligence against each individual defendant, lack of informed consent against the physician defendants, failure to warn, breach of warranty and alleged improper use against Boston O&P, and loss of consortium against all defendants. Trial is currently scheduled to begin in December 2025.

Although we believe Boston O&P has strong defenses to this lawsuit and we intend to vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

Purchase Obligations and Performance Requirements

As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASHTM Navigation platform during 2021, the Company agreed to a minimum purchase commitment for the first twelve months of that agreement. Additionally, the contract requires future purchase commitments based upon a percentage of historical purchases. As a result and as of March 31, 2024, the remaining purchase commitment under the agreement was $1,820 for the year ended December 31, 2024 and $1,456 for the year ended December 31, 2025.

On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three months ended March 31, 2024, the Company recorded an expense of $542 based on current estimates. The Company recorded $300 of expense for the three months ended March 31, 2023.

Royalties

As of March 31, 2024, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales.
23


We have products in development that have royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of March 31, 2024, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.

NOTE 14 – SUBSEQUENT EVENT

ApiFix Acquisition Installment Payment

On April 1, 2024, the fourth-year anniversary of the acquisition of ApiFix, the Company paid $2,250 in cash and issued 245,812 shares of the Company's common stock, representing $6,929 of fair value (based on the April 1, 2024 closing share price of $28.19), to fulfill its installment obligation to ApiFix. This was the third and final installment payment paid since the acquisition.

MedTech Anniversary Payment

On May 1, 2024, the first-year anniversary of the acquisition of MedTech, the Company paid $1,250 in cash and issued 42,882 shares of the Company's common stock, representing $1,331 of fair value (based on the May 1, 2024 closing share price of $31.04), to fulfill its installment obligation to MedTech. This was the first installment payment paid since the acquisition.


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the condensed consolidated financial statements and related notes thereto contained elsewhere in this quarterly report, as well as the information under "Note Regarding Forward-Looking Statements."

The description of our business included in this quarterly report is summary in nature and only includes material developments that have occurred since the latest full description. The full description of the history and general development of our business is included in "Item 1. Description of Business" section of the Company's Annual Report on Form 10-K filed with the SEC on March 8, 2024, which section is incorporated herein by reference.

Overview

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants, instruments and specialized braces to meet the needs of pediatric surgeons or orthotists and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3.9 billion opportunity globally, including over $1.7 billion in the United States.

We sell implants, instruments and specialized braces to our customers for use by pediatric orthopedic surgeons, orthotists or physical therapists to treat orthopedic conditions in children. We provide our implants in sets that consist of a range of implant sizes and include the instruments necessary to perform the surgical procedure. In the United States and a few selected international markets, our customers typically expect us to have full sets of implants and instruments on site at each hospital but do not purchase the implants until they are used in surgery. Accordingly, we must make an up-front
24

investment in inventory of consigned implants and instruments before we can generate revenue from a particular hospital and we maintain substantial levels of inventory at any given time. In the international markets where we sell to stocking distributors or in the case of our braces, we transfer control of our products to the distributor or customer when title passes upon shipment.

We currently market 71 surgical and specialized bracing systems that serve three of the largest categories within the pediatric orthopedic market: (i) trauma and deformity correction, (ii) scoliosis and (iii) sports medicine/other. We rely on a broad network of third parties to manufacture the components of our products, which we then inspect and package. We believe our innovative products promote improved surgical accuracy, increase consistency of outcomes and enhance surgeon confidence in achieving high standards of care. In the future, we expect to expand our product offering within these categories, as well as to address additional categories of the pediatric orthopedic market.

The majority of our revenue has been generated in the United States, where we sell our products through a network of multiple direct sales representatives as well as 38 independent sales agencies employing more than 210 sales representatives specifically focused on pediatrics. These independent sales agents are trained by us, distribute our products and are compensated through sales-based commissions and performance bonuses. We do not sell our products through or participate in physician-owned distributorships, or PODs.

We market and sell our products internationally in over 70 countries, through independent stocking distributors and sales agencies. Our independent distributors manage the billing relationship with each hospital in their respective territories and are responsible for servicing the product needs of their surgeon customers. In 2017, we began to supplement our international stocking distributors with sales agencies using direct sales programs in the United Kingdom, Ireland, Australia and New Zealand where we sell directly to the hospitals. We began selling direct to Canada in September 2018, Belgium and the Netherlands in January 2019, Italy in March 2020 and Germany, Switzerland and Austria in January 2021. In order to further enhance our operations in Europe, we established operating companies in the Netherlands and Germany in March 2019 and April 2022, respectively. In January 2023, we established a direct sales organization in Germany, the Company's first direct selling organization serving an international market. In our international markets, excluding Germany, we work through sales agencies that are paid a commission, similar to our U.S. sales model. These arrangements have generated an increase in revenue and gross margin.

We believe there are significant opportunities for us to strengthen our position in U.S. and international markets by increasing investments in consigned implant and instrument sets, strengthening our global sales and distribution infrastructure and expanding our product offering.

Environmental, Social and Governance ("ESG") Activities

OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 1,000,000 children, when including those served by our acquired companies. We believe we should continue to expand our social efforts while minimizing our impact to the environment and ensuring corporate governance. In 2021, we created an internal ESG team, which reports directly to our Board’s Governance Committee, to identify ESG topics for disclosure by assessing both the impact on our business and the importance to our stakeholders.

We encourage you to review our ESG page and summary report which can be found under the "About" section of our corporate website for more detailed information regarding our ESG efforts and current initiatives. On our website, among other information, are the following highlights:

•OrthoPediatrics cares about our environmental impact while working in a highly regulated industry and we are certified according to ISO 13485. Our team in Warsaw, Indiana recently implemented
25

an enhanced recycling program and our team in the United Kingdom created a carbon reduction plan.

•The Company and its associates regularly participate in philanthropic causes important to our local communities. We also partner with charitable organizations that provide pediatric orthopedic care around the world. In 2020, we were named as "Corporate Partner of the Year" by World Pediatrics - with whom we work to provide access to medical care for children in developing countries.

•We are committed to fostering an environment that is respectful, compassionate, and inclusive of everyone in our community which is communicated in our diversity and inclusion policy. For eight years we have been recognized by the Indiana Chamber of Commerce - Best Companies to Work in Indiana.

•The Company and its Board of Directors understand the value of diversity. In 2022 and again in 2023, the Company added diverse Directors to our Board and will continue its Board diversity initiative in the future.

We believe effectively managing our priorities, as well as increasing our transparency related to ESG programs, will help create long-term value for our stakeholders. We expect to increase our disclosures and communicate our ESG efforts in future SEC filings.

Nothing on our website shall be deemed part of or incorporated by reference into this Quarterly Report on Form 10-Q.

Trends and Uncertainties

From time to time we acquire, make investments in or license other technologies, products and business that may enhance our capabilities, complement our current products or expand the breadth of our markets or customer base. As a result of these transactions, we may record certain intangible assets, including goodwill and trademarks, which are subject to annual impairment testing. Fair value is based on our current assessment of the expected future cash flows based on recent results and other specific market factors. During 2023 and 2022, we determined that a triggering event had occurred indicating it was more likely than not the fair value of the ApiFix trademark was less than the associated carrying value. Subsequently, the Company completed a quantitative analysis and concluded that the fair value was in fact less than the carrying value and a partial impairment losses of $1.0 million and $3.6 million were recorded in 2023 and 2022, respectively. We believe that the expected future cash flows in the most recent calculations represent management’s best estimate; however, if actual results differ materially from these estimates, we could record an additional impairment charge which could be material to our consolidated financial statements and have an adverse impact on our results of operations.

In 2022 and 2023, there was a significant and unprecedented increase in cases of respiratory syncytial virus, or RSV, and other respiratory illnesses. RSV is a common respiratory virus that follows a seasonal pattern. The typical season shows an increase in mid-September, peaks in late December and drops around mid-April. In 2023 the United States experienced a significant increase in RSV activity outside of the typical peak season as well as a heightened impact during the winter months. The volume of elective procedures utilizing our products were negatively impacted as a significant percent of hospital capacity was absorbed to cover the increase in RSV-related hospitalizations. This had a negative impact on our sales volume in 2022 and 2023 and may continue to do so into the future. We are unable to accurately determine exactly how this will impact us in the future.

As a result of the COVID-19 pandemic, we experienced significant business disruption throughout the last several years. Elective procedures were delayed in some cases as hospitals continue to struggle with adequate staffing levels. As a majority of our products are utilized in elective surgeries or procedures, the
26

deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. Throughout the pandemic, we took a variety of steps to address the impact. We continue to monitor the impact of the pandemic on our employees and customers and the markets in which we operate and will take further actions that are considered prudent to address the pandemic. We cannot accurately predict with certainty the full extent to which the pandemic will impact demand for our products in the future.

We encourage the readers of this document to read our risk factors in their entirety contained in Item 1A “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 8, 2024 and in other reports filed with the SEC that discuss the risks and factors that may affect our business.

Summary of Statements of Operations for the Three Months Ended March 31, 2024 and 2023

The following table sets forth our results of operations for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023Increase
(Decrease)		%
Net revenue$44,685 $31,588 $13,097 41 %
Cost of revenue12,511 8,027 4,484 56 %
Sales and marketing expenses14,169 12,549 1,620 13 %
General and administrative expenses24,730 17,157 7,573 44 %
Research and development expenses2,998 2,446 552 23 %
Other expense (income), net613 (1,211)1,824 (151)%
Provision for income taxes (benefit)(2,531)(574)(1,957)(341)%
Net loss$(7,805)$(6,806)$999 15 %

Net Revenue

The following tables set forth our net revenue by geography and product category for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
Product sales by geographic location:20242023
U.S.$34,305 $23,800 
International10,380 7,788 
Total$44,685 $31,588 
Three Months Ended March 31,
Product sales by category:20242023
Trauma and deformity$33,302 $23,395 
Scoliosis10,203 7,072 
Sports medicine/other1,180 1,121 
Total$44,685 $31,588 

Net revenue increased $13.1 million, or 41%, from $31.6 million for the three months ended March 31, 2023 to $44.7 million for the three months ended March 31, 2024. The increase during the three months ended March 31, 2024 was primarily driven by the addition of Boston O&P sales, as well as strong performance across global Trauma and Deformity, International Scoliosis and OP Specialty Bracing.

27

Trauma and deformity sales increased $9.9 million, or 42%, from $23.4 million during the three months ended March 31, 2023, to $33.3 million for the three months ended March 31, 2024. The increase for the three months ended March 31, 2024 was primarily driven by strong growth across numerous product lines, specifically our Cannulated Screws, PNP Femur, PediPlate, external fixation and Pega systems, as well as the addition of Boston O&P. Scoliosis sales increased $3.1 million, or 44%, during the three months ended March 31, 2024. The increase for the three months ended March 31, 2024 was primarily driven by increased sales of our RESPONSE 5.5/6.0 and ApiFix systems and revenue generated from 7D Technology, as well as the addition of Boston O&P. Sports medicine / other increased $0.1 million, or 5%, during the three months ended March 31, 2024. The change in sports medicine / other was primarily driven by sales from our Telos operations. Nearly all the change in each category was due to an increase or decrease in the unit volume sold and not a result of price changes.

Cost of Revenue and Gross Margin

Cost of revenue increased $4.5 million, or 56%, from $8.0 million for the three months ended March 31, 2023 to $12.5 million for the three months ended March 31, 2024. The increase is due primarily to sales volume, including the added cost of revenue associated with the revenue generated by acquisitions and mix related to additional international sales. Gross margin was 72% and 75% for the three months ended March 31, 2024 and March 31, 2023, respectively.

Sales and Marketing Expenses

Sales and marketing expenses increased $1.6 million, or 13%, to $14.2 million for the three months ended March 31, 2024 from $12.5 million for the three months ended March 31, 2023. The changes in the three month periods ended March 31, 2024 was due primarily to increased sales commission expenses, as well as the addition of Boston O&P.

General and Administrative Expenses

General and administrative expenses increased $7.6 million, or 44%, from $17.2 million for the three months ended March 31, 2023 to $24.7 million for the three months ended March 31, 2024. The increases for the three month period ended March 31, 2024 was due primarily to the addition of Boston O&P. Stock compensation increased by $0.5 million with the increase in personnel and also as a result of restricted stock issued as part of the Boston O&P acquisition.

Depreciation and amortization expenses increased $1.2 million, or 31%, from $3.8 million for the three months ended March 31, 2023 to $5.0 million for the three months ended March 31, 2024. The increase in depreciation for the three month period ended March 31, 2024 was primarily due to higher set deployments and increased amortization associated with acquisitions, as well as the addition of Boston O&P.

Research and Development Expenses

Research and development expenses increased $0.6 million, or 23%, from $2.4 million for the three months ended March 31, 2023 to $3.0 million for the three months ended March 31, 2024. The increase for the three month period ended March 31, 2024 was primarily due to incremental product development and the addition of personnel to support the future growth of the business, including $0.4 million of additional non-cash stock based compensation expense.

Total Other (Income) Expenses

Other expense was $0.6 million for the three months ended March 31, 2024 compared to other income of $1.2 million for the three months ended March 31, 2023, a change of $1.8 million or 151%. The change for the three months ended March 31, 2024 was primarily due to the fair value adjustment of contingent
28

consideration associated with our ApiFix acquisition, as well as an increase to net interest expense related to the new Term Loan with MidCap.

Liquidity and Capital Resources

We have incurred operating losses since inception which resulted in negative cash flows used in operating activities of $6.7 million and $6.5 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an accumulated deficit of $205.5 million. We anticipate that our losses will continue in the near term as we continue to expand our product portfolio and invest in additional consigned implant and instrument sets to support our expansion into existing and new markets. Since inception, we have funded our operations primarily with proceeds from the sales of our common and preferred stock, convertible securities and debt, as well as through sales of our products. At March 31, 2024, we had cash and cash equivalents, restricted cash and short-term investments of $49.7 million.

Cash Flows

The following table sets forth our cash flows from operating, investing and financing activities for the periods indicated:
Three Months Ended March 31,
20242023
Net cash used in operating activities$(6,690)$(6,461)
Net cash (used in) provided by investing activities(3,679)32,310 
Net cash used in financing activities(573)(36)
Effect of exchange rate changes on cash, cash equivalents and restricted cash1,479 (138)
Net (decrease) increase in cash, cash equivalents and restricted cash$(9,463)$25,675 

Cash Used in Operating Activities

Net cash used in operating activities was $6.7 million and $6.5 million for the three months ended March 31, 2024 and 2023, respectively. The primary use of this cash was to fund our operations related to the development and commercialization of our products in each of these periods. Net cash used for working capital was $4.5 million for the three months ended March 31, 2024 compared to $4.8 million for the three months ended March 31, 2023. The increase in cash used in operating activities was primarily driven by additional inventory purchased to support sales growth as well as accounts receivable from the increased sales which was offset by cash provided by accounts payable associated with the acquired inventory.

Cash (Used in) Provided by Investing Activities

Net cash used in investing activities for the three months ended March 31, 2024 was $3.7 million compared to cash provided of $32.3 million for the three months ended March 31, 2023. Net cash used in investing activities for the three months ended March 31, 2024 consisted primarily of the sale of short-term marketable securities, when netted against the purchase of similar securities, offset by purchases of property, plant and equipment of $6.5 million, the majority of which is instrument sets. The change in cash related to investing activities is primarily driven by business combinations and the purchase of short term marketable securities which decreased from the prior year.

Cash Used in Financing Activities

Net cash used in financing activities for the three months ended March 31, 2024 was $0.6 million consisting primarily of $0.5 million payments on acquisition note payable that was assumed with the
29

Boston O&P acquisition. Net cash used in financing activities for the three months ended March 31, 2023 was not material to the results of our operations.

Indebtedness

The Company is party to a $80 million Credit, Security and Guaranty Agreement with Midcap Funding IV Trust and Midcap Financial Trust and other parties named therein. As of March 31, 2024, there was $10 million outstanding indebtedness under the Credit Agreement.

In August 2013, pursuant to the purchase of our office and warehouse space, we entered into a mortgage note payable to Tawani Enterprises Inc., the owner of which is a member of Squadron’s management committee. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $15,543, with interest compounded at 5% until maturity in August 2028, at which time a final payment of remaining principal and interest will become due.

See Note 6 - Debt and Credit Arrangements in Item 1 for further detail regarding our debt.
Pediatric Orthopedic Business Seasonality

Our revenue is typically higher in the summer months and holiday periods, driven by higher sales of our trauma and deformity and scoliosis products, which is influenced by the higher incidence of pediatric surgeries during these periods due to recovery time provided by breaks in the school year. Additionally, our scoliosis patients tend to have additional health challenges that make scheduling their procedures variable in nature.

Critical Accounting Policies and Significant Judgments and Estimates

There were no material changes to our critical accounting policies that are disclosed in our audited consolidated financial statements for the year ended December 31, 2023 filed with the SEC on March 8, 2024.

Recent Accounting Pronouncements

See Note 2 - Significant Accounting Policies in Item 1 Financial Statements of Part 1 of this Quarterly report on Form 10-Q for a description of recent accounting pronouncements applicable to our condensed consolidated financial statements.

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We consider our greatest potential area of market risk exposure to be interest rate risk related to our indebtedness and foreign currency exchange rate risk on our operating results. Quantitative and qualitative disclosures about exchange rate risk are included in Item 7A "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for 2023. There were no material changes from the information provided therein.

ITEM 4.        CONTROLS AND PROCEDURES

a.Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) at the end of the period covered by this quarterly report.
30


Based on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives, and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

b. Changes in Internal Control over Financial Reporting

On January 5, 2024, the Company completed the acquisition of Boston O&P. The company continues to evaluate Boston O&P's systems and controls and to integrate them into the Company's existing control structure. Except as it relates to the integration of the Boston O&P business, there were no changes in our internal control over financial reporting during the period covered by this quarterly report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).



31

PART II. OTHER INFORMATION

ITEM 1.        LEGAL PROCEEDINGS

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

A discussion of certain of those legal proceedings is contained in Note 13 – Commitments and Contingencies (under the heading “Legal Proceedings”) of the notes to the condensed consolidated financial statements included in Item 1. Financial Statements of Part I of this quarterly report on Form 10-Q, which discussion is incorporated herein by reference.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position, results of operations or cash flows.

ITEM 1A.    RISK FACTORS

In addition to the other information set forth in this quarterly report, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 8, 2024. There have been no material changes to these Risk Factors since the filing of our Annual Report on Form 10-K.

ITEM 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

a. Sale of Unregistered Securities.

None.

b. Use of Proceeds.

None.

c. Issuer Purchases of Equity Securities.

None.

ITEM 3.        DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.        MINE SAFETY DISCLOSURES

None.

ITEM 5.        OTHER INFORMATION

a. Information required under Form 8-K.

None.
32


b. Modifications to nomination process.

None.

c. Insider trading arrangements.

During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6.        EXHIBITS

The following exhibits are included within this Report or incorporated herein by reference.




33

Exhibit
Number
Description
*
34

+
+
++
++
101.INS+Inline XBRL Instance Document (The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.)
101.SCH+Inline XBRL Taxonomy Extension Schema Document
101.CAL+Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE+Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)

w The exhibits and schedules to the applicable agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of any schedule omitted from such agreement to the SEC upon request.

*    Exhibits that describe or evidence management contracts or compensatory plans or arrangements required to be filed as Exhibits to this Report.

+ Filed herewith.

++ Furnished herewith.

35

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 7, 2024By:/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)


May 7, 2024
By:
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial and Accounting Officer)

36
 EX-31.1 2 exhibit311-ceocertificatio.htm EX-31.1 Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Bailey, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)

Date:     May 7, 2024


 EX-31.2 3 exhibit312-cfocertificatio.htm EX-31.2 Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Fred L. Hite, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial and Accounting Officer)

Date:     May 7, 2024


 EX-32.1 4 exhibit321-ceocertificatio.htm EX-32.1 Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended March 31 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David R. Bailey, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.
/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)

Date:     May 7, 2024


 EX-32.2 5 exhibit322-cfocertificatio.htm EX-32.2 Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Fred L. Hite, Chief Financial Officer and Chief Operating Officer of the Company, hereby certifies, pursuant to 18 Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial and Accounting Officer)

Date:     May 7, 2024


 EX-101.SCH 6 kids-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - DEBT AND CREDIT ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - BUSINESS SEGMENT link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - BUSINESS SEGMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Acquisition, Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Discounting the Future Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - BUSINESS SEGMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - SUBSEQUENT EVENT (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 kids-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 kids-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 kids-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Sale of short-term marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Statistical Measurement [Domain] Statistical Measurement [Domain] Revolving credit facility Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in certain operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction Related Party Transaction [Line Items] Debt instrument, debt repayment trigger, as a basis of capital stock ownership (percent) Debt Instrument, Debt Repayment Trigger, As a Basis Of Capital Stock Ownership Debt Instrument, Debt Repayment Trigger, As a Basis Of Capital Stock Ownership Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Equity Award [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Outstanding at period start (in shares) Outstanding at period end (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number DEBT AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Cash consideration Payments to Acquire Businesses, Gross Business combination, consideration paid In cash (as a percent) Asset Acquisition, Equity Consideration Settled In Cash, Percentage Business Combination, Consideration Paid In Cash, Percentage Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred income taxes Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Accounts payable - trade Accounts Payable, Current Accounts payable-trade Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Restatement Determination Date: Restatement Determination Date [Axis] Total other expense (income), net Nonoperating Income (Expense) Trademark impairment Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Previously Reported Previously Reported [Member] Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of Product Sales by Geographic Location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Scoliosis Spine [Member] Spine [Member] Geographical [Axis] Geographical [Axis] Stock based compensation service period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period INCOME TAXES Income Tax Disclosure [Text Block] Restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Option Five Option Five [Member] Option Five Current liabilities: Liabilities, Current [Abstract] Accretion of acquisition installment payable Business Combination, Contingent Consideration, Change In Fair Value, Accretion of Acquisition Installment Payable Business Combination, Contingent Consideration, Change In Fair Value, Accretion of Acquisition Installment Payable Business Acquisition Business Acquisition [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Option One Option One [Member] Option One Net loss per share - diluted (in dollars per share) Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable - trade, net of allowances of $1,195 and $1,373, respectively Accounts Receivable, after Allowance for Credit Loss, Current Goodwill Goodwill [Roll Forward] SUPPLEMENTAL DISCLOSURES Supplemental Cash Flow Elements [Abstract] Share acquisition price (in dollars per share) Business Acquisition, Share Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Other expense (income): Other Nonoperating Income (Expense) [Abstract] Trading Symbol(s) Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Short-term investments Investments, Fair Value Disclosure Net loss Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Three Month LIBOR Three Month LIBOR [Member] Three Month LIBOR Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Stockholders' equity: Equity, Attributable to Parent [Abstract] Long-term debt, net of current portion Long-term debt with affiliate, net of current portion Notes and Loans, Noncurrent Schedule of Reconciliation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of revenue Cost of Goods and Services Sold Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Remaining economic useful life (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Patents Patents [Member] Name Forgone Recovery, Individual Name Present Value Reported Value Measurement [Member] Goodwill Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Certificates of Deposit Certificates of Deposit [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Entity Small Business Entity Small Business Local Phone Number Local Phone Number Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Business combination, number of individuals received restricted stock awards Business Combination, Number Of Individuals Received Restricted Stock Awards Business Combination, Number Of Individuals Received Restricted Stock Awards Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Trademarks Trademarks [Member] Retirement Benefits [Abstract] Option [Domain] Option [Domain] Option [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Repayments of related party debt Repayments of Related Party Debt Less: debt discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Reclassification Revision of Prior Period, Reclassification, Adjustment [Member] Mortgage payable to affiliate Mortgages [Member] Other assets: Other Assets, Noncurrent [Abstract] ApiFix Ltd ApiFix Ltd. [Member] ApiFix Ltd. Schedule of Total Consideration Transferred after Discounting Future Payments Asset Acquisition [Table Text Block] Products and Services [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Interest expense Interest Expense, Debt Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories, net Increase (Decrease) in Inventories Adjustment for realized (gain) loss on securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Rhino Pediatric Orthopedic Designs, Inc. Rhino Pediatric Orthopedic Designs, Inc. [Member] Rhino Pediatric Orthopedic Designs, Inc. Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Acquisition note payable Notes Payable, Other Payables [Member] Finite-lived intangible assets acquired Finite-Lived Intangible Assets Acquired Trading Arrangement: Trading Arrangement [Axis] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Reclassification [Line Items] Reclassification [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Squadron Capital LLC Squadron Capital LLC [Member] Squadron Capital LLC Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Amortizable intangible assets, net Net Intangible Assets Finite-Lived Intangible Assets, Net Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of year Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Boston Brace International, Inc. Boston Brace International, Inc. [Member] Boston Brace International, Inc. Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Asset acquisition, consideration (in shares) Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Fair value of estimated total acquisition consideration Business Combination, Consideration Transferred Gross profit Gross Profit Unused commitment fee percentage (as a percent) Line of Credit Facility, Commitment Fee Percentage Name of each exchange on which registered Security Exchange Name Long term debt Long-Term Debt Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Employee Stock Option Employee Stock Option [Member] Term Loan Term Loan [Member] Term Loan Unrecognized compensation expense, weighted average period of recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Number of related party suppliers Number Of Related Party Entities Suppliers Number Of Related Party Entities Suppliers Boston O&P acquisition Goodwill, Acquired During Period Tabular List, Table Tabular List [Table Text Block] Debt instrument, number of tranches Debt Instrument, Number of Tranches Debt Instrument, Number of Tranches Entity Address, Address Line One Entity Address, Address Line One Subsequent Event [Table] Subsequent Event [Table] STOCKHOLDERS' EQUITY Share-Based Payment Arrangement [Text Block] Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Trademarks / Names Trademarks and Trade Names [Member] Subsequent Event Subsequent Event [Member] Schedule of the Balances of Amortizable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Monthly interest and principal installments Debt Instrument, Periodic Payment Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Title of Each Class Title of 12(b) Security Other non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Business Combination Disclosure [Text Block] Related Party [Domain] Related Party, Type [Domain] Other intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Net loss Business Acquisition, Pro Forma Net Income (Loss) Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Intellectual Property & Capitalized Software Intellectual Property And Capitalized Software [Member] Intellectual Property And Capitalized Software Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation impact Goodwill, Foreign Currency Translation Gain (Loss) Inventories, net Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Stock based compensation capitalized Share-Based Payment Arrangement, Amount Capitalized Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Structure Medical, LLC Structure Medical, LLC [Member] Structure Medical, LLC Other non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Medtech Medtech [Member] Medtech Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Other Other Debt Obligations [Member] Long term debt face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Purchase obligation, to be paid, year one Purchase Obligation, to be Paid, Year One Aggregate value of equity consideration Asset Acquisition, Equity Interest Issued or Issuable, Value Aggregate Value Asset Acquisition, Equity Interest Issued or Issuable, Value Aggregate Value Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Financial Instruments Concentration Risk, Credit Risk, Policy [Policy Text Block] EMPLOYEE BENEFIT PLAN Retirement Benefits [Text Block] Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Option [Axis] Option [Axis] Option Class of Stock [Domain] Class of Stock [Domain] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Revenues from External Customers and Long-Lived Assets Revenues from External Customers and Long-Lived Assets [Line Items] Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Reclassifications Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Trademark impairment Litigation Settlement, Expense Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Operating lease liability Operating Lease, Liability Credit Facility [Axis] Credit Facility [Axis] Vilex and Orthex Vilex and Orthex [Member] Vilex and Orthex Total liabilities Liabilities Asset Acquisition [Axis] Asset Acquisition [Axis] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Long-term liabilities: Liabilities, Noncurrent [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Debt prepayment premium (percent) Debt Prepayment Premium Debt Prepayment Premium Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Subsequent Event Subsequent Event [Line Items] Sales and marketing Selling and Marketing Expense Affiliated Entity Affiliated Entity [Member] Common stock, $0.00025 par value; 50,000,000 shares authorized; 23,540,411 shares and 23,378,408 shares issued as of March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Operating Lease, Liability, Current, Statement of Financial Position Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Total current assets Assets, Current Option Two Option Two [Member] Option Two Other comprehensive loss: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Revolving Loan Revolving Loan [Member] Revolving Loan All Individuals All Individuals [Member] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Applicable debt rate (percent) Debt Instrument, Applicable Rate Debt Instrument, Applicable Rate Acquisition installment payable, net of current portion Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] PEO Name PEO Name Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Royalty agreement percentage (as a percent) Research and Development Arrangement Contract to Perform for Others Royalty Agreement Percent Restricted cash Restricted Cash, Current Schedule of Goodwill Schedule of Goodwill [Table Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] BUSINESS Nature of Operations [Text Block] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Depreciation and amortization Depreciation, Depletion and Amortization Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Net revenue Business Acquisition, Pro Forma Revenue Restricted Stock Restricted Stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Subsequent Events [Abstract] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Anniversary payments Asset Acquisition, Consideration Transferred, Contingent Consideration Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Boston O&P Boston O&P [Member] Boston O&P Level 2 Fair Value, Inputs, Level 2 [Member] Transfer of instruments between property and equipment and inventory Transfer Of Property And Equipment To Inventory MD Orthopaedics MD Orthopaedics [Member] MD Orthopaedics Entity Emerging Growth Company Entity Emerging Growth Company Current portion of acquisition installment payable Business Combination, Contingent Consideration, Acquisition Installment Payable, Current Business Combination, Contingent Consideration, Acquisition Installment Payable, Current Cash consideration Payments to Acquire Productive Assets Exchange Trade Mutual Funds Exchange Trade Mutual Funds [Member] Exchange Trade Mutual Funds Less: total net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Amortizable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Intangible asset, useful life (in years) Finite-Lived Intangible Asset, Useful Life Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Issuance of common stock Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Products and Services [Axis] Product and Service [Axis] NET LOSS PER SHARE Earnings Per Share [Text Block] Payments on mortgage notes Repayments of Secured Debt Percentage of prepayment of facility (percent) Percentage Of Prepayment Of Facility Percentage Of Prepayment Of Facility Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Weighted-Average Remaining Contractual Terms (in Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Asset Acquisition, acquisition price (per share) Asset Acquisition, Share Price Asset Acquisition, Share Price Minimum Minimum [Member] Property and equipment, net Property, Plant and Equipment, Net Firefly Technology Firefly Technology [Member] Firefly Technology Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Fourth Amended Loan Agreement Fourth Amended Loan Agreement [Member] Fourth Amended Loan Agreement Goodwill and Intangible Assets Disclosure [Abstract] Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Issuance of common stock Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Nonrelated Party Nonrelated Party [Member] Option Four Option Four [Member] Option Four Sports medicine/other Sports Medicine And Other [Member] Sports Medicine And Other [Member] Operating Lease, Right-of-Use Asset, Statement of Financial Position Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Long-term Purchase Commitment Long-Term Purchase Commitment [Line Items] Treasury Bonds US Treasury Securities [Member] Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Unrealized gain (loss) on short-term investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Accumulated Deficit Retained Earnings [Member] Less: current maturities Current portion of long-term debt with affiliate Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset Weighted-Average Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Net loss per share - basic (in dollars per share) Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Product Sales by Category Schedule of Segment Reporting Information, by Segment [Table Text Block] Related Party Related Party [Member] Total long-term liabilities Liabilities, Noncurrent Business combination, consideration of unregistered common stock (as a percent) Business Combination, Equity Consideration Settled In Shares, Percentage Business Combination, Consideration Of Unregistered Common Stock, In Percentage Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Concentration of Credit Risk Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Accounts payable - trade Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Debt instrument, maximum distribution per tranche Debt Instrument, Maximum Distribution Per Tranche Debt Instrument, Maximum Distribution Per Tranche Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Purchase obligation, to be paid, remainder of fiscal year Purchase Obligation, to be Paid, Remainder of Fiscal Year All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Additional paid-in capital Additional Paid in Capital Reclassification [Table] Reclassification [Table] Deferred income taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Finite lived intangible asset useful life extension period (in years) Finite-Lived Intangible Asset, Useful Life Extension Period Finite-Lived Intangible Asset, Useful Life Extension Period Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Consideration for acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Supplier Supplier [Member] Supplier Employer contribution as a percentage of employees' salary (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Insider Trading Arrangements [Line Items] Related Party [Axis] Related Party, Type [Axis] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Total consideration transferred Asset Acquisition, Total Compensation Asset Acquisition, Total Compensation Asset acquisition Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Trauma and deformity Trauma And Deformity [Member] Intellectual Property & Capitalized Software Intellectual Property [Member] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Fair value adjustment of contingent consideration Fair value adjustment of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Team Note B Team Note B [Member] Team Note B Proceeds from lines of credit Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Entity Central Index Key Entity Central Index Key Segment Reporting Information Segment Reporting Information [Line Items] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Intangible Assets Finite-Lived Intangible Assets, Gross Provision for income taxes (benefit) Income tax benefit Income Tax Expense (Benefit) International Non-US [Member] Weighted-average remaining contractual terms (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Accounts receivable - trade Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Total other assets Assets, Noncurrent, Excluding Property, Plant And Equipment Assets, Noncurrent, Excluding Property, Plant And Equipment Accrued compensation and benefits Employee-related Liabilities, Current FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Other comprehensive loss, net of tax Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Net revenue Total Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Other intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payments on acquisition note Repayments of Notes Payable Acquisition of Boston O&P, net of cash acquired Cash paid to acquire Payments to Acquire Businesses, Net of Cash Acquired License Agreements Licensing Agreements [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Interest expense (income), net Interest Income (Expense), Net Credit Facility [Domain] Credit Facility [Domain] Debt instrument, basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net of current maturities Mortgage balance Long-Term Debt, Excluding Current Maturities Acquisition note payable Acquisition Notes [Member] Acquisition Notes Weighted average common stock - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Fair value of identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Operating expenses: Operating Expenses [Abstract] Indefinite-lived intangible assets acquired Indefinite-Lived Intangible Assets Acquired Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Accounts receivable - trade Increase (Decrease) in Accounts and Notes Receivable Company Selected Measure Amount Company Selected Measure Amount Medtech Concepts LLC Medtech Concepts LLC [Member] Medtech Concepts LLC Additional Paid-in Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Revision of Prior Period [Axis] Revision of Prior Period [Axis] Cover [Abstract] SUBSEQUENT EVENT Subsequent Events [Text Block] U.S. UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Short-term investments Short-Term Investments Payments to related party Related Party Transaction, Purchases from Related Party Option Three Option Three [Member] Option Three Total consideration transferred Asset Acquisition, Consideration Transferred Total operating expenses Operating Expenses BUSINESS SEGMENT Segment Reporting Disclosure [Text Block] NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument Debt Instrument [Line Items] Weighted average shares outstanding - basic (in shares) Weighted average shares outstanding for basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Operating loss Operating Income (Loss) Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Security and Guaranty Agreement Security and Guaranty Agreement [Member] Security and Guaranty Agreement Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Current portion of long-term debt with affiliate Long-term Debt, Current Maturities, Related Party Long-term Debt, Current Maturities, Related Party Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer Relationships & Other Customer Relationships & Other Customer Relationships [Member] EX-101.PRE 10 kids-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COVER - shares
 3 Months Ended
Mar. 31, 2024
May 03, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-38242  
Entity Registrant Name OrthoPediatrics Corp  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-1761833  
Entity Address, Address Line One 2850 Frontier Drive  
Entity Address, City or Town Warsaw  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46582  
City Area Code 574  
Local Phone Number 268-6379  
Title of Each Class Common Stock, $0.00025 par value per share  
Trading Symbol(s) KIDS  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   23,828,882
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Entity Central Index Key 0001425450  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 21,602 $ 31,055
Restricted cash 1,962 1,972
Short-term investments 26,141 49,251
Accounts receivable - trade, net of allowances of $1,195 and $1,373, respectively 36,275 34,617
Inventories, net 112,689 105,851
Prepaid expenses and other current assets 5,056 3,750
Total current assets 203,725 226,496
Property and equipment, net 48,721 41,048
Other assets:    
Amortizable intangible assets, net 70,382 69,275
Goodwill 91,481 83,699
Other intangible assets 18,792 15,287
Other non-current assets 4,084 2,940
Total other assets 184,739 171,201
Total assets 437,185 438,745
Current liabilities:    
Accounts payable - trade 19,736 12,649
Accrued compensation and benefits 9,772 11,325
Current portion of long-term debt with affiliate 154 152
Current portion of acquisition installment payable 10,368 10,149
Other current liabilities 5,790 7,391
Total current liabilities 45,820 41,666
Long-term liabilities:    
Acquisition installment payable, net of current portion 3,613 3,551
Deferred income taxes 5,202 5,483
Other long-term liabilities 1,815 1,112
Total long-term liabilities 20,781 20,054
Total liabilities 66,601 61,720
Stockholders' equity:    
Common stock, $0.00025 par value; 50,000,000 shares authorized; 23,540,411 shares and 23,378,408 shares issued as of March 31, 2024 and December 31, 2023, respectively 6 6
Additional paid-in capital 583,086 580,287
Accumulated deficit (205,547) (197,742)
Accumulated other comprehensive loss (6,961) (5,526)
Total stockholders' equity 370,584 377,025
Total liabilities and stockholders' equity 437,185 438,745
Nonrelated Party    
Long-term liabilities:    
Long-term debt, net of current portion 9,579 9,297
Long-term debt with affiliate, net of current portion 9,579 9,297
Related Party    
Long-term liabilities:    
Long-term debt, net of current portion 572 611
Long-term debt with affiliate, net of current portion $ 572 $ 611
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 1,195 $ 1,373
Common stock, par value (in dollars per share) $ 0.00025 $ 0.00025
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 23,540,411 23,378,408
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net revenue $ 44,685 $ 31,588
Cost of revenue 12,511 8,027
Gross profit 32,174 23,561
Operating expenses:    
Sales and marketing 14,169 12,549
General and administrative 24,730 17,157
Research and development 2,998 2,446
Total operating expenses 41,897 32,152
Operating loss (9,723) (8,591)
Other expense (income):    
Interest expense (income), net 637 (210)
Fair value adjustment of contingent consideration 0 (670)
Other income, net (24) (331)
Total other expense (income), net 613 (1,211)
Loss before income taxes (10,336) (7,380)
Provision for income taxes (benefit) (2,531) (574)
Net loss $ (7,805) $ (6,806)
Weighted average shares outstanding - basic (in shares) 22,820,779 22,506,024
Weighted average common stock - diluted (in shares) 22,820,779 22,506,024
Net loss per share - basic (in dollars per share) $ (0.34) $ (0.30)
Net loss per share - diluted (in dollars per share) $ (0.34) $ (0.30)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net loss $ (7,805) $ (6,806)
Other comprehensive loss:    
Foreign currency translation adjustment (1,426) (962)
Unrealized gain (loss) on short-term investments 109 617
Adjustment for realized (gain) loss on securities (118) (301)
Other comprehensive loss, net of tax (1,435) (646)
Comprehensive loss $ (9,240) $ (7,452)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2022 $ 378,648 $ 6 $ 560,810 $ (176,768) $ (5,400)
Beginning balance (in shares) at Dec. 31, 2022   22,877,962      
Increase (Decrease) in Stockholders' Equity          
Net loss (6,806)     (6,806)  
Other comprehensive loss (646)       (646)
Restricted stock 1,959   1,959    
Restricted stock (in shares)   264,156      
Ending balance at Mar. 31, 2023 373,155 $ 6 562,769 (183,574) (6,046)
Ending balance (in shares) at Mar. 31, 2023   23,142,118      
Beginning balance at Dec. 31, 2023 377,025 $ 6 580,287 (197,742) (5,526)
Beginning balance (in shares) at Dec. 31, 2023   23,378,408      
Increase (Decrease) in Stockholders' Equity          
Net loss (7,805)     (7,805)  
Other comprehensive loss (1,435)       (1,435)
Restricted stock 2,799   2,799    
Restricted stock (in shares)   162,003      
Ending balance at Mar. 31, 2024 $ 370,584 $ 6 $ 583,086 $ (205,547) $ (6,961)
Ending balance (in shares) at Mar. 31, 2024   23,540,411      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
OPERATING ACTIVITIES    
Net loss $ (7,805) $ (6,806)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 5,028 3,848
Stock-based compensation 2,799 2,113
Fair value adjustment of contingent consideration 0 (670)
Accretion of acquisition installment payable 281 381
Deferred income taxes (2,445) (574)
Changes in certain operating assets and liabilities:    
Accounts receivable - trade 1,155 (2,002)
Inventories, net (6,631) (5,979)
Prepaid expenses and other current assets (953) (33)
Accounts payable - trade 6,562 5,541
Accrued expenses and other liabilities (5,049) (1,571)
Other 368 (709)
Net cash used in operating activities (6,690) (6,461)
INVESTING ACTIVITIES    
Acquisition of Boston O&P, net of cash acquired (20,693) 0
Sale of short-term marketable securities 23,474 37,250
Purchases of property and equipment (6,460) (4,940)
Net cash (used in) provided by investing activities (3,679) 32,310
FINANCING ACTIVITIES    
Payments on acquisition note (538) 0
Payments on mortgage notes (35) (36)
Net cash used in financing activities (573) (36)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 1,479 (138)
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (9,463) 25,675
Cash, cash equivalents and restricted cash, beginning of year 33,027 10,462
Cash, cash equivalents and restricted cash, end of period 23,564 36,137
SUPPLEMENTAL DISCLOSURES    
Cash paid for interest 223 11
Transfer of instruments between property and equipment and inventory $ 117 $ 332
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLoc Duo®, Pediatric Nailing Platform | Femur, Devise Rail, Orthex®, The Fassier-Duval Telescopic Intramedullary System®, SLIMTM Nail, The GAP NailTM, The Free Gliding SCFE Screw SystemTM, GIRO® Growth Modulation System, PNP Tibia System, ApiFix® Mid-C System and Mitchell Ponseti® specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation while our clubfoot orthopedic products are manufactured in-house.
We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants, instruments and specialized braces to meet the needs of pediatric surgeons or orthotists and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2023 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 8, 2024. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of
operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $205,547 and $197,742 as of March 31, 2024 and December 31, 2023, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short-term investments, at March 31, 2024 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months.

Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.

Significant Accounting Policies

There have been no changes in the Company's significant accounting polices as disclosed in Note 2 to the audited consolidated financial statements included in the 2023 Annual Report on Form 10-K.

Reclassification

In the condensed consolidated financial statements, the Company has reclassified stock-based compensation to conform to the current period presentation. All stock-based compensation was previously recorded within general and administrative expenses, and such costs have now been allocated between general and administrative expenses, research and development expenses and sales and marketing expenses. The current presentation results in stock-based compensation expense being recorded in the same manner in which the award recipient's payroll costs are classified. This reclassification did not affect previously reported total operating expenses, loss before income taxes, or net loss in the condensed consolidated statements of operations.

The following tables present the impact of the reclassification on our condensed consolidated statements of operations:
Three Months Ended March 31, 2023
Sales and marketing (prior presentation)$12,216 
Reclassification333 
Sales and marketing (new presentation)$12,549 
Three Months Ended March 31, 2023
General and administrative (prior presentation)$17,666 
Reclassification(509)
General and administrative (new presentation)$17,157 
Three Months Ended March 31, 2023
Research and development (prior presentation)$2,270 
Reclassification176 
Research and development (new presentation)$2,446 

Financial Instruments and Concentration of Credit Risk

Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds.

Recent Accounting Pronouncements

In October 2023, the FASB issued ASU No. 2023-06 "Disclosure Improvements - Codification Amendments in Response to SEC's Disclosure Update and Simplification Initiative". This amendment modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. For entities subject to the SEC's existing disclosure requirements and entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. Amendments in this Update should be applied prospectively. The Company continues to analyze this ASU. The update is specific to disclosures and, therefore, is not expected to have a material impact to the condensed consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The standard requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. This authoritative guidance will be effective for us in fiscal 2024 for annual periods and in the first quarter of fiscal 2025 for interim periods, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures.
In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09), which enhances the transparency and decision usefulness of income tax disclosures. The ASU is effective for public companies for fiscal years beginning on or after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS BUSINESS COMBINATIONS AND ASSET ACQUISITIONS
Boston Brace International, Inc.

On January 5, 2024, the Company purchased all of the issued and outstanding share capital of Boston Brace International, Inc., a Massachusetts corporation ("Boston O&P"). Boston O&P has developed and manufactures pediatric orthotic and prosthetic devices, including non-surgical scoliosis treatment options, and provides related clinical services.

Under the terms of the stock purchase agreement, the Company paid to the shareholders of Boston O&P consideration of $22,000 in cash, subject to customary adjustments related to net working capital, transaction expenses, and funded indebtedness. Additionally, certain employees and executives of Boston O&P also received awards of restricted stock of the Company which will vest in three years subject to continuous service. The Restricted Stock Award Agreements were to approximately 170 individuals for an aggregate of approximately 83,000 shares representing approximately $2,500 (based on a share price of $30.12, which was the average closing price during the four-month period ending on January 4, 2024) and were granted pursuant to the Company’s 2017 Plan. The restricted stock units are not considered part of the purchase consideration.

The following table summarizes the total consideration paid for Boston O&P and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

Fair value of estimated total acquisition consideration$22,000 
Assets
Cash1,307 
Accounts receivable - trade2,876 
Inventories1,093 
Prepaid expenses and other current assets378 
Property and equipment4,360 
Amortizable intangible assets3,720 
Other intangible assets3,650 
Other non-current assets2,208 
Total assets19,592 
Liabilities
Accounts payable-trade581 
Other current liabilities2,063 
Long-term debt724 
Deferred tax liability2,268 
Other non-current liabilities1,003 
Total liabilities6,639 
Less: total net assets12,953 
Goodwill$9,047 

The fair value of identifiable intangible assets and certain long-lived assets were based on valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:
AmountRemaining Economic Useful Life
Trademarks / Names$3,650 Indefinite
Customer Relationships & Other 3,720 12 years
$7,370 

The following table represents the pro forma net revenue and net loss assuming the acquisition of Boston O&P occurred on January 1, 2023.
Three Months Ended March 31,
20242023
Net revenue$45,116 $38,435 
Net loss$(7,786)$(6,690)

Rhino Pediatric Orthopedic Designs, Inc.

On July 1, 2023, the Company completed an acquisition of assets, including inventory and certain intangible assets, of Rhino Pediatric Orthopedic Designs, Inc. ("Rhino"). Rhino's product portfolio included several pediatric orthopedic products in the bracing and soft goods space, including the Cruiser TM, Kicker TM, and Rhino Stomper TM. The Company paid $1,024 in total consideration for the assets which was comprised of $546 of cash, including $46 of transactions costs, and 11,133 shares of the Company’s common stock, par value $0.00025 per share, representing approximately $478 (based on closing price of $42.91 on July 1, 2023).

Medtech Concepts LLC

On May 1, 2023, the Company purchased all of the issued and outstanding membership interest of Medtech Concepts LLC, a Delaware limited liability company (“MedTech”). MedTech has developed an early-stage, pre-commercial enabling technology platform designed to increase efficiency in the perioperative environment. The solution combines hardware, software, and data analytics to help streamline operative care and support better decision making in the operating room. In the future, the Company believes this enabling technology platform will provide valuable intraoperative resources for surgeons that will improve decision making, drive operating room efficiency, and ultimately improve healthcare for children. The Company also expects that the acquisition will further support future market share gains for its implant systems, similar to what the Company has experienced with the FIREFLY® Technology and the 7D Surgical FLASHTM Navigation platform. No revenue was recorded from this platform in 2023, and the Company does not anticipate material revenue contributions from the platform in 2024.

The sellers of MedTech are being paid a purchase price of approximately $15,274 in the following manner: (i) cash in the aggregate amount of $3,000 was paid on May 1, 2023, the transaction closing date (the “Closing Date”); (ii) 43,751 unregistered shares of the Company’s common stock, par value $0.00025 per share, representing approximately $2,274 (based on a closing share price of $51.98 on May 1, 2023), were issued on the Closing Date; and (iii) an aggregate of $2,500 payable 50% in cash and 50% in shares of unregistered common stock, will be paid on each of the first four anniversaries of the Closing Date, all subject to the conditions set forth in the Membership Interest Purchase Agreement (the "Purchase Agreement"), as amended, relating to the transaction.

The Company concluded that the business acquired did not comprise an integrated set of activities that meet the definition of a business and therefore did not result in the acquisition of a business. Instead, the Company accounted for the transaction as an asset acquisition for accounting purposes.
Under the Purchase Agreement, a number of future payments in the form of common stock are contingent on continued service through each applicable payment anniversary date. As such, these amounts have been excluded from measuring the cost of the acquisition. The result is $4,500 of stock compensation which is being recognized on a straight-line basis over the four year service period. Future cash payments and stock issuances that are not contingent on continuous service are included in the calculation of consideration. The total consideration is $10,043 after discounting the future guaranteed fixed payments to their present value. Additionally, since this was treated as an asset acquisition, the Company included $97 of transaction costs in the total consideration. The table below reconciles the payments and issuances to total consideration transferred after discounting the future payments to present value.
ConsiderationPresent Value
Cash consideration$3,000 $3,000 
Issuance of common stock2,274 2,274 
Anniversary payments5,500 4,672 
Transaction costs97 97 
Total consideration transferred$10,871 $10,043 

As result of this asset acquisition, the Company recorded a trademark asset in the amount of $520 with an indefinite useful life and an intellectual property asset relating to software acquired of $9,523 which is being amortized over a useful life of ten years.

Kevin Unger, a member of the Company’s Board of Directors (the “Board”) through April 28, 2023, was one of the sellers in the transaction. As a result, the Board formed a special committee comprised of independent and disinterested directors (the “Special Committee”) with the exclusive authority to review, evaluate, and negotiate, or reject, the potential MedTech acquisition. The Purchase Agreement and the transactions contemplated thereby were approved by both the Special Committee and the full Board (with Mr. Unger abstaining).
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill

Changes in the carrying amount of goodwill for the three months ended March 31, 2024 were as follows:
Total
Goodwill at January 1, 2024$83,699 
Boston O&P acquisition9,047 
Foreign currency translation impact(1,265)
Goodwill at March 31, 2024
$91,481 

Intangible Assets

As of March 31, 2024, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents11.0 years$44,969 $(11,619)$33,350 
Intellectual Property & Capitalized Software8.9 years16,027 (2,911)13,116 
Customer Relationships & Other12.1 years22,417 (3,675)18,742 
License Agreements3.6 years10,733 (5,559)5,174 
Total amortizable assets$94,146 $(23,764)$70,382 
As of December 31, 2023, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents11.2 years$45,646 $(11,008)$34,638 
Intellectual Property & Capitalized Software9.1 years16,026 (2,524)13,502 
Customer Relationships & Other12.4 years18,862 (3,270)15,592 
License Agreements3.8 years10,733 (5,190)5,543 
Total amortizable assets$91,267 $(21,992)$69,275 

Licenses are tied to product launches and do not begin amortizing until the product is launched to the market.

Trademarks are non-amortizing intangible assets which were $18,792 and $15,287 as of March 31, 2024 and December 31, 2023, respectively. Trademarks are recorded in Other intangible assets on the condensed consolidated balance sheets. The change in balance during the three months ended March 31, 2024 was driven by foreign currency translation adjustments and the Boston O&P acquisition.
During 2023, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the Company completed a quantitative analysis whereby we determined the fair value of the ApiFix trademark asset was below the carrying value. We recorded an impairment charge of $985 for the year ended December 31, 2023 to reduce the carrying amount of the intangible asset to its estimated fair value.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE OF FINANCIAL INSTRUMENTS
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.

The following tables summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023.
March 31, 2024
Level 1Level 2Level 3Total
Financial Assets
Short-term investments
Certificates of Deposit$— $26,141 $— $26,141 
December 31, 2023
Level 1Level 2Level 3Total
Financial Assets
Short-term investments
Certificates of Deposit$— $25,792 $— $25,792 
Exchange Trade Mutual Funds$5,015 $— $— $5,015 
Treasury Bonds$18,235 $— $— $18,235 
Other$207 $— $— $207 

The Company's Level 1 assets consist of short-term, liquid investments with original maturity of three months or less at inception and other short-term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months.

The Company's Level 2 assets pertain to certain asset-backed securities, collateralized by non-mortgage-related consumer debt, or certificates of deposit. These securities are predominately priced by third parties, either by a pricing vendor or dealer with significant inputs observable in active markets.
The Company's Level 3 instruments consist of contingent consideration. The fair value of the contingent consideration liability assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as forecasted annual revenues, expected volatility and discount rates. The contingent consideration was zero as of both March 31, 2024 and December 31, 2023.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT AND CREDIT ARRANGEMENTS
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT AND CREDIT ARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS
Long-term debt consisted of the following as of the dates indicated:
March 31, 2024December 31, 2023
Term loan and final payment$10,300 $10,300 
Mortgage payable to affiliate726 763 
Acquisition note payable261 — 
Total debt11,287 11,063 
Less: debt discount and issuance costs982 1,003 
Less: current maturities154 152 
Long-term debt, net of current maturities$10,151 $9,908 

On December 29, 2023, the Company entered into an $80 million Credit, Security and Guaranty Agreement (the “Credit Agreement”) by and among (i) the Company and other borrowers party to the Credit Agreement (collectively, the “Borrowers”), (ii) MidCap Funding IV Trust, as Agent (“Agent”), (iii) MidCap Financial Trust, as Term Loan Servicer (“Servicer”), and (iv) the financial institutions or other entities from time to time party thereto as Lenders (collectively, “Lenders”). Under the terms of the Credit Agreement, the Lenders have provided to Borrowers a term loan in an aggregate principal amount that will not exceed $30 million available in three tranches of $10 million each subject to certain draw conditions (the “Term Loan”) and a revolving loan in an aggregate principal amount that will not exceed $50 million (the “Revolving Loan”). Borrowings are available subject to certain levels of working capital for the Revolving Loan. The second tranche of the Term Loan is eligible to be drawn between July 1, 2024 through June 30, 2025. The third tranche of the Term Loan is eligible to be drawn between January 1, 2025 through June 30, 2025. The Company must meet certain cash usage requirements at the time of each draw to be eligible to access these term loans. Interest on the Term Loan will accrue at the greater of (a) One Month Term SOFR plus 6.50% or (b) 9.0% and interest on the Revolving Loan will accrue at the greater of (a) One Month Term SOFR plus 4.0% or (b) 6.50% (the “Applicable Rate”) and
will be payable monthly by the Borrowers. The Term Loans may be prepaid in full through December 29, 2024 with payment of a 3.00% prepayment premium, after which they may be prepaid in full through December 29, 2025 with payment of a 2.00% prepayment premium, after which they may be prepaid in full through December 29, 2026 with payment of a 1.00% prepayment premium, after which they may be prepaid in full with no prepayment premium. An additional final payment of 3.00% ("Final Payment") of the amount of the Terms Loans advanced by the Lenders will be due upon prepayment or repayment of the Terms Loans in full, and is accounted for as debt discount. The first tranche of $10 million was issued under the Term Loan upon execution. Payments of principal and all accrued but unpaid interest will be due and payable upon the earlier of: (i) December 1, 2028; (ii) the occurrence of any transaction or series of transactions pursuant to which any person or entity in the aggregate acquire(s) 35% or more of the voting capital stock of the Company; (iii) a change in the majority of the Company’s Board of Directors over a 12-month period; (iv) the Company ceases to own directly or indirectly, 100% of the capital stock of any of its subsidiaries (with the exception of any subsidiaries permitted to be dissolved, merged or otherwise disposed of by the Credit Agreement), or (v) the occurrence of a change in control, fundamental change, deemed liquidation event or terms of similar import under any document or instrument governing or relating to debt of or equity interests of the Company. The loans under the Credit Agreement are secured by a security interest in the Company’s and other Borrowers' assets. The Credit Agreement provides for customary events of default. If an event of default is not cured within the time periods specified (if any), the Lenders and Agent have the right to accelerate the Company’s payment of principal and interest in addition to other rights and remedies.

The Credit Agreement includes certain customary non-financial covenants, and also include certain financial covenants related to the Company achieving minimum revenue targets over a trailing twelve month period. The Credit Agreement was amended on May 3, 2024 to clarify the inputs into the financial covenant calculations. No other changes were made to the Credit Agreement. The Company was in compliance with all covenants under the Credit Agreement, as amended, as of March 31, 2024 and December 31, 2023.

The debt facilities available under the Credit Agreement replace the Fourth Amended and Restated Loan and Security Agreement with Squadron Capital, LLC ("Squadron"), (as amended, the “Squadron Loan Agreement”), which provided the Company with a $50 million revolving credit facility. During the year ended December 31, 2023, there was no indebtedness outstanding under the Squadron Loan Agreement and it was terminated in connection with the Credit Agreement.

Borrowings under the Squadron Loan Agreement accrued interest at an annual rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%, and the Company was permitted to make interest only payments on amounts outstanding. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company paid Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee was payable quarterly in arrears.

Borrowings under the Squadron Loan Agreement were made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note matured at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Squadron Loan Agreement were secured by substantially all of the Company's assets and were unconditionally guaranteed by each of its subsidiaries with the exception of Vilex in Tennessee, Inc. ("Vilex"). There were no traditional financial covenants associated with the Squadron Loan Agreement. However, there were negative covenants that prohibited us from, among other things,
transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions.

In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. At March 31, 2024, the mortgage balance was $726 of which current principal of $154 was included in the current portion of long-term debt. As of December 31, 2023, the mortgage balance was $763 of which current principal due of $152 was included in the current portion of long-term debt.

The aggregate interest expense relating to the notes payable to Squadron, the mortgage note payable to Tawani Enterprises Inc. and the term loan with MidCap was $339 and $11 for the three months ended March 31, 2024 and 2023, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss).

For the three months ended March 31, 2024, the income tax benefit was $2,531 compared to $574 for the three months ended March 31, 2023. Our effective income tax rate was (24.5)% and (7.8)% for the three months ended March 31, 2024 and 2023, respectively. The higher effective rate compared to the prior period is from the remeasurement of the valuation allowance subsequent to recording the deferred tax liability as a result of the purchase accounting from the Boston O&P acquisition.

The deferred tax assets were fully offset by a valuation allowance at March 31, 2024 and December 31, 2023, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix, Ltd. ("ApiFix") and Pega Medical. See Note 3 under Item 8 in the Company's Annual Report on Form 10-K for additional information regarding the ApiFix business combination. The Company has recorded a tax benefit during the period ended March 31, 2024 for losses generated in Canada and Israel, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Restricted Stock

Our restricted stock activity and related information are summarized as follows:
Weighted-AverageWeighted-Average
RestrictedRemainingRestrictedRemaining
StockContractual TermsStockContractual Terms
Awards(in Years)Units(in Years)
Outstanding at January 1, 2024592,453 1.613,851 1.7
Granted165,473 7,900 
Forfeited(3,470)(100)
Vested(82,659)— 
Outstanding at March 31, 2024
671,797 1.921,651 1.9
At March 31, 2024, there was $16,757 of unrecognized compensation expense remaining related to our service-based restricted stock awards and restricted stock units. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.9 years or earlier upon an elimination of the restriction period as a result of a change in control event.
Stock-based compensation expense on restricted stock amounted to $2,799 and $1,959 for the three months ended March 31, 2024 and 2023, respectively.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
The following is a reconciliation of basic and diluted net loss per share:
Three Months Ended
March 31,
20242023
Net loss$(7,805)$(6,806)
Weighted average shares outstanding for basic and diluted22,820,779 22,506,024 
Net loss per share - basic and diluted$(0.34)$(0.30)

Our basic and diluted net loss per share is computed using the two-class method.  For purposes of our equity disclosures and calculation of weighted average shares for basic earnings per share calculations, the two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. 
The contingently issuable shares in the paragraph above do not include shares of our common stock associated with our obligation to issue a variable number of our common shares as a result of our recent acquisitions of Pega Medical, ApiFix or MedTech. See Note 3 for additional information regarding our commitment to issue future equity under the MedTech acquisition. Additionally, as a component of the acquisition of ApiFix, the Company is obligated to make anniversary installment payments on the second, third and fourth anniversary of the acquisition date. These payments included a minimum cash component with the remaining settled in common stock. See Note 3 under Item 8 in the Company's Annual Report on Form 10-K for additional information regarding this business combination.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
BUSINESS SEGMENT BUSINESS SEGMENT
Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reportable segment, which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No individual customer accounted for more than 10% of total product sales for the three months ended March 31, 2024 or 2023.
No individual customer accounted for more than 10% of consolidated accounts receivable as of March 31, 2024 and December 31, 2023.

Product sales by source were as follows:
Three Months Ended March 31,
Product sales by geographic location:20242023
U.S.$34,305 $23,800 
International10,380 7,788 
Total$44,685 $31,588 
Three Months Ended March 31,
Product sales by category:20242023
Trauma and deformity$33,302 $23,395 
Scoliosis10,203 7,072 
Sports medicine/other1,180 1,121 
Total$44,685 $31,588 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RELATED PARTY TRANSACTIONS
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONSIn addition to the expired debt and credit agreements and mortgage with Squadron (the Company's largest investor) and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $382 and $246 for the three months ended March 31, 2024 and 2023, respectively
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EMPLOYEE BENEFIT PLAN
 3 Months Ended
Mar. 31, 2024
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. Additionally, employees of MD Ortho receive contribution matches up to 3% of their salary.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Leases

As of March 31, 2024, the Company has recorded a lease liability of $2,235 and corresponding right-of-use asset of $2,529 on its condensed consolidated balance sheet. We assumed $1,749 of operating right-of-use assets and $1,582 of total lease liabilities in connection with our acquisition of Boston O&P.

Legal Proceedings

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.
IMED Surgical - Software Ownership Dispute

On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron, and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company ("IMED"), in Broward County, Florida Circuit Court. In the lawsuit, IMED claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).

In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point & Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent. According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with IMED. IMED, among other things, requests that the defendants be ordered to convey and assign to IMED all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants.

On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent IMED desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, IMED initiated an arbitration proceeding; however, IMED failed to pay the fees it was required to pay for the arbitration to continue, resulting in the arbitration panel terminating the arbitration proceedings in mid-October 2022. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to IMED before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order.

On February 3, 2023, the Court partially lifted the stay in this case for the sole purpose of, as clarified by the Court's order on March 7, 2023, "permitting any party to argue any motion challenging the events that occurred which led to the arbitration panel's termination order." No filing was made in response to that order. No further filings were made in this case until October 30, 2023, when defendants filed a motion to dismiss.

On December 12, 2023, the Court ordered IMED has until March 13, 2024, to appear before the Court and show cause why this case should not be dismissed for failure to pursue arbitration consistent with the Court’s orders. On March 13, 2024, a hearing took place to discuss the status of IMED’s effort to re-initiate arbitration. Thereafter, on March 25, 2024, the court ordered, if, by April 27, 2024, IMED has not begun arbitration, resolved this case, or substantiated (in the form of an attorney and client declaration) that it has executed an agreement with a litigation funder to pay for arbitration proceedings, to pay the balance due to the subject arbitration association and to re-instate the arbitration, the Court will dismiss this case without prejudice. On April 26, 2024, IMED informed the Court it has executed an agreement with a litigation funder to pay for arbitration proceedings, to pay the balance due to the subject arbitration association, and to reinstate the arbitration, and is in the final stages of resolving the balance due to the subject arbitration association.
Although we believe the Company has strong defenses to the IMED lawsuit and we intend to vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.

Boston O&P Litigation

This lawsuit arises from the alleged wrongful death of a patient following his January 2016, tracheal and laryngeal resection procedure at Boston Children’s Hospital, which was performed by two physicians named as defendants in the suit. The Plaintiffs allege that as a result of the patient’s post-operative care, which included placing his neck in a position of flexion in a modified brace provided by Boston O&P, the patient was paralyzed, and years later, he died due to complications caused by his paralysis. The Company acquired all of the outstanding shares of Boston O&P on January 5, 2024 as described more fully under Note 3 - Business Combinations and Asset Acquisitions.

The lawsuit commenced in December 2018, in Suffolk Superior Court in Boston, Massachusetts. The Plaintiffs assert counts of negligence against each individual defendant, lack of informed consent against the physician defendants, failure to warn, breach of warranty and alleged improper use against Boston O&P, and loss of consortium against all defendants. Trial is currently scheduled to begin in December 2025.

Although we believe Boston O&P has strong defenses to this lawsuit and we intend to vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

Purchase Obligations and Performance Requirements

As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASHTM Navigation platform during 2021, the Company agreed to a minimum purchase commitment for the first twelve months of that agreement. Additionally, the contract requires future purchase commitments based upon a percentage of historical purchases. As a result and as of March 31, 2024, the remaining purchase commitment under the agreement was $1,820 for the year ended December 31, 2024 and $1,456 for the year ended December 31, 2025.

On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three months ended March 31, 2024, the Company recorded an expense of $542 based on current estimates. The Company recorded $300 of expense for the three months ended March 31, 2023.

Royalties

As of March 31, 2024, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales.
We have products in development that have royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of March 31, 2024, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENT
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENT
ApiFix Acquisition Installment Payment

On April 1, 2024, the fourth-year anniversary of the acquisition of ApiFix, the Company paid $2,250 in cash and issued 245,812 shares of the Company's common stock, representing $6,929 of fair value (based on the April 1, 2024 closing share price of $28.19), to fulfill its installment obligation to ApiFix. This was the third and final installment payment paid since the acquisition.

MedTech Anniversary Payment
On May 1, 2024, the first-year anniversary of the acquisition of MedTech, the Company paid $1,250 in cash and issued 42,882 shares of the Company's common stock, representing $1,331 of fair value (based on the May 1, 2024 closing share price of $31.04), to fulfill its installment obligation to MedTech. This was the first installment payment paid since the acquisition.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net loss $ (7,805) $ (6,806)
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2023 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 8, 2024. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of
operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.
The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern.
Use of Estimates
Use of Estimates
Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
Reclassification
Reclassification
In the condensed consolidated financial statements, the Company has reclassified stock-based compensation to conform to the current period presentation. All stock-based compensation was previously recorded within general and administrative expenses, and such costs have now been allocated between general and administrative expenses, research and development expenses and sales and marketing expenses. The current presentation results in stock-based compensation expense being recorded in the same manner in which the award recipient's payroll costs are classified. This reclassification did not affect previously reported total operating expenses, loss before income taxes, or net loss in the condensed consolidated statements of operations.
Financial Instruments
Financial Instruments and Concentration of Credit Risk
Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds.
Concentration of Credit Risk
Financial Instruments and Concentration of Credit Risk
Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

In October 2023, the FASB issued ASU No. 2023-06 "Disclosure Improvements - Codification Amendments in Response to SEC's Disclosure Update and Simplification Initiative". This amendment modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. For entities subject to the SEC's existing disclosure requirements and entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. Amendments in this Update should be applied prospectively. The Company continues to analyze this ASU. The update is specific to disclosures and, therefore, is not expected to have a material impact to the condensed consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The standard requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. This authoritative guidance will be effective for us in fiscal 2024 for annual periods and in the first quarter of fiscal 2025 for interim periods, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures.
In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09), which enhances the transparency and decision usefulness of income tax disclosures. The ASU is effective for public companies for fiscal years beginning on or after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Reclassifications
The following tables present the impact of the reclassification on our condensed consolidated statements of operations:
Three Months Ended March 31, 2023
Sales and marketing (prior presentation)$12,216 
Reclassification333 
Sales and marketing (new presentation)$12,549 
Three Months Ended March 31, 2023
General and administrative (prior presentation)$17,666 
Reclassification(509)
General and administrative (new presentation)$17,157 
Three Months Ended March 31, 2023
Research and development (prior presentation)$2,270 
Reclassification176 
Research and development (new presentation)$2,446 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the total consideration paid for Boston O&P and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

Fair value of estimated total acquisition consideration$22,000 
Assets
Cash1,307 
Accounts receivable - trade2,876 
Inventories1,093 
Prepaid expenses and other current assets378 
Property and equipment4,360 
Amortizable intangible assets3,720 
Other intangible assets3,650 
Other non-current assets2,208 
Total assets19,592 
Liabilities
Accounts payable-trade581 
Other current liabilities2,063 
Long-term debt724 
Deferred tax liability2,268 
Other non-current liabilities1,003 
Total liabilities6,639 
Less: total net assets12,953 
Goodwill$9,047 
Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination
The fair value of identifiable intangible assets and certain long-lived assets were based on valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:
AmountRemaining Economic Useful Life
Trademarks / Names$3,650 Indefinite
Customer Relationships & Other 3,720 12 years
$7,370 
Schedule of Business Acquisition, Pro Forma Information
The following table represents the pro forma net revenue and net loss assuming the acquisition of Boston O&P occurred on January 1, 2023.
Three Months Ended March 31,
20242023
Net revenue$45,116 $38,435 
Net loss$(7,786)$(6,690)
Schedule of Total Consideration Transferred after Discounting Future Payments The table below reconciles the payments and issuances to total consideration transferred after discounting the future payments to present value.
ConsiderationPresent Value
Cash consideration$3,000 $3,000 
Issuance of common stock2,274 2,274 
Anniversary payments5,500 4,672 
Transaction costs97 97 
Total consideration transferred$10,871 $10,043 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
Changes in the carrying amount of goodwill for the three months ended March 31, 2024 were as follows:
Total
Goodwill at January 1, 2024$83,699 
Boston O&P acquisition9,047 
Foreign currency translation impact(1,265)
Goodwill at March 31, 2024
$91,481 
Schedule of the Balances of Amortizable Intangible Assets
As of March 31, 2024, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents11.0 years$44,969 $(11,619)$33,350 
Intellectual Property & Capitalized Software8.9 years16,027 (2,911)13,116 
Customer Relationships & Other12.1 years22,417 (3,675)18,742 
License Agreements3.6 years10,733 (5,559)5,174 
Total amortizable assets$94,146 $(23,764)$70,382 
As of December 31, 2023, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents11.2 years$45,646 $(11,008)$34,638 
Intellectual Property & Capitalized Software9.1 years16,026 (2,524)13,502 
Customer Relationships & Other12.4 years18,862 (3,270)15,592 
License Agreements3.8 years10,733 (5,190)5,543 
Total amortizable assets$91,267 $(21,992)$69,275 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023.
March 31, 2024
Level 1Level 2Level 3Total
Financial Assets
Short-term investments
Certificates of Deposit$— $26,141 $— $26,141 
December 31, 2023
Level 1Level 2Level 3Total
Financial Assets
Short-term investments
Certificates of Deposit$— $25,792 $— $25,792 
Exchange Trade Mutual Funds$5,015 $— $— $5,015 
Treasury Bonds$18,235 $— $— $18,235 
Other$207 $— $— $207 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT AND CREDIT ARRANGEMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Long-term debt consisted of the following as of the dates indicated:
March 31, 2024December 31, 2023
Term loan and final payment$10,300 $10,300 
Mortgage payable to affiliate726 763 
Acquisition note payable261 — 
Total debt11,287 11,063 
Less: debt discount and issuance costs982 1,003 
Less: current maturities154 152 
Long-term debt, net of current maturities$10,151 $9,908 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Activity
Our restricted stock activity and related information are summarized as follows:
Weighted-AverageWeighted-Average
RestrictedRemainingRestrictedRemaining
StockContractual TermsStockContractual Terms
Awards(in Years)Units(in Years)
Outstanding at January 1, 2024592,453 1.613,851 1.7
Granted165,473 7,900 
Forfeited(3,470)(100)
Vested(82,659)— 
Outstanding at March 31, 2024
671,797 1.921,651 1.9
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders
The following is a reconciliation of basic and diluted net loss per share:
Three Months Ended
March 31,
20242023
Net loss$(7,805)$(6,806)
Weighted average shares outstanding for basic and diluted22,820,779 22,506,024 
Net loss per share - basic and diluted$(0.34)$(0.30)
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Schedule of Product Sales by Geographic Location Product sales by source were as follows:
Three Months Ended March 31,
Product sales by geographic location:20242023
U.S.$34,305 $23,800 
International10,380 7,788 
Total$44,685 $31,588 
Schedule of Product Sales by Category
Three Months Ended March 31,
Product sales by category:20242023
Trauma and deformity$33,302 $23,395 
Scoliosis10,203 7,072 
Sports medicine/other1,180 1,121 
Total$44,685 $31,588 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Accumulated deficit $ 205,547 $ 197,742
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reclassifications (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Reclassification [Line Items]    
Sales and marketing $ 14,169 $ 12,549
General and administrative 24,730 17,157
Research and development $ 2,998 2,446
Previously Reported    
Reclassification [Line Items]    
Sales and marketing   12,216
General and administrative   17,666
Research and development   2,270
Reclassification    
Reclassification [Line Items]    
Sales and marketing   333
General and administrative   (509)
Research and development   $ 176
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narratives (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 05, 2024
USD ($)
individual
$ / shares
shares
Jul. 01, 2023
USD ($)
$ / shares
shares
May 01, 2023
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
$ / shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
$ / shares
Business Acquisition            
Cash paid to acquire       $ 20,693 $ 0  
Common stock, par value (in dollars per share) | $ / shares       $ 0.00025   $ 0.00025
Rhino Pediatric Orthopedic Designs, Inc.            
Business Acquisition            
Total consideration transferred   $ 1,024        
Cash consideration   546        
Asset acquisition   46        
Issuance of common stock   $ 478        
Medtech Concepts LLC            
Business Acquisition            
Total consideration transferred     $ 15,274      
Cash consideration     3,000      
Asset acquisition     97      
Issuance of common stock     $ 2,274      
Business combination, consideration paid In cash (as a percent)     50.00%      
Stock based compensation capitalized     $ 4,500      
Stock based compensation service period (in years)     4 years      
Total consideration transferred     $ 10,871      
Present Value | Medtech Concepts LLC            
Business Acquisition            
Cash consideration     3,000      
Asset acquisition     97      
Issuance of common stock     2,274      
Total consideration transferred     10,043      
Intellectual Property & Capitalized Software | Medtech Concepts LLC            
Business Acquisition            
Finite-lived intangible assets acquired     $ 9,523      
Intangible asset, useful life (in years)     10 years      
Trademarks | Medtech Concepts LLC            
Business Acquisition            
Indefinite-lived intangible assets acquired     $ 520      
Common Stock | Rhino Pediatric Orthopedic Designs, Inc.            
Business Acquisition            
Asset acquisition, consideration (in shares) | shares   11,133        
Common stock, par value (in dollars per share) | $ / shares   $ 0.00025        
Asset Acquisition, acquisition price (per share) | $ / shares   $ 42.91        
Common Stock | Medtech Concepts LLC            
Business Acquisition            
Asset acquisition, consideration (in shares) | shares     43,751      
Common stock, par value (in dollars per share) | $ / shares     $ 0.00025      
Asset Acquisition, acquisition price (per share) | $ / shares     $ 51.98      
Aggregate value of equity consideration     $ 2,500      
Business combination, consideration of unregistered common stock (as a percent)     50.00%      
Boston Brace International, Inc.            
Business Acquisition            
Cash paid to acquire $ 22,000          
Issuance of common stock $ 2,500          
Boston Brace International, Inc. | Restricted Stock            
Business Acquisition            
Vesting period (in years) 3 years          
Business combination, number of individuals received restricted stock awards | individual 170          
Consideration for acquisition (in shares) | shares 83,000          
Share acquisition price (in dollars per share) | $ / shares $ 30.12          
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
Jan. 05, 2024
Mar. 31, 2024
Dec. 31, 2023
Liabilities      
Goodwill   $ 91,481 $ 83,699
Boston Brace International, Inc.      
Business Acquisition      
Fair value of estimated total acquisition consideration $ 22,000    
Assets      
Cash 1,307    
Accounts receivable - trade 2,876    
Inventories 1,093    
Prepaid expenses and other current assets 378    
Property and equipment 4,360    
Amortizable intangible assets 3,720    
Other intangible assets 3,650    
Other non-current assets 2,208    
Total assets 19,592    
Liabilities      
Accounts payable-trade 581    
Other current liabilities 2,063    
Long-term debt 724    
Deferred tax liability 2,268    
Other non-current liabilities 1,003    
Total liabilities 6,639    
Less: total net assets 12,953    
Goodwill $ 9,047    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) - Boston Brace International, Inc.
$ in Thousands
Jan. 05, 2024
USD ($)
Business Acquisition  
Other intangible assets $ 3,650
Amortizable intangible assets 3,720
Fair value of identifiable intangible assets 7,370
Customer Relationships & Other  
Business Acquisition  
Amortizable intangible assets $ 3,720
Remaining economic useful life (in years) 12 years
Trademarks / Names  
Business Acquisition  
Other intangible assets $ 3,650
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Acquisition, Pro Forma Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]    
Net revenue $ 45,116 $ 38,435
Net loss $ (7,786) $ (6,690)
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Discounting the Future Payments (Details) - Medtech Concepts LLC
$ in Thousands
May 01, 2023
USD ($)
Business Acquisition  
Cash consideration $ 3,000
Issuance of common stock 2,274
Anniversary payments 5,500
Transaction costs 97
Total consideration transferred 10,871
Present Value  
Business Acquisition  
Cash consideration 3,000
Issuance of common stock 2,274
Anniversary payments 4,672
Transaction costs 97
Total consideration transferred $ 10,043
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Goodwill  
Goodwill, beginning balance $ 83,699
Boston O&P acquisition 9,047
Foreign currency translation impact (1,265)
Goodwill, ending balance $ 91,481
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets, Net [Abstract]    
Gross Intangible Assets $ 94,146 $ 91,267
Accumulated Amortization (23,764) (21,992)
Net Intangible Assets $ 70,382 $ 69,275
Patents    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 11 years 11 years 2 months 12 days
Gross Intangible Assets $ 44,969 $ 45,646
Accumulated Amortization (11,619) (11,008)
Net Intangible Assets $ 33,350 $ 34,638
Intellectual Property & Capitalized Software    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 8 years 10 months 24 days 9 years 1 month 6 days
Gross Intangible Assets $ 16,027 $ 16,026
Accumulated Amortization (2,911) (2,524)
Net Intangible Assets $ 13,116 $ 13,502
Customer Relationships & Other    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 12 years 1 month 6 days 12 years 4 months 24 days
Gross Intangible Assets $ 22,417 $ 18,862
Accumulated Amortization (3,675) (3,270)
Net Intangible Assets $ 18,742 $ 15,592
License Agreements    
Finite-Lived Intangible Assets, Net [Abstract]    
Weighted-Average Amortization Period 3 years 7 months 6 days 3 years 9 months 18 days
Gross Intangible Assets $ 10,733 $ 10,733
Accumulated Amortization (5,559) (5,190)
Net Intangible Assets $ 5,174 $ 5,543
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Mar. 31, 2024
Business Acquisition    
Other intangible assets $ 15,287 $ 18,792
Trademarks    
Business Acquisition    
Other intangible assets 15,287 $ 18,792
Trademarks | ApiFix Ltd    
Business Acquisition    
Trademark impairment $ 985  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments $ 26,141 $ 25,792
Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   5,015
Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   18,235
Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   207
Level 1 | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments 0 0
Level 1 | Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   5,015
Level 1 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   18,235
Level 1 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   207
Level 2 | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments 26,141 25,792
Level 2 | Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   0
Level 2 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   0
Level 2 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   0
Level 3 | Certificates of Deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments $ 0 0
Level 3 | Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   0
Level 3 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   0
Level 3 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short-term investments   $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument    
Long term debt $ 11,287 $ 11,063
Less: debt discount and issuance costs 982 1,003
Less: current maturities 154 152
Long-term debt, net of current maturities 10,151 9,908
Revolving Credit Facility | Term Loan    
Debt Instrument    
Long term debt 10,300 10,300
Mortgage payable to affiliate    
Debt Instrument    
Long term debt 726 763
Less: current maturities 154 152
Acquisition note payable | Acquisition note payable    
Debt Instrument    
Long term debt $ 261 $ 0
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)
 3 Months Ended
Dec. 29, 2023
USD ($)
tranche
Jun. 13, 2022
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Debt Instrument          
Mortgage balance     $ 10,151,000   $ 9,908,000
Current portion of long-term debt with affiliate     154,000   152,000
Interest expense     339,000 $ 11,000  
Long term debt     $ 11,287,000   11,063,000
Mortgage payable to affiliate          
Debt Instrument          
Interest rate (as a percent)     5.00%    
Monthly interest and principal installments     $ 16,000    
Current portion of long-term debt with affiliate     154,000   152,000
Long term debt     726,000   763,000
Revolving Credit Facility | Security and Guaranty Agreement          
Debt Instrument          
Long term debt face amount $ 80,000,000        
Debt instrument, maximum distribution per tranche $ 30,000,000        
Debt instrument, number of tranches | tranche 3        
Revolving Credit Facility | Term Loan          
Debt Instrument          
Debt instrument, maximum distribution per tranche $ 10,000,000        
Proceeds from lines of credit $ 10,000,000        
Debt instrument, debt repayment trigger, as a basis of capital stock ownership (percent) 35.00%        
Long term debt     10,300,000   $ 10,300,000
Revolving Credit Facility | Revolving Loan          
Debt Instrument          
Debt instrument, maximum distribution per tranche $ 50,000,000        
Percentage of prepayment of facility (percent) 3.00%        
Revolving Credit Facility | Revolving Loan | Option One          
Debt Instrument          
Interest rate (as a percent) 9.00%        
Revolving Credit Facility | Revolving Loan | Option Two          
Debt Instrument          
Applicable debt rate (percent) 6.50%        
Revolving Credit Facility | Revolving Loan | Option Three          
Debt Instrument          
Debt prepayment premium (percent) 3.00%        
Revolving Credit Facility | Revolving Loan | Option Four          
Debt Instrument          
Debt prepayment premium (percent) 2.00%        
Revolving Credit Facility | Revolving Loan | Option Five          
Debt Instrument          
Debt prepayment premium (percent) 1.00%        
Revolving Credit Facility | Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Option One          
Debt Instrument          
Debt instrument, basis spread on variable rate (as a percent) 6.50%        
Revolving Credit Facility | Revolving Loan | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Option Two          
Debt Instrument          
Debt instrument, basis spread on variable rate (as a percent) 4.00%        
Revolving Credit Facility | Fourth Amended Loan Agreement          
Debt Instrument          
Interest rate (as a percent)   10.00%      
Revolving credit facility     $ 50,000,000    
Unused commitment fee percentage (as a percent)   0.50%      
Revolving Credit Facility | Fourth Amended Loan Agreement | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate          
Debt Instrument          
Debt instrument, basis spread on variable rate (as a percent)   8.69%      
Revolving Credit Facility | Fourth Amended Loan Agreement | Three Month LIBOR          
Debt Instrument          
Debt instrument, basis spread on variable rate (as a percent)   8.61%      
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Income tax benefit $ 2,531 $ 574
Effective income tax rate (as a percent) (24.50%) (7.80%)
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY - Restricted Stock (Details) - shares
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Restricted Stock    
Restricted Stock    
Outstanding at period start (in shares) 592,453  
Granted (in shares) 165,473  
Forfeited (in shares) (3,470)  
Vested (in shares) (82,659)  
Outstanding at period end (in shares) 671,797 592,453
Weighted-Average Remaining Contractual Terms (in Years)    
Weighted-average remaining contractual terms (in years) 1 year 10 months 24 days 1 year 7 months 6 days
Restricted Stock Units (RSUs)    
Restricted Stock    
Outstanding at period start (in shares) 13,851  
Granted (in shares) 7,900  
Forfeited (in shares) (100)  
Vested (in shares) 0  
Outstanding at period end (in shares) 21,651 13,851
Weighted-Average Remaining Contractual Terms (in Years)    
Weighted-average remaining contractual terms (in years) 1 year 10 months 24 days 1 year 8 months 12 days
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award    
Stock-based compensation $ 2,799 $ 2,113
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award    
Unrecognized compensation expense $ 16,757  
Unrecognized compensation expense, weighted average period of recognition (in years) 1 year 10 months 24 days  
Stock-based compensation $ 2,799 $ 1,959
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net loss $ (7,805) $ (6,806)
Weighted average shares outstanding for basic (in shares) 22,820,779 22,506,024
Weighted average common stock - diluted (in shares) 22,820,779 22,506,024
Net loss per share - basic (in dollars per share) $ (0.34) $ (0.30)
Net loss per share - diluted (in dollars per share) $ (0.34) $ (0.30)
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
segment
Segment Reporting [Abstract]  
Number of operating segments 1
Number of reportable segments 1
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues from External Customers and Long-Lived Assets    
Total $ 44,685 $ 31,588
U.S.    
Revenues from External Customers and Long-Lived Assets    
Total 34,305 23,800
International    
Revenues from External Customers and Long-Lived Assets    
Total $ 10,380 $ 7,788
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BUSINESS SEGMENT - Schedule of Revenue by Category (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information    
Total $ 44,685 $ 31,588
Trauma and deformity    
Segment Reporting Information    
Total 33,302 23,395
Scoliosis    
Segment Reporting Information    
Total 10,203 7,072
Sports medicine/other    
Segment Reporting Information    
Total $ 1,180 $ 1,121
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
RELATED PARTY TRANSACTIONS (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
supplier
Mar. 31, 2023
USD ($)
Structure Medical, LLC | Supplier    
Related Party Transaction    
Payments to related party | $ $ 382 $ 246
Affiliated Entity    
Related Party Transaction    
Number of related party suppliers | supplier 1  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EMPLOYEE BENEFIT PLAN - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
Business Acquisition  
Employer contribution as a percentage of employees' salary (as a percent) 4.00%
MD Orthopaedics  
Business Acquisition  
Employer contribution as a percentage of employees' salary (as a percent) 3.00%
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jul. 20, 2021
Dec. 31, 2019
Jun. 30, 2019
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Long-term Purchase Commitment            
Operating lease liability       $ 2,235    
Operating lease, right-of-use asset       $ 2,529    
Operating Lease, Liability, Current, Statement of Financial Position       Other long-term liabilities   Other long-term liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position       Assets, Noncurrent, Excluding Property, Plant And Equipment   Assets, Noncurrent, Excluding Property, Plant And Equipment
Purchase obligation, to be paid, remainder of fiscal year       $ 1,820    
Purchase obligation, to be paid, year one       1,456    
Cost of revenue       $ 12,511 $ 8,027  
Minimum            
Long-term Purchase Commitment            
Royalty agreement percentage (as a percent)       0.50%    
Maximum            
Long-term Purchase Commitment            
Royalty agreement percentage (as a percent)       20.00%    
Firefly Technology | License Agreements            
Long-term Purchase Commitment            
Finite lived intangible asset useful life extension period (in years) 5 years          
Cost of revenue       $ 542    
Trademark impairment         $ 300  
Squadron Capital LLC | Team Note B | Affiliated Entity            
Long-term Purchase Commitment            
Repayments of related party debt   $ 25,000        
Boston O&P            
Long-term Purchase Commitment            
Operating lease liability       1,582    
Operating lease, right-of-use asset       $ 1,749    
Vilex and Orthex            
Long-term Purchase Commitment            
Fair value of estimated total acquisition consideration     $ 60,000      
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENT (Details) - Subsequent Event
$ / shares in Units, $ in Thousands
Apr. 01, 2024
USD ($)
$ / shares
shares
ApiFix Ltd  
Subsequent Event  
Cash consideration $ 2,250
Consideration for acquisition (in shares) | shares 245,812
Issuance of common stock $ 6,929
Share acquisition price (in dollars per share) | $ / shares $ 28.19
Medtech  
Subsequent Event  
Cash consideration $ 1,250
Consideration for acquisition (in shares) | shares 42,882
Share acquisition price (in dollars per share) | $ / shares $ 31.04
EXCEL 68 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 70 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 144 243 1 false 65 0 false 8 false false R1.htm 0000001 - Document - COVER Sheet http://www.orthopediatrics.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - BUSINESS Sheet http://www.orthopediatrics.com/role/BUSINESS BUSINESS Notes 8 false false R9.htm 0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS BUSINESS COMBINATIONS AND ASSET ACQUISITIONS Notes 10 false false R11.htm 0000011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 11 false false R12.htm 0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 12 false false R13.htm 0000013 - Disclosure - DEBT AND CREDIT ARRANGEMENTS Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS Notes 13 false false R14.htm 0000014 - Disclosure - INCOME TAXES Sheet http://www.orthopediatrics.com/role/INCOMETAXES INCOME TAXES Notes 14 false false R15.htm 0000015 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 0000016 - Disclosure - NET LOSS PER SHARE Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 16 false false R17.htm 0000017 - Disclosure - BUSINESS SEGMENT Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENT BUSINESS SEGMENT Notes 17 false false R18.htm 0000018 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 18 false false R19.htm 0000019 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 19 false false R20.htm 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 0000021 - Disclosure - SUBSEQUENT EVENT Sheet http://www.orthopediatrics.com/role/SUBSEQUENTEVENT SUBSEQUENT EVENT Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 25 false false R26.htm 9954473 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables) Tables http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS 26 false false R27.htm 9954474 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS 27 false false R28.htm 9954475 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS 28 false false R29.htm 9954476 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables DEBT AND CREDIT ARRANGEMENTS (Tables) Tables http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS 29 false false R30.htm 9954477 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY 30 false false R31.htm 9954478 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.orthopediatrics.com/role/NETLOSSPERSHARE 31 false false R32.htm 9954479 - Disclosure - BUSINESS SEGMENT (Tables) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables BUSINESS SEGMENT (Tables) Tables http://www.orthopediatrics.com/role/BUSINESSSEGMENT 32 false false R33.htm 9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) Sheet http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) Details 33 false false R34.htm 9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reclassifications (Details) Sheet http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reclassifications (Details) Details 34 false false R35.htm 9954482 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narratives (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narratives (Details) Details 35 false false R36.htm 9954483 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) Details 36 false false R37.htm 9954484 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details) Details 37 false false R38.htm 9954485 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Acquisition, Pro Forma Information (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessAcquisitionProFormaInformationDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Acquisition, Pro Forma Information (Details) Details 38 false false R39.htm 9954486 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Discounting the Future Payments (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Discounting the Future Payments (Details) Details 39 false false R40.htm 9954487 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) Details 40 false false R41.htm 9954488 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details) Details 41 false false R42.htm 9954489 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 42 false false R43.htm 9954490 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) Details 43 false false R44.htm 9954491 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Details 44 false false R45.htm 9954492 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Details 45 false false R46.htm 9954493 - Disclosure - INCOME TAXES (Details) Sheet http://www.orthopediatrics.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.orthopediatrics.com/role/INCOMETAXES 46 false false R47.htm 9954494 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails STOCKHOLDERS' EQUITY - Restricted Stock (Details) Details 47 false false R48.htm 9954495 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY - Narrative (Details) Details 48 false false R49.htm 9954496 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) Details 49 false false R50.htm 9954497 - Disclosure - BUSINESS SEGMENT - Narrative (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails BUSINESS SEGMENT - Narrative (Details) Details 50 false false R51.htm 9954498 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Details 51 false false R52.htm 9954499 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Details 52 false false R53.htm 9954500 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS 53 false false R54.htm 9954501 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails EMPLOYEE BENEFIT PLAN - Narrative (Details) Details 54 false false R55.htm 9954502 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES 55 false false R56.htm 9954503 - Disclosure - SUBSEQUENT EVENT (Details) Sheet http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails SUBSEQUENT EVENT (Details) Details http://www.orthopediatrics.com/role/SUBSEQUENTEVENT 56 false false All Reports Book All Reports kids-20240331.htm kids-20240331.xsd kids-20240331_cal.xml kids-20240331_def.xml kids-20240331_lab.xml kids-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "kids-20240331.htm": { "nsprefix": "kids", "nsuri": "http://www.orthopediatrics.com/20240331", "dts": { "inline": { "local": [ "kids-20240331.htm" ] }, "schema": { "local": [ "kids-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "kids-20240331_cal.xml" ] }, "definitionLink": { "local": [ "kids-20240331_def.xml" ] }, "labelLink": { "local": [ "kids-20240331_lab.xml" ] }, "presentationLink": { "local": [ "kids-20240331_pre.xml" ] } }, "keyStandard": 221, "keyCustom": 22, "axisStandard": 23, "axisCustom": 1, "memberStandard": 34, "memberCustom": 29, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 4 }, "contextCount": 144, "entityCount": 1, "segmentCount": 65, "elementCount": 508, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 472, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.orthopediatrics.com/role/COVER", "longName": "0000001 - Document - COVER", "shortName": "COVER", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R5": { "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R6": { "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R8": { "role": "http://www.orthopediatrics.com/role/BUSINESS", "longName": "0000008 - Disclosure - BUSINESS", "shortName": "BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS", "longName": "0000010 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "0000011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS", "longName": "0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS", "longName": "0000013 - Disclosure - DEBT AND CREDIT ARRANGEMENTS", "shortName": "DEBT AND CREDIT ARRANGEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.orthopediatrics.com/role/INCOMETAXES", "longName": "0000014 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY", "longName": "0000015 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARE", "longName": "0000016 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENT", "longName": "0000017 - Disclosure - BUSINESS SEGMENT", "shortName": "BUSINESS SEGMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS", "longName": "0000018 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN", "longName": "0000019 - Disclosure - EMPLOYEE BENEFIT PLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.orthopediatrics.com/role/SUBSEQUENTEVENT", "longName": "0000021 - Disclosure - SUBSEQUENT EVENT", "shortName": "SUBSEQUENT EVENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables", "longName": "9954473 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954474 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables", "longName": "9954475 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables", "longName": "9954476 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables)", "shortName": "DEBT AND CREDIT ARRANGEMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954477 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables", "longName": "9954478 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables", "longName": "9954479 - Disclosure - BUSINESS SEGMENT (Tables)", "shortName": "BUSINESS SEGMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "longName": "9954480 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails", "longName": "9954481 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reclassifications (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reclassifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-36", "name": "us-gaap:SellingAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R35": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "longName": "9954482 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narratives (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "kids:AssetAcquisitionTotalCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R36": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954483 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-38", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R37": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "longName": "9954484 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Indefinite-Lived Intangible Assets Acquired as Part of Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-40", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-40", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R38": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessAcquisitionProFormaInformationDetails", "longName": "9954485 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Acquisition, Pro Forma Information (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Business Acquisition, Pro Forma Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails", "longName": "9954486 - Disclosure - BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Discounting the Future Payments (Details)", "shortName": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Schedule of Discounting the Future Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-48", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-48", "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R40": { "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "longName": "9954487 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R41": { "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails", "longName": "9954488 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Amortizable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "longName": "9954489 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R43": { "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "9954490 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "longName": "9954491 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R45": { "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "longName": "9954492 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R46": { "role": "http://www.orthopediatrics.com/role/INCOMETAXESDetails", "longName": "9954493 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R47": { "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "longName": "9954494 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-110", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R48": { "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954495 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R49": { "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails", "longName": "9954496 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details)", "shortName": "NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails", "longName": "9954497 - Disclosure - BUSINESS SEGMENT - Narrative (Details)", "shortName": "BUSINESS SEGMENT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "longName": "9954498 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-119", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R52": { "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "longName": "9954499 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-123", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "unique": true } }, "R53": { "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9954500 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-130", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "longName": "9954501 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details)", "shortName": "EMPLOYEE BENEFIT PLAN - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954502 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails", "longName": "9954503 - Disclosure - SUBSEQUENT EVENT (Details)", "shortName": "SUBSEQUENT EVENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-141", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-141", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "kids-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable - trade", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r720" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable - trade, net of allowances of $1,195 and $1,373, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r250", "r251" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r29", "r30", "r90", "r162", "r551", "r573", "r577" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r13", "r30", "r452", "r455", "r485", "r568", "r569", "r828", "r829", "r830", "r841", "r842", "r843" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining economic useful life (in years)", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r109" ] }, "kids_AcquisitionNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AcquisitionNotesMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition note payable", "label": "Acquisition Notes [Member]", "documentation": "Acquisition Notes" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r770" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r85", "r720", "r907" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r419", "r420", "r421", "r589", "r841", "r842", "r843", "r885", "r908" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r776" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r776" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r776" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r776" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity", "label": "Affiliated Entity [Member]" } } }, "auth_ref": [ "r632", "r687", "r726", "r877", "r891", "r892", "r893" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r741", "r752", "r762", "r787" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r744", "r755", "r765", "r790" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r776" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r783" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r748", "r756", "r766", "r783", "r791", "r795", "r803" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r801" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r163", "r252", "r290" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "kids_ApiFixLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "ApiFixLtdMember", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ApiFix Ltd", "label": "ApiFix Ltd. [Member]", "documentation": "ApiFix Ltd." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r880" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total consideration transferred", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r719", "r881", "r882", "r883" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anniversary payments", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r881", "r882", "r883" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r881", "r882", "r883" ] }, "kids_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, consideration (in shares)", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares", "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition", "verboseLabel": "Transaction costs", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r719", "r881", "r882", "r883" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r880" ] }, "kids_AssetAcquisitionEquityConsiderationSettledInCashPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AssetAcquisitionEquityConsiderationSettledInCashPercentage", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, consideration paid In cash (as a percent)", "label": "Asset Acquisition, Equity Consideration Settled In Cash, Percentage", "documentation": "Business Combination, Consideration Paid In Cash, Percentage" } } }, "auth_ref": [] }, "kids_AssetAcquisitionEquityInterestIssuedOrIssuableValueAggregateValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AssetAcquisitionEquityInterestIssuedOrIssuableValueAggregateValue", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate value of equity consideration", "label": "Asset Acquisition, Equity Interest Issued or Issuable, Value Aggregate Value", "documentation": "Asset Acquisition, Equity Interest Issued or Issuable, Value Aggregate Value" } } }, "auth_ref": [] }, "kids_AssetAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AssetAcquisitionSharePrice", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition, acquisition price (per share)", "label": "Asset Acquisition, Share Price", "documentation": "Asset Acquisition, Share Price" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Consideration Transferred after Discounting Future Payments", "label": "Asset Acquisition [Table Text Block]", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": [ "r880" ] }, "kids_AssetAcquisitionTotalCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AssetAcquisitionTotalCompensation", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total consideration transferred", "label": "Asset Acquisition, Total Compensation", "documentation": "Asset Acquisition, Total Compensation" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r125", "r156", "r185", "r228", "r236", "r241", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r447", "r449", "r470", "r548", "r625", "r720", "r732", "r872", "r873", "r894" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r150", "r165", "r185", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r447", "r449", "r470", "r720", "r872", "r873", "r894" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "AssetsNoncurrentExcludingPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other assets", "label": "Assets, Noncurrent, Excluding Property, Plant And Equipment", "documentation": "Assets, Noncurrent, Excluding Property, Plant And Equipment" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r798" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r799" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r794" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r797" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r796" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r795" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r795" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "kids_BostonBraceInternationalInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BostonBraceInternationalInc.Member", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Boston Brace International, Inc.", "label": "Boston Brace International, Inc. [Member]", "documentation": "Boston Brace International, Inc." } } }, "auth_ref": [] }, "kids_BostonOPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BostonOPMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Boston O&P", "label": "Boston O&P [Member]", "documentation": "Boston O&P" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r443", "r715", "r716" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r55", "r56", "r443", "r715", "r716" ] }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity." } } }, "auth_ref": [ "r122" ] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration for acquisition (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": [ "r122" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r443" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisition, Pro Forma Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r810", "r811" ] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionSharePrice", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share acquisition price (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessAcquisitionProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r441", "r442" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSBusinessAcquisitionProFormaInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r441", "r442" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of estimated total acquisition consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r11" ] }, "kids_BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of acquisition installment payable", "label": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Current", "documentation": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Current" } } }, "auth_ref": [] }, "kids_BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Acquisition installment payable, net of current portion", "label": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent", "documentation": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment of contingent consideration", "verboseLabel": "Fair value adjustment of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r446", "r831" ] }, "kids_BusinessCombinationContingentConsiderationChangeInFairValueAccretionOfAcquisitionInstallmentPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BusinessCombinationContingentConsiderationChangeInFairValueAccretionOfAcquisitionInstallmentPayable", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of acquisition installment payable", "label": "Business Combination, Contingent Consideration, Change In Fair Value, Accretion of Acquisition Installment Payable", "documentation": "Business Combination, Contingent Consideration, Change In Fair Value, Accretion of Acquisition Installment Payable" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS COMBINATIONS AND ASSET ACQUISITIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r119", "r444" ] }, "kids_BusinessCombinationEquityConsiderationSettledInSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BusinessCombinationEquityConsiderationSettledInSharesPercentage", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, consideration of unregistered common stock (as a percent)", "label": "Business Combination, Equity Consideration Settled In Shares, Percentage", "documentation": "Business Combination, Consideration Of Unregistered Common Stock, In Percentage" } } }, "auth_ref": [] }, "kids_BusinessCombinationNumberOfIndividualsReceivedRestrictedStockAwards": { "xbrltype": "integerItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "BusinessCombinationNumberOfIndividualsReceivedRestrictedStockAwards", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, number of individuals received restricted stock awards", "label": "Business Combination, Number Of Individuals Received Restricted Stock Awards", "documentation": "Business Combination, Number Of Individuals Received Restricted Stock Awards" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable - trade", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable-trade", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair value of identifiable intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "weight": 1.0, "order": 2.0 }, "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Less: total net assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present Value", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r152", "r692" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r102", "r183" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r102" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of Deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r10", "r727", "r728", "r729", "r730" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r774" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r145", "r159", "r160", "r161", "r185", "r211", "r212", "r214", "r216", "r222", "r223", "r285", "r315", "r317", "r318", "r319", "r322", "r323", "r354", "r355", "r357", "r358", "r360", "r470", "r580", "r581", "r582", "r583", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r613", "r634", "r656", "r671", "r672", "r673", "r674", "r675", "r809", "r834", "r845" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r775" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r775" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r112", "r309", "r310", "r677", "r869" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r723", "r724", "r725", "r727", "r728", "r729", "r730", "r841", "r842", "r885", "r906", "r908" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r613" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r84", "r613", "r631", "r908", "r909" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.00025 par value; 50,000,000 shares authorized; 23,540,411 shares and 23,378,408 shares issued as of March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r550", "r720" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r780" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r779" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r781" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r778" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r31", "r170", "r172", "r176", "r544", "r558" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r74", "r139" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r96", "r528" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r189", "r190", "r328", "r356", "r492", "r694", "r696" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships & Other", "verboseLabel": "Customer Relationships & Other", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r61" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT AND CREDIT ARRANGEMENTS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r113", "r184", "r324", "r330", "r331", "r332", "r333", "r334", "r335", "r340", "r347", "r348", "r350" ] }, "kids_DebtInstrumentApplicableRate": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "DebtInstrumentApplicableRate", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable debt rate (percent)", "label": "Debt Instrument, Applicable Rate", "documentation": "Debt Instrument, Applicable Rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r19", "r80", "r81", "r126", "r127", "r191", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r479", "r704", "r705", "r706", "r707", "r708", "r835" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread on variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "kids_DebtInstrumentDebtRepaymentTriggerAsABasisOfCapitalStockOwnership": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "DebtInstrumentDebtRepaymentTriggerAsABasisOfCapitalStockOwnership", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, debt repayment trigger, as a basis of capital stock ownership (percent)", "label": "Debt Instrument, Debt Repayment Trigger, As a Basis Of Capital Stock Ownership", "documentation": "Debt Instrument, Debt Repayment Trigger, As a Basis Of Capital Stock Ownership" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term debt face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r67", "r69", "r325", "r479", "r705", "r706" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r25", "r326" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r191", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r479", "r704", "r705", "r706", "r707", "r708", "r835" ] }, "kids_DebtInstrumentMaximumDistributionPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "DebtInstrumentMaximumDistributionPerTranche", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, maximum distribution per tranche", "label": "Debt Instrument, Maximum Distribution Per Tranche", "documentation": "Debt Instrument, Maximum Distribution Per Tranche" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r26", "r191", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r479", "r704", "r705", "r706", "r707", "r708", "r835" ] }, "kids_DebtInstrumentNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "DebtInstrumentNumberOfTranches", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, number of tranches", "label": "Debt Instrument, Number of Tranches", "documentation": "Debt Instrument, Number of Tranches" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly interest and principal installments", "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r26", "r73" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r26", "r53", "r54", "r66", "r67", "r69", "r72", "r114", "r115", "r191", "r325", "r326", "r327", "r328", "r329", "r331", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r479", "r704", "r705", "r706", "r707", "r708", "r835" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: debt discount and issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r68", "r336", "r351", "r705", "r706" ] }, "kids_DebtPrepaymentPremium": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "DebtPrepaymentPremium", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt prepayment premium (percent)", "label": "Debt Prepayment Premium", "documentation": "Debt Prepayment Premium" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r118", "r142", "r436", "r437", "r837" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r425", "r426", "r549" ] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution as a percentage of employees' salary (as a percent)", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r231" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r384", "r387", "r415", "r416", "r418", "r718" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r736" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r769" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share - basic (in dollars per share)", "terseLabel": "Net loss per share - basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r177", "r197", "r198", "r200", "r201", "r203", "r209", "r211", "r214", "r215", "r216", "r220", "r460", "r461", "r545", "r559", "r698" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share - diluted (in dollars per share)", "terseLabel": "Net loss per share - diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r177", "r197", "r198", "r200", "r201", "r203", "r211", "r214", "r215", "r216", "r220", "r460", "r461", "r545", "r559", "r698" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r208", "r217", "r218", "r219" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r471" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (as a percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r428" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation capitalized", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r414" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense, weighted average period of recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r417" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r878" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r734" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r734" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r734" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r808" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r734" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r734" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r734" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r734" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r146", "r173", "r174", "r175", "r192", "r193", "r194", "r196", "r204", "r206", "r221", "r286", "r289", "r361", "r419", "r420", "r421", "r432", "r433", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r472", "r473", "r474", "r475", "r476", "r477", "r485", "r568", "r569", "r570", "r589", "r656" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r777" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r741", "r752", "r762", "r787" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r738", "r749", "r759", "r784" ] }, "kids_ExchangeTradeMutualFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "ExchangeTradeMutualFundsMember", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange Trade Mutual Funds", "label": "Exchange Trade Mutual Funds [Member]", "documentation": "Exchange Trade Mutual Funds" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r783" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r463", "r464", "r467" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r463", "r464", "r467" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r338", "r367", "r368", "r369", "r370", "r371", "r372", "r464", "r500", "r501", "r502", "r705", "r706", "r712", "r713", "r714" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r15", "r63", "r338", "r705", "r706" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r463", "r464", "r465", "r466", "r468" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r338", "r705", "r706" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r462" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r338", "r367", "r372", "r464", "r500", "r712", "r713", "r714" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r338", "r367", "r372", "r464", "r501", "r705", "r706", "r712", "r713", "r714" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r338", "r367", "r368", "r369", "r370", "r371", "r372", "r464", "r502", "r705", "r706", "r712", "r713", "r714" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r338", "r367", "r368", "r369", "r370", "r371", "r372", "r500", "r501", "r502", "r705", "r706", "r712", "r713", "r714" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r462", "r468" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r9", "r18" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r349", "r359", "r457", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r557", "r702", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r848", "r849", "r850", "r851" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset, useful life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "kids_FiniteLivedIntangibleAssetUsefulLifeExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "FiniteLivedIntangibleAssetUsefulLifeExtensionPeriod", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite lived intangible asset useful life extension period (in years)", "label": "Finite-Lived Intangible Asset, Useful Life Extension Period", "documentation": "Finite-Lived Intangible Asset, Useful Life Extension Period" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r154", "r306" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r302", "r305", "r306", "r308", "r529", "r530" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Intangible Assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r110", "r530" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r529" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r49", "r51" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0, "order": 3.0 }, "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortizable intangible assets, net", "totalLabel": "Net Intangible Assets", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r110", "r529" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Amortization Period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r529" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r303" ] }, "kids_FireflyTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "FireflyTechnologyMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Firefly Technology", "label": "Firefly Technology [Member]", "documentation": "Firefly Technology" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r745", "r756", "r766", "r791" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r745", "r756", "r766", "r791" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r745", "r756", "r766", "r791" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r745", "r756", "r766", "r791" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r745", "r756", "r766", "r791" ] }, "kids_FourthAmendedLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "FourthAmendedLoanAgreementMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fourth Amended Loan Agreement", "label": "Fourth Amended Loan Agreement [Member]", "documentation": "Fourth Amended Loan Agreement" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r97", "r636" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "netLabel": "Goodwill", "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r153", "r299", "r543", "r703", "r720", "r857", "r864" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Boston O&P acquisition", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r300", "r703" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r108" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation impact", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r301" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r95", "r185", "r228", "r235", "r240", "r243", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r470", "r700", "r872" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademark impairment", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r832", "r867" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r92", "r131", "r228", "r235", "r240", "r243", "r546", "r555", "r700" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r186", "r424", "r429", "r430", "r431", "r434", "r438", "r439", "r440", "r585" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes (benefit)", "negatedLabel": "Income tax benefit", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r135", "r143", "r205", "r206", "r232", "r427", "r435", "r560" ] }, "us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsAndNotesReceivable", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable - trade", "label": "Increase (Decrease) in Accounts and Notes Receivable", "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable - trade", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in certain operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r304", "r307" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r111" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r50", "r111" ] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets acquired", "label": "Indefinite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r748", "r756", "r766", "r783", "r791", "r795", "r803" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r801" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r737", "r807" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r737", "r807" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r737", "r807" ] }, "kids_IntellectualPropertyAndCapitalizedSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "IntellectualPropertyAndCapitalizedSoftwareMember", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual Property & Capitalized Software", "label": "Intellectual Property And Capitalized Software [Member]", "documentation": "Intellectual Property And Capitalized Software" } } }, "auth_ref": [] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual Property & Capitalized Software", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r17" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r99", "r344", "r353", "r707", "r708" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense (income), net", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r133" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r179", "r181", "r182" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r164", "r693", "r720" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r463" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r22", "r185", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r448", "r449", "r450", "r470", "r612", "r699", "r732", "r872", "r894", "r895" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r89", "r128", "r553", "r720", "r836", "r852", "r888" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r151", "r185", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r448", "r449", "r450", "r470", "r720", "r872", "r894", "r895" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r19", "r77", "r78", "r79", "r82", "r185", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r448", "r449", "r450", "r470", "r872", "r894", "r895" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreements", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r62", "r423", "r879" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused commitment fee percentage (as a percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademark impairment", "label": "Litigation Settlement, Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r19", "r127", "r337", "r352", "r705", "r706", "r904" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: current maturities", "terseLabel": "Current portion of long-term debt with affiliate", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r157" ] }, "kids_LongTermDebtCurrentMaturitiesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "LongTermDebtCurrentMaturitiesRelatedParty", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt with affiliate", "label": "Long-term Debt, Current Maturities, Related Party", "documentation": "Long-term Debt, Current Maturities, Related Party" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current maturities", "verboseLabel": "Mortgage balance", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r158" ] }, "us-gaap_LongTermNotesAndLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesAndLoans", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt, net of current portion", "terseLabel": "Long-term debt with affiliate, net of current portion", "label": "Notes and Loans, Noncurrent", "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment", "label": "Long-Term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Purchase Commitment [Table]", "label": "Long-Term Purchase Commitment [Table]", "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r26", "r52" ] }, "kids_MDOrthopaedicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "MDOrthopaedicsMember", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MD Orthopaedics", "label": "MD Orthopaedics [Member]", "documentation": "MD Orthopaedics" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r383", "r527", "r567", "r604", "r605", "r662", "r664", "r666", "r667", "r669", "r688", "r689", "r701", "r709", "r717", "r722", "r874", "r896", "r897", "r898", "r899", "r900", "r901" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r775" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r775" ] }, "kids_MedtechConceptsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "MedtechConceptsLLCMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medtech Concepts LLC", "label": "Medtech Concepts LLC [Member]", "documentation": "Medtech Concepts LLC" } } }, "auth_ref": [] }, "kids_MedtechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "MedtechMember", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medtech", "label": "Medtech [Member]", "documentation": "Medtech" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r383", "r527", "r567", "r604", "r605", "r662", "r664", "r666", "r667", "r669", "r688", "r689", "r701", "r709", "r717", "r722", "r874", "r896", "r897", "r898", "r899", "r900", "r901" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r794" ] }, "us-gaap_MortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgagesMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage payable to affiliate", "label": "Mortgages [Member]", "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r802" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r776" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r136", "r144" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r180" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r180" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r102", "r103", "r104" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "netLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r93", "r104", "r132", "r149", "r168", "r171", "r175", "r185", "r195", "r197", "r198", "r200", "r201", "r205", "r206", "r213", "r228", "r235", "r240", "r243", "r285", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r461", "r470", "r556", "r633", "r654", "r655", "r700", "r731", "r872" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r775" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r745", "r756", "r766", "r783", "r791" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r773" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r772" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r783" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r802" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r802" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r910", "r911", "r912", "r913" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expense (income), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r98" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r838", "r839" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r16" ] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition note payable", "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r847" ] }, "kids_NumberOfRelatedPartyEntitiesSuppliers": { "xbrltype": "integerItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "NumberOfRelatedPartyEntitiesSuppliers", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of related party suppliers", "label": "Number Of Related Party Entities Suppliers", "documentation": "Number Of Related Party Entities Suppliers" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r847" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r228", "r235", "r240", "r243", "r700" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r482" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r483" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r481" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r483" ] }, "kids_OptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionAxis", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option [Axis]", "label": "Option [Axis]", "documentation": "Option" } } }, "auth_ref": [] }, "kids_OptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionDomain", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option [Domain]", "label": "Option [Domain]", "documentation": "Option [Domain]" } } }, "auth_ref": [] }, "kids_OptionFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionFiveMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Five", "label": "Option Five [Member]", "documentation": "Option Five" } } }, "auth_ref": [] }, "kids_OptionFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionFourMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Four", "label": "Option Four [Member]", "documentation": "Option Four" } } }, "auth_ref": [] }, "kids_OptionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionOneMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option One", "label": "Option One [Member]", "documentation": "Option One" } } }, "auth_ref": [] }, "kids_OptionThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionThreeMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Three", "label": "Option Three [Member]", "documentation": "Option Three" } } }, "auth_ref": [] }, "kids_OptionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "OptionTwoMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Two", "label": "Option Two [Member]", "documentation": "Option Two" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r76", "r105", "r106", "r123" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r155" ] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets:", "label": "Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment for realized (gain) loss on securities", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r5", "r12", "r124" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r5", "r12", "r124" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on short-term investments", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r166", "r167" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive loss, net of tax", "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r5", "r12", "r124", "r169", "r172" ] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r855", "r876", "r887" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r720" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense (income):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r775" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r743", "r754", "r764", "r789" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r746", "r757", "r767", "r792" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r746", "r757", "r767", "r792" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r121" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r771" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r33", "r445" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Boston O&P, net of cash acquired", "terseLabel": "Cash paid to acquire", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r33" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash consideration", "label": "Payments to Acquire Productive Assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r134", "r881", "r882", "r883" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r101" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r774" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r774" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFIT PLAN", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r364", "r365", "r366", "r372", "r373", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r714" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r773" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r783" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r776" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r772" ] }, "kids_PercentageOfPrepaymentOfFacility": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "PercentageOfPrepaymentOfFacility", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of prepayment of facility (percent)", "label": "Percentage Of Prepayment Of Facility", "documentation": "Percentage Of Prepayment Of Facility" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r469" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r827" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r824" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lines of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r34", "r835" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of short-term marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r32", "r178", "r253", "r284" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and Services [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r245", "r528", "r561", "r562", "r563", "r564", "r565", "r566", "r690", "r710", "r721", "r813", "r870", "r871", "r875", "r905" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and Services [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r245", "r528", "r561", "r562", "r563", "r564", "r565", "r566", "r690", "r710", "r721", "r813", "r870", "r871", "r875", "r905" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r547", "r554", "r720" ] }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation, to be paid, year one", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation, to be paid, remainder of fiscal year", "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r771" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r771" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r365", "r383", "r410", "r411", "r412", "r503", "r527", "r567", "r604", "r605", "r662", "r664", "r666", "r667", "r669", "r688", "r689", "r701", "r709", "r717", "r722", "r725", "r868", "r874", "r897", "r898", "r899", "r900", "r901" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r311", "r312", "r313", "r314", "r365", "r383", "r410", "r411", "r412", "r503", "r527", "r567", "r604", "r605", "r662", "r664", "r666", "r667", "r669", "r688", "r689", "r701", "r709", "r717", "r722", "r725", "r868", "r874", "r897", "r898", "r899", "r900", "r901" ] }, "us-gaap_ReclassificationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationLineItems", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification [Line Items]", "label": "Reclassification [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r148" ] }, "us-gaap_ReclassificationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationTable", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification [Table]", "label": "Reclassification [Table]", "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r148" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r738", "r749", "r759", "r784" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r374", "r489", "r490", "r607", "r608", "r609", "r610", "r611", "r630", "r632", "r661" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r187", "r188", "r489", "r490", "r491", "r492", "r607", "r608", "r609", "r610", "r611", "r630", "r632", "r661" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r489", "r490", "r893" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r637", "r638", "r641" ] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to related party", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r374", "r489", "r490", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r607", "r608", "r609", "r610", "r611", "r630", "r632", "r661", "r893" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r486", "r487", "r488", "r490", "r493", "r586", "r587", "r588", "r639", "r640", "r641", "r659", "r660" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on acquisition note", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r35" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of related party debt", "label": "Repayments of Related Party Debt", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r35" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on mortgage notes", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r35" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r189", "r190", "r328", "r356", "r492", "r695", "r696" ] }, "kids_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty agreement percentage (as a percent)", "label": "Research and Development Arrangement Contract to Perform for Others Royalty Agreement Percent" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r75", "r422", "r902" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r147", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r220", "r287", "r288", "r433", "r458", "r459", "r460", "r461", "r480", "r484", "r485", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r739", "r750", "r760", "r785" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r740", "r751", "r761", "r786" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r747", "r758", "r768", "r793" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r147", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r220", "r287", "r288", "r433", "r458", "r459", "r460", "r461", "r480", "r484", "r485", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r825", "r833" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "verboseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r40" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedTerseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r86", "r116", "r552", "r572", "r577", "r584", "r614", "r720" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r146", "r192", "r193", "r194", "r196", "r204", "r206", "r286", "r289", "r419", "r420", "r421", "r432", "r433", "r451", "r453", "r454", "r456", "r459", "r568", "r570", "r589", "r908" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net revenue", "verboseLabel": "Total", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r229", "r230", "r234", "r238", "r239", "r245", "r247", "r249", "r362", "r363", "r528" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]" } } }, "auth_ref": [ "r148" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "kids_RevolvingLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "RevolvingLoanMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Loan", "label": "Revolving Loan [Member]", "documentation": "Revolving Loan" } } }, "auth_ref": [] }, "kids_RhinoPediatricOrthopedicDesignsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "RhinoPediatricOrthopedicDesignsIncMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rhino Pediatric Orthopedic Designs, Inc.", "label": "Rhino Pediatric Orthopedic Designs, Inc. [Member]", "documentation": "Rhino Pediatric Orthopedic Designs, Inc." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r802" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r802" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Previously Reported", "label": "Previously Reported [Member]" } } }, "auth_ref": [ "r147", "r192", "r194", "r195", "r196", "r197", "r198", "r206", "r220", "r433", "r458", "r459", "r460", "r480", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r812", "r814", "r815", "r816", "r844", "r853", "r854", "r886", "r889", "r890" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSScheduleofDiscountingtheFuturePaymentsDetails", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r55", "r56", "r443" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r26", "r53", "r54", "r66", "r67", "r69", "r72", "r114", "r115", "r705", "r707", "r840" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r846" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reclassifications", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": [ "r37", "r38", "r39" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r463", "r464" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSAmortizableIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r49", "r51", "r529" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Balances of Amortizable Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r49", "r51" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r703", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination", "label": "Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "documentation": "Tabular disclosure of characteristics and cost, by total and major class, of indefinite-lived intangible assets acquired as part of a business combination. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. The future benefit is not expected to diminish over a stated period of time. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total." } } }, "auth_ref": [ "r50", "r59" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r70", "r71", "r637", "r638", "r641" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Sales by Geographic Location", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r47", "r94" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r47", "r91" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r44", "r45", "r46", "r48" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Sales by Category", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r44", "r45", "r46", "r48" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r385", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r884" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Each Class", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r733" ] }, "kids_SecurityAndGuarantyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "SecurityAndGuarantyAgreementMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security and Guaranty Agreement", "label": "Security and Guaranty Agreement [Member]", "documentation": "Security and Guaranty Agreement" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Name of each exchange on which registered", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r735" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r247", "r248", "r601", "r602", "r603", "r663", "r665", "r668", "r670", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r691", "r711", "r725", "r875", "r905" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENT" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS SEGMENT", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r228", "r233", "r237", "r241", "r242", "r243", "r244", "r245", "r246", "r249" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation service period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r718" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r718" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Contractual Terms (in Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at period start (in shares)", "periodEndLabel": "Outstanding at period end (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r399", "r400" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual terms (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r117" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r129", "r130", "r826" ] }, "kids_SpineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "SpineMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scoliosis", "label": "Spine [Member]", "documentation": "Spine [Member]" } } }, "auth_ref": [] }, "kids_SportsMedicineAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "SportsMedicineAndOtherMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sports medicine/other", "label": "Sports Medicine And Other [Member]", "documentation": "Sports Medicine And Other [Member]" } } }, "auth_ref": [] }, "kids_SquadronCapitalLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "SquadronCapitalLLCMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Squadron Capital LLC", "label": "Squadron Capital LLC [Member]", "documentation": "Squadron Capital LLC" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r145", "r159", "r160", "r161", "r185", "r211", "r212", "r214", "r216", "r222", "r223", "r285", "r315", "r317", "r318", "r319", "r322", "r323", "r354", "r355", "r357", "r358", "r360", "r470", "r580", "r581", "r582", "r583", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r613", "r634", "r656", "r671", "r672", "r673", "r674", "r675", "r809", "r834", "r845" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r28", "r146", "r173", "r174", "r175", "r192", "r193", "r194", "r196", "r204", "r206", "r221", "r286", "r289", "r361", "r419", "r420", "r421", "r432", "r433", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r472", "r473", "r474", "r475", "r476", "r477", "r485", "r568", "r569", "r570", "r589", "r656" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r247", "r248", "r601", "r602", "r603", "r663", "r665", "r668", "r670", "r676", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r691", "r711", "r725", "r875", "r905" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r192", "r193", "r194", "r221", "r528", "r579", "r600", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r626", "r627", "r628", "r629", "r630", "r632", "r635", "r636", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656", "r726" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r192", "r193", "r194", "r221", "r528", "r579", "r600", "r606", "r607", "r608", "r609", "r610", "r611", "r613", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r626", "r627", "r628", "r629", "r630", "r632", "r635", "r636", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r656", "r726" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r742", "r753", "r763", "r788" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r14", "r83", "r84", "r116" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted stock", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r14", "r116" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r87", "r88", "r107", "r615", "r631", "r657", "r658", "r720", "r732", "r836", "r852", "r888", "r908" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "kids_StructureMedicalLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "StructureMedicalLLCMember", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Structure Medical, LLC", "label": "Structure Medical, LLC [Member]", "documentation": "Structure Medical, LLC" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r478", "r495" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r478", "r495" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r478", "r495" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r478", "r495" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r478", "r495" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.orthopediatrics.com/role/SUBSEQUENTEVENT" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENT", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r494", "r496" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURES", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "kids_SupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "SupplierMember", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier", "label": "Supplier [Member]", "documentation": "Supplier" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r782" ] }, "kids_TeamNoteBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "TeamNoteBMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Team Note B", "label": "Team Note B [Member]", "documentation": "Team Note B" } } }, "auth_ref": [] }, "kids_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "TermLoanMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "kids_ThreeMonthLIBORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "ThreeMonthLIBORMember", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Three Month LIBOR", "label": "Three Month LIBOR [Member]", "documentation": "Three Month LIBOR" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r774" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSIndefiniteLivedIntangibleAssetsAcquiredasPartofBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks / Names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r60" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TrademarksMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSANDASSETACQUISITIONSNarrativesDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r60" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r801" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r803" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.orthopediatrics.com/role/COVER" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol(s)", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "kids_TransferOfPropertyAndEquipmentToInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "TransferOfPropertyAndEquipmentToInventory", "crdr": "debit", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of instruments between property and equipment and inventory", "label": "Transfer Of Property And Equipment To Inventory" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r349", "r359", "r457", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r557", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r848", "r849", "r850", "r851" ] }, "kids_TraumaAndDeformityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "TraumaAndDeformityMember", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trauma and deformity", "label": "Trauma And Deformity [Member]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r804" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r805" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r803" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r803" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r806" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r804" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Bonds", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r697", "r712", "r714", "r903" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r800" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.orthopediatrics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r41", "r42", "r43", "r137", "r138", "r140", "r141" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "kids_VilexAndOrthexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orthopediatrics.com/20240331", "localname": "VilexAndOrthexMember", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vilex and Orthex", "label": "Vilex and Orthex [Member]", "documentation": "Vilex and Orthex" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common stock - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r210", "r216" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "netLabel": "Weighted average shares outstanding - basic (in shares)", "verboseLabel": "Weighted average shares outstanding for basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r209", "r216" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r809": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 75 0001425450-24-000033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001425450-24-000033-xbrl.zip M4$L#!!0 ( %:*IUC[M;OIY < %(D > 97AH:6)I=#,Q,2UC96]C M97)T:69I8V%T:6\N:'1MY5IM4QNW%O[>7Z&2N2G,V. U)H!-F'' :9EI P4R M[?UT1UYIL09YM96T-NZO[Z.C]0L8B.G-"TGRP6%7TM$Y.L\^S]%J#P9^J \/ M!I*+PQ\.?JS7V;%)RZ',/4NMY%X*5CJ57[$_A'37K%ZO>AV98F+5U<"S9J/9 M8G\8>ZU&/+9[Y;4\G-HYV(K7!ULTR4'?B,GA@5 CIL3K-97)--G?V=Y)]W=W M6\G^=G]/]D6K*632$K(A7OTO6<-0=(]CG)]H^7IMJ/+Z0(;YV[O-PG?&2OA! M.VDT_K-&_0X/,I-[3&8Q./X9;2Q9JCN9UN6-MSSU;5<.A]Q..AXWZERKJ[R= M(@1IUZ+!Z:#4:&/;+QKTKQ-:ZAD?*CUI_]2UBNN?:H[G#J:MRF*S4W_+]AX\ MI:MQ=+V%P5KE M2[9Y/6FM\XV7+UJ[G61'Q"MV.\Z%"+]H,*=OV>4O/7;1.WI_?G)YTKM@O3^/ M?NF^^[G'ND>7#,W(>:OV3+WO7K#N\>G99>_X5AX0#>5FN]%DTP"[YV^Z[WH7 M]=,_?^W]=QI;L]%H/CFR>U [0_1GB?JDQH[Y2 EVOLG><*7EI,92:;W*)LP/ MN'_Y8F>OLYRQQ[R?^EUP(< F=2TSW]Y^!7=H%50NL +M>@('/V=^D\VIIY]I MRLZM!4B2S>U6B/B$#?A(,BM'2HY!N7Z@'/N]Y!:HT!-V+@MC/3,Y>VOLD"6- M^N_,9.S4^H$YDT)Q;U7JP,FVV$1R]CNKK_^CF'NF66L^DZR]X0ZY0E:&$W:= MF[&6XDK68O)L3)DPTK'<0$PQ!5F<^1/RMV M9=J,W12V5EXIAQH-$_%P,_H-+VL+Z'-39Y:\_0X V'HF +R\E:V7+_::R6[' M51"KJHA (B;+%"XICR>,6TF( 0)47\N0628!T[Y6;A"ZAVY#$&@@T7 ME$NU M<27&!6JU1D?H%-:D4N"V8^M BI" 7H1#[R8=\/Q*LBY8Z[S4Z$&E],ZZW*"A M5$J'JWBI0DF61\@&^RQ0VP*2([*"+RM/E-V:*,-$(G <:2YQFG$2#F%+38,*E(@J+34/5(RPR(FY'&-$ M%/?%F@1_]67H"+;$>"F>P(X!,U\CTOHK(FWEAWX)<*O3Q MB.N2GO>P^C++4!6I$=;-W5/=S/1R!?Z*E_<7/(0G# 3WN%A6]4WI'_9@%8;E ML]XRU(S9A^M^UI]6H_2(R+@2\(< 01-\VZ@0#]-.7/#EQ(4-8E4_4,N]Z'@" MV031,FE:VI">!86XQ^K0.(_[X644;+D4AOZ*[R#8^@-#,N ,-'"G=^4XRGA) M>]NP[%.Q\ MU9L">BNS%/:!&]\U[5_5Z,6 M06VD@(6P(0I;JU1))*\2O5D-/I;\.JA8K$U(QZBJHK=GTU<*3X)$52['[6A5 M=4T6J(@+#'1RQD0/PJ>JQ3 $&$#)5(M2ZJ"C\9 )*T7!5+1_[\N7I\KDMU>= M=Z&&F<6S5T-F)-$%%-A.)UO' M1%KAMR &2'P4N=UDG[2@F0M*/#:B UB8\;0WJ$;T@39IZTB8YH63[>D?'3!I MH?FDK7+* WJ (E7*J_WC?=FV-Z!_5&@8ZAY-0=-%YNK4]96:[-):3OP<-R+ MZ<35&>PF-6UYL=RVO[>YWWBXN;&9S-JVR':TCPA%?-*>KQ;Q^%O?YX,&E4#<>2O 6L<]'8\G;+/:9U>L82A2/Q!]2L=_X MA.W6Z$N9)X?P>."+W\ 4QM')2CN^CAS)I:]BYC1"DS3F0W@?7%+ZY2$?^)"F M^HW?]&S1MT3_ %!+ P04 " !6BJ=8Z"4N.MX' !E) '@ &5X:&EB M:70S,3(M8V9O8V5R=&EF:6-A=&EO+FAT;>5:VW+;.!)]WZ_ .K49NTJ2=?/8 MEA17:6QYXZILG+&5FMFG+9 $391)@@. 4K1?OP<-ZF;9CKPS<9PD#XI) (UN M],$Y#9*#Q&;IR2 1/#KYV^#O]3H[4V&9B=RR4 MN1<1*(_,;]ELDS"VKUZM> MIZJ8:7F36-9NMKOL-Z5OY83[=BMM*D[F=@;[_GJP3Y,, A7-3@:1G# 9O=F1 MG:#9YN'Q<1P&4?<@;O/C ]$)#H^.^>%1&!R$_VGM8"BZ^S'&SE+Q9B>3>3T1 M;O[>8;NP_:F,;-)K-9O_V*%^)X-8Y1:3:0SV?WH;&Y;J1H1U\*;., MZUG?XD:=I_(F[X4(0>@=;W ^*%2ITKU73?K7=RWUF&A>#4YF+>2BMCO/_='0UOCB_.!V.+R[?LP\?KZX_ M#M^/V?B277U\-V*M#J^WNKM\[_6K[F&_=1#Y*[8>YTJ$7S68RW,V?CMBUZ/3 MCU<7XXO1-1O]?OIV^/Z?(S8\'3,TMXX[W=H+]7YXS89GEQ_&H[.U/" :RDVG MV6;S (=7OPS?CZ[KE[^_&_U['EN[V6P_.;)[4+M ]+-$?5%CYQH;_UV#O956 MU%@HM)7QC-F$V]>O#H[ZF^EZS/6YTP6/(E!)/16Q[75^AB^T!#*/$'ZOWH)W MSYG<5F/NZ3--V5];@%:KT>FZB"]8PB>":3&18HIEMXDT[->2:T BG;$K42AM MF22 MLPQ7SD\60X:8TDQETC*K?+^-#KD(A3%0*MK@Z82IL@0%.(D!QT M=@NXIB*$.1&.-X+9ZC+\ )CLO'1,"A;+'%EW %IFN09 HCN:]4J[S&/P#+<2 M=F0>IF4$FT#22DIK0*%TW%0 " [##MMIN@1IA0]S9VKL@T@ZPS77HTS1 MR];K5T?MUF'?5!"KJ@A'(BJ.)2XICQ>,:T&( 0)DD J7628 TR"5)G'=7;<, M!.I(U%U'TH2I,B7&.6K5*O70*;0*183;ANT"*9$ ]#P<1I_"A.LL\\Q3=Z MN&J JJPOB5DZ-7U5S')4*ZV?F_W-WS-A4!1C/4F5/I_LFA/,D)=F^R%.N0*! MQ%4S>2U4I88!\,E$&F(I]!(YV7&E[Y+?5CE2BY03$BHQ7&:S5O&G:Y3@.OAB M5"HC.E6;,C 2U9N6+@#I)9M8.W>62N-DE#:.(DW +<]76R- M.V!U(B,')VY4SATO<@,HNMK-88SK:)YO(%#R0*;2SIQDWC>M0S]!@[+N@;O6 M=:7V(_K]5 54E+H Z@Q)?!@J'9$#5 7>B!S*G;K[HG"8=AU0WWIX ?NR /]] MXPO MJP)5VH<]V(9A^:*W<#5C_/FZGP7S:I2VB/ K 7\($#3!]XV*Z&':\0N^F3AW M0*SJ!VJY%QU/(!LG6BH,2^W2LZ(0]UC-E+&X[YY$P98)8>@/_PR"[3XP) ;. M0 -W>E>.HXP7=+9UQ]Z\7/BUY[U*N%G(*=2+$RY%1,R*]4CEK4BKT^V=3K4_ MO2X+ '[?AX*#;_I00,_$HOE&J2W9Q)';*EB7Q.+@]@0-WZC7%JYQU&Q6:;.0 M3;H!DUDFK17B$>H.%(39M4<2_I&174 :3&D<$^-_5SG.]Z'XHY1PG_9S1\I M/ D25;GLCZ-5U35;H2(>8: 1"R9Z$#Y5+88AP !*IIJ74@,=]6^8L%(43$7[ M]SY\>:I,?G_5^1!J&&OLO1HR(X@ND%MZ'EF!H.;%1.83E4Z$4Y23%BF?]61.&:!!?2#Q1N;U0%FKLMX![$\<'4/-JSEH.M]N7L VJ&G?1IMMQT>-X^;#SGL MW%F67KOXQ%KKB^)6:B,(5>Q\@5=H9*8G+28)'XHOP MJQPCK!ZB9_1(@!EK\^A*_+GH_Z\ GRVVTT2*F)TOR.%RI:;Q;9=>FJ V M5=MB";[YX'<_^$,_XEZN@(M\N'PN4 6]MQGU/G'27\:=Z]SVS)IV!GWR+\H? MTK9_\1D[K-'',T\.X?' 5S^+*92A]RT]_Y!R(C8^E%F2"DW27 [A 9BEM)M# M/O-M3?7K/_/9I\^+_@=02P,$% @ 5HJG6"<:,Q["! 11$ !X !E M>&AI8FET,S(Q+6-E;V-E'Y M2K#+6$';:7?A*Q=7[)J4C)0]7AZ.070,+#QIL2?NT MW>^$PSX9=CM]=]!SG)Z[']".@_>][M]N U5Q>:DCU2JA!XV4959,M7^OW\Z5 M?\-"%7NNX_S6,.L.1Q'/%#H3J%S>EC:V+%F2!A:]58($RI-%FA*Q\A6^L$C" M+C,O0 A4-$J#M5+ $RZ\' M ",U3S=EZ%U43EA&:RAN1\<_F9XO3HY/)N/%R>P4SB[.YQ?CTP4L9N .X,*> MVQ,;YM.)D;J=?:=Y'^$&MI\*8SR'\='L;#$]VL3P/F.MTSET>C [AL7O4YB/ MSS^-3Z=S:_;G']._8#Q9:$G;<=HOAO"=-ERWZ)O .\D@X%E& \5X!C=,Q:!B M"E\*(C#*9 7G-.=" 0J/N4C!=:POP".8"17S,QHRH@0+) Z]R&W8U;H?=@;M MMN-/>)J3;&6>7'\/(BZ,Z6]KTSE&S$.@68A4\IF(((:.:TBC"41"Q!)\OPYI M3H-",,6H!)*%,+T-8I)=4O2, M Z4ENN,T"F+48B;A*N,WF+1+^F%G?^ _TE??[[FZVW(2ADCJ5D(CY75ZV$2F M=QGF*5.>Y6);O>7XN78=Z1NY].\EP'7M3E &N?Z&9<-ZB@ MWPHFJ-[8I"[/7;%WR1Y@][O[N^'>NJ1W[;QNY:JN[K#3Q0(.?=WHSR_4DY3R M3LO;?D?E91E25$I,S9 3%4'5$-_"9NT),\PEJ-1E;FHQ21) -:HCPYG.L>RR M))>(920+]&NT%S)C67,7:A=)V20<2="XE ](Q7[1]+YAR1:::"JF"S33XN.2 MZG-@5(B,R1B3)GE",4V:\I'9C3+L- MS]E8S9D3FU>194)K^9(+)'@+,Y*07%*OOO%#)O.$K#R6&8A&R<<3WB4>'Y=< M*9YZ^YB/:PTT($GEP[@KQ=7!LMNUVR8O(X5U46'MN#IVVD;44N&V;#BPA\[C M8L=VU[*6L5W:1P02&^2@T6D\&&JOG=^"6X]T&;!N\RT0/'_E&3=F/*;0?O!T M"QG 'W:Z?5^:Z\,]=UWH9\"N:HMP/$2MFPXMU2#^4TY>:Y)C9/+P&/;R MY\C_H?!/PCM#GF-Z7S'#_LA9ZB4%_ZDU?1[FW3/!D/)SY/PMJ'N/%;AEV.?5 M]OC[+/;&._H1;@GF](FG;K?G^-O7SV0%_:8YY[\8PM/ -W_VXZ9C-EQ/T(3H M*FQ]"+BC$>/$N5,A2^220FVK_.#;074M/V.TS.>3?P%02P,$% @ 5HJG M6 @O;"*_! @!$ !X !E>&AI8FET,S(R+6-F;V-E_7S[W M]UV2_DS2Q7&?\EO@]*C&22N).Z1!#T@G;M%6.&MU6/N@VPY)R)J--ODCK*$K M+B]]M%ED[*@VY\)+F M9K''[HTBL8ET,9\3M>@9_(-',GXMHA@A,%4K U9.L A7_L0?^C 9#9TU;+:#^F.$:]C^4QB#"0Q.QA?3 MTO[9N>PT0AZ0SG/B5BXI["W!XE4+O3G5>@<*Y84F* H M)1^(BE-HAG6G&G4@&A*>H6%5TX3%A>*&,PU$4!C=QRD1UPQ3S^=<:UL__MJ5 M%,4)4J88%KI>4HFEJJCNUA:876D<#*-U.%68\+T/[[AA=1BFG"5PR@41,?89 MQDG"8Z9<]M(V1@C$6 VL;)C11EV"K[LJ9@M D^$)EEZ'O%"Z(#A>(^VNG2Q; M[[:K14VHS*VVKJ^K%ED2+C-,B)H1P;0WOL_8 @:QL19+0HN+.+>4:[@1\@[; M>,W>[+0/>]^@VM=I6!$P)Y0B1B]CB8F:'>25HS/'S@D3>2$R;9L[,O2K2K>4 MLO>H 6'H-UL6L9W")7N &R)L M[]*]U4@?"+XB]W*N8;?9P@%V>Y9\WS^H9U7FE8ZW\8K&RP6JUIRXF:%,&H*N M%/\*Z[,GW(F98MJ.N6[-),L W9BM#/=TCF/7I=PD*S7!>)2[R%9/T+O(2I+( M4E2DT$_4Q'_1[MWBR*96:)82%UOMQ<<9L[*8%$IPG6+3M,P8MLF> JALN=3L MT8ZPRF;[@)Y"FLK;'0"HB3E1IFI&V78?7LKG\O1U%U.DLR&SC%4>,ZGP$/"P M1QG)-8NJ+SW*=9Z11<2% ^V<>G@-O,8[YDP:(^=1&^/?6N@QR98Y7+K2O+Q] MMEI^PW6J;W!2AE:)EW=3WYGV#=VT=0_];O!M<^"'*]N^BUW&1P0:*7-4:]:> MM"5JY/<0/FZ*[=0&")G7_@4>N3 1-Y@D?IY9#O6;G=9!3[O/1X?SDYO[=\!? MSAAA18C>TI%3J'"\CMX\VXF_A_Z' &X-VP]:](_=!1YKVY9/_A,\.MPM%>_K82?H;7Y^( LX*/]#>#&$ MYX&OOS' P\D=S)%B&9+NEFV\0W@0%9' A,U26PFRZ_,5KA^5G^09DW[UY M^1-02P,$% @ 5HJG6(K)9QS1_0 M7 , !$ !K:61S+3(P,C0P,S,Q M+FAT;>R]:W?B2+(H^GW_BKS,[-U5:P&%>&/77^]]OCW?DQE*],3-=TK89=9E& M7G5W1-P1(_^T[)_Z"R4/!G6'ECW.Y?S7VM9D:NO/(Y<4"\5RV"Q\:E\5AP6E M42B6*VJA6BL-AKE;3GG+EX9#F M&B5:R*GU!E6+U4:Y0@M9[:I48L5R95BJ5AJ5I4]%6I:3:DJFL+' M';FP9EBWZ?PM,W+=R=67+Z^OK_G74MZRG[\HC4;CRQNVR?B-KMZ>;$-?:HJ_ M\,;%0J'T13<=EYHJ"]L;NOGS@^;X^(DZL^8:FW?.6SI,S3];+U_@ ;Q1+,WF ML=+QTI3Q:=C4>)-@P=+_3JVN]H0?EP>W-'7#0TK4K[\[_>[ MOCIB8YI[#PJF:NO7!@^6NM??W!P\6QHB;*N;L#2&]/?%M:GI('E1%P@6>E J MN4(]5U+"?E3+,UU[NG[0X.&[@3>A2BDMC#QK[ECEHE+[B!K\%HO$H[U#<-"V M^L5_N "#]?U^!(!B(55OF;9ENL#XN<%T MA5_6]_ MR[CLS?W"F>5+\[_^Z[^^NKIKL"9.(A<.\O6+_^/7+W[73Y8V;7[5]!?BN%.# M_2VCZ<[$H-,KTS(93$!_N\*&S/8_ZIK&3/X1GM^#](%5^.._N8]L^+>,FH-U MF'2,/3']*A11M[JC4N-?C-JW\(N3(3J0XC!7K&2:.+.O7Y9ZW'N !VAN:\M4_2GT71@6X=L; MWNHFB"L=T&@Y.G)4YPWHVM&?#'C1<<.Y512@FH]$Z5]ZH /M<"R=.?/1XES, M(RK2WO"'PUJ.P_9:2'6VD&W"X2]\C(65=-Y4PT/+X,&&=VQW"KK>=%NFU@$1 M,1E'76OIZ&NM)66M,1%I/3XB_;(L>FTV9-!.9N)O&43"']YT%:OSJ1_\F:E^@$OHXB5F? MH.MTC2TVY7"FKF7O.>S*^_CC#3.M,=#*FFYW!^(G9&Q ]@8^1>D/;":AT_0R#AY$Z=-@S[^_=E$^#]R[,9 M+/<^X:91^ T< ]M%A<_-KUQ!@?^%[\V?S::I+30M<9M@^4GX/1SDR]*ZUX.A M* 8? _)#58&WDMIUE'P9)^5E81;V2+.#EE96:R5E4(+]?"558Z]LH"W?#GD M?]5@L#<0(JKN?FM- M!Q4U8\[ ,YO:V:BK*G&P'PYBY(-:FG#PF$ FJ$L$G)<# M&@+HN"7SK+2[>5:*SSQ3"J(2XLP91^_?G;:M\<0RX:NS3'OP^]@R^ZZE_DP* MZ2E'=PV.#/.6IO&8"#4>J*YUS3:=Z"XU$@/_H_LD1X;_(W.I;C*M0VU3-Y^= MQ #^Z"[3L0E?5;VQQY4=C^MA.YN-L+<7UC55:\P2@XNC.WF)9P(!HB>*L ZK MR!PC N*$]7)%L*M$0)"P+K!H1I@(R!+671:!FXX3H5".[B&GA4&. _]BTCWS MDWHI<0(^\>[YF;V4.'&1=%?]5(*_&)]G6$R\EWX&P1\G_*5G?B; 2V=;'%P< MW7\^W]*2[GF>./)VGHVQ8M)=SO-'WLZ$N*3[K:>+O)T'0:6D.[;GB;R="5E) M=X9/EQ\0F]-;2KK3>Y[\@/C@GW0'^,3Y ?$!/NF>[[D=L#AQ<71G^'Q+$VYO MUK%=8%HG)#*?J/#'OLI,"BM[L-F+;GF.,7UD$\L&^DJGM2&<:[P1,X^ $&S2 M&S[ ^FS_2/(C4PWJ.#"6RL^*M[0_/,?%%].)+F%]Y&^> PK0<5HJR&O_ *>/ M.GZHZYOEN);YS:8J"&67V2;UK160T/F3[)]7=D'4NZ8'(4I8G[CU2FT-ZQN\ MMV 6RY)$P+:P[CV5' MAKJIN^P._!-PU&&-SUCBP*_,\&WZG?YAV6TT:99I86!3C8VI_=-IF1K_7%I@?A2KBXTREPM?,D M9C%6+E)Z0VYFGG%K]!P4(ES\2U+(QG#T(M(/TO["1M$^0/IWIKE,';4M4V43 MU[F[:Q^?(2N[,V0E+H84-G 6*R](BMB]@I"P,;.+I(AED5R)2217Q W.I1+< MPD;(;JEN_TX-CX&WZU?^PPZ^44=_[_-2VY[JYG.X/=L:8]WKV>LWNJ,:%KZ? M$KX301(+&T.+(:XJR20V,A$VN!8G;G:7:/O0)<;2#(.IKD>-L#AS.HDEB>&T MBR26(UDBPH;H]D+% \4;(Q)S\KHB;/@K$O0Y4Z[C@I:I!:G0^G^8UK>&[BO= M:A&*@QUAXU0GVZ42!Q?"QJ7VPL6=KF(_YG/KV6;<>*[#6RBQA>G6[E+=VNQ/CYGJ=,-,%IHZCPPOI0-U&F/DT+\_KPOR MP?;F9^=FQA28M_XY.>;TAC=L@O?L)49[B!L*$9 48F"5HJ3+G>A2W+!0.NFR M).ER%[JLB1LD$Y NTTT*XD;LI$F7-+J,\T8\<6.5 I*"-.E.1I?BQFW329=I M-NGBI$MAH]@BTF6Z24'86/I&N//8:>=-'5'SF?&8[7;H87:+)4FYI M2$KP*2$)FPC2G-N'+/D]$S?LR4T@5YNAJ3*BXW-U<7= MR[@(JA2'$(3=/&C;3-/=6ZKJ!DSK_>4!+Y;Q BA>;A07PA&5:T/# V:/[RQJ M'A6[,69'UH4-P5\L=N/D76&CZG>6^>P"-!'4JU=_?+=L]YD^'UE(QLA'C MQ"( .D:*;@@;^=PH-!;.4=Y;;GSFZ,>8Y4,]T"E],ABW/H+/R6$I88.)$M,Q M\[2PP4(1;9# @\!*+;]ZU :@3V4R("*0@;AA*1%&;CII<>A(U&_4YM'!0PKJC%ORJ,0V)[C1[0C'N]RH%8:/^TF,4E!*7Y%0Q5ZCFE-(N&;H'H441+N < K[U2FUM%1^/#)A)5UVF]5U+_7G\ ML&Q,'H4B;%CV7( 6X(H511$N=!D-*S],W74>^S^2PP;"AN[.#7 AV$'8.)<0 M0NI<.EK88)10/',N[ @;2.< M(^W8[E7?A05A^U^9]6S3R4A7:5""0K4\T[6G5S_Z:1/]1>&&<:X%P7-HQLZHUI M"];,AI8]WAZ:3RJS".=ZBX:80#%@5=H#P&$*^MUT MJ(J)O(3'VV(T-9PJ!LZ/NCPA:23F4K"N?E;\+7(5]X$.MG*23NQ;QNC M!\R>X&CW=+S$OJX-C.W9C',P->[NVBFE!>'B#)(6SB7'2\+%-T):^.8YH$4= M9Z$(V *"OM_T;'=D32CB)Z6QIY)P<8[=)A N-#%3LIJ#\MRYX$_J%Q%QUB]\-NQ MM>.?'M5LRVS3B>Z>0#D"02WE!WU,>_&E$I6$"]7,-H\=A[GKA<*M;K.A,1TP M=61:AO4<&]G=ZJ;NLCO]A6E=$X3ML_YD,#X1\*V^TS\LNVU0$%5+VQ!WX")# M/^;S+#7\V,H:-'4M5RSL0"OOFQY&*\*%DB2M"&O8"1?9DK0BK(,F7* -C8-' MO*YW;NE\!Q2.O7$ZN;4L7.AL'0;H6XHQ(&S JN\].?R>'+?S O^LIO.]:Q"7 MS/S8+VQ-]%O][<[5CD\.Y=W)8;'I8>0@;,SJXLAA.2"SB.&# C)E82-?8F+X M.]-U MXL2]?M4U=W2E% K_G>'MFE^="36;7Y_L+_"V_]GO9*6K'-!/#B9M4]6]@C+S@WI6#>F5[^T;)T: MOV0=:CK0M:T/_<>._A]VI2@P5_[U-9@\O&T BL/% _ "G[<=P>=&](?M := M_O+T%R9^WCGV.^T?C]U!M],GK?L;TOG?]F^M^U\[I-W[_KW;[W=[]X)._)_4 M&8$[Z5IFEMSDVWE2+%3*C8V3!7)X!F)SK_Q._D*W&1: MYKTWADY4$C#=(QMR*9HA)D4)J3']ZL92>>@8!5:&\]L0&C250NX?G"?GO31/ MC:WZN_66UZ[WTW=J_R0]DWV./+]US+^*UR?+=:WQ%6)V0C4-""-GL"$,O_"# M[4_H,.3_$WK"WIP-\&AL@T>1R[;(J/^'!\J;V<;TD6'64H9@_BMU0?*^N5=# M_8UI.=?V9M0!%O?__*51*U>O-Q%(#+C?;:W_\Q>E6KA>_?>($UEA.CZ1?_QH M/0XZCW?_(H^=A][C@#S\>.S_:-T/R*!'0 X.0-@1I41ZCT2I?-(^D]XM&?S6 M(0LB6^T!/E8:I7+<%'TD1MT-6;>63=P1(W^&Y$9\TX#PDC%[B*P'_GK' MMR>7J5:#7W)C+,N$K^4T.LU-&;5SS RI&+R*[WBYL$\P)25+T)1Y3]$D51CH M/0JTG'-).[X]R^WDS>)N2 UG)N_*@;PK2WDWF\C@L77?[W*IMEG@^7.34H]+ M/7=&=J'8&]K6F/S;_X^X5O@Q+:OGQEG;&H]U!SU6,M0-1DP//F*93/(_ND+9E3][#("\F!7[JO('7SI=*K"&Q9TLDU"'.A*D8]]&(;A+= M=8@ZXK;)S)5PL>1C.,\GR]:8G8/I&G3BL*OPP[6F.Q.#3J]TDX_/7[I>]AXJ M,-D79KN80!K @H/%?SP/3N0+?H#"M>'_6CAR\#@/C[ZL_EZNYQN%]8\*>67M M[P=T]85/S9\>0 #A]+=,*1,V#CPB<)?>R#M_"+VF%2!8D\P6I^M$Y+/"0H5H M]H7/0EU3!=ZP;(J2GA_-;?MGU-N6MFRC8E )XZ8NF]C6"_8S-TYKF>8-,^@K MM=G'HN:+JTE$K$7$@+YU@["NRI&Q+,WKF6:QFE-J5:5>*NT XWBIW@>J(/!> MD9LUHB"5%\D=-[,?J:F_A_^_?.QJ#0)@.OF M'_/]/.F,)X8U!<@MDR'QZ7 =A#B-?>':8TV_K)%(:4=3FWXV+,'UNM,5V/%V7]2 MVZ&O[R&3C1#36AJ$B]Z>_0!V 8C9>5A>R32[]ZLAJOT&>;# ^##^7WWB6R;! M$,5,LURMU+=X."D5Z.LIY=/N $;J:-F,+H&TE&E6:BN1Q<\1\'9G < >1I;Y MSB7%\I;%:CU7+=4:EV7#;-T:\C$7D#K:*Q,;6$F?4(.P-Z9Z+D@R^!FT,G.R M:,P8'BZ>_$>? &RT]YM)*2'X'<$VCP/\SU_J1:5V[1"7&6R"%!B$623S,;6>P('+->10QTU^#AI0Y51X2GJ,]88;OD*."R @ E=/TVY9*@/QT_ M6<8GY_-%K?X^B"TR1#Y[4T>8CDW U7L=Z?"+'W)D-M.6H+*%Z@/!QY-*)BYQ M+$/7""[@6BB(K-<@NYLV_)(OL)J4XA-GHIEI4_$W#P"*O/9IEOR5.Y_%"IE0 MF[Q0PV.XD4*2>0#?[NROM8 M,$J.Y3 P5HB^IXY&_R2_&M83V*Z8Z\3<#Q$2W>"* 6+O4]/6[X7^^TC_[;+S M](?GN/IP>LK,M*Z)]4)<1IZF1!TQ]2<98ZK:ZXCQB"KN"L^WHZ[()^6SOV,^ MH@[?+=4(-0QHPDM)P=\_/1V4"&X5/[&@ ?0,Q(5QQ=EFNV4'F^V@D7"(@/AT MYI"0_DA+=?$Q;K83#9Z"ZL:F$YNIC"MRI4AX]HQ#/D%_0*G$\4"5.2,+M\?" M'6QW1-UWRR"O='FJ?-N7OQPLY'.64%,CGXH+JWT"HH=&3W_ 6O EWAX/S,-4 M@L[XL3X^$SY3ZKBD42 :G3KYC5D1$0,C;<^V810_+02EH4M=SYDQ8SW3_!=S MWO/>7@D8VW)?=J.O( LOSLWTW0:^MZ*.&=>"E6K].@W<3I#J@>#'NNL"GX!S MK;JV9:(^,Z:$@6Z;DBZ*9ZPC\<+(#74IP9R$]V)@WL?$LQT/NX8'CQZT+! *N'G&OHVU['LN0I:-#KC;*:Q(1Z7 MQX*&R,<8JRO"^C;,C#]6KL-F6QNLS"N1.SDB]42O&$Z91\L5R/I:MB/5\H-V*;5>646ZMC7=/ MW]_QQ(5_P )^.:6'=[>>E8Z^-1#'8:'W&8+K5SA+;-[9HX\5N^\VA,^*['TR M1.TV4,6S94_7>/.\$:<7-6@T=^SQHI76*EF=>,OUQ&16O8X2_TR?-+E?9P&D M#'U'A\OCO\P._$C(^U?K(^7!?:)C556"G: MY9A:CXVQXH1&;YT\@A)<8WV/!G.E^/7 M"8O,K G,."-F&"'-DD] B3Q,XA_Q^3@@$88BR;^8<\:XX&F)8!:>6Q>"/5>X M,+*I@4C?61&4MA8PV)T-=C]\>0;V:?&XX'G;Z_M;V"U<3 MS]1]>//\"C#?EG%0S !;J3I8>,[?,MW[VS6;:3QY@^=N]'D7/<_E8AJ(8QE% MIC?.:9:;"SH$70K6"/15F"$,TUQ+V7JQGJW/,Y/#J3:)->_93P?ARU;][!%G M>_9(?J=3_O'@?N_F5 M*(>)WU=%VJTH4VU6E&EDS\VC9Y9[LAG]F:-#&/2*&J]TZJ"AE(+*3;L=REUW MEO;D9V=WG.LML"GQ2P&).C\NS&85;(A?$X1TT,:,48WN6#@JS@V]'4&PMHC) MV=8]HX]SEB;8$7*#UK>[#M:<:/?N!YW[0?\\^U%[GJJKYPNE/:\TJG'L(45ULQ.;._P &C&TM?/; UW5.(Z=;%S>?%1AVP3GA M*P_DLHVM8"9TK9)F;R/]27>OSS0M,K+1POW+#D4G"QC2!]_TD3U3FQN?H(Y> MX6/NSK)^\G3X\&INY^L7NOM^SEY9L;N>-8H@>Z3# MD:>+HG=!U 1)P/%OP4GU$;N\J(+[,HMESS4%^>29U--TEVF?(VD-J1N$QG7Y M8]UP/$M7LO-)4-S \VKPHHF;5/")6VT\S^,;-8#+&>F/& /^SA%."2E8[W>: MEI78ZB@U6"FE92%*6A;"HW)I64PY+0M)#<-C&OX-4_T;0H(8<%K6MLFCEB9P M I$I3>!4H[A8V6@"+[BWUI#T)LP?!HWA ?3/TB"NPOC"R)WE@ F3%HDE33'Q5R5-,8$7(TTQ,9FJ-,72C.*2LJ,I MQH^6C"P#AG!^(9T_/=V=2F-,T-5(8RP!ZY'&F(@+D<:8-,:$Q"9JZIHTQE*- MXO*N<3'JC,BM8;VF*1Z6EH5(4U+X54E34N#%2%-2S.5(4S)-=D9#FI*I1G'- M/R[K8$&N#3;ENO-0DL73@W^EOA2?&.M%-+E-^LQES.R2RQO= M43W'P?I7:"FU3&I,'9T[N'/1A+++KUN(;1Z9XQGOTUJES$H/F10/S%H76V:1 MDA17XM.A@M=R_P.KF>HNKP3'10_\8(3?47(9EN-A[;O6D^6YP4UQY%%W?DIQ ME"(R**7:AB)E*8^20(C^41_7!N1P6?1@6RK34/Q(89,B'&\3-N$2946CN"H: M=?.D-_BM\RC+&9ZP)^;Z14!FG";JF8:LM3:4DYDP1* M+&>:Z-226YBW94L1DR;$IES$R+V!1!!B+=/\8?KW8S"\MKI/#?]*B>"009^I MGJV[.O-]WQ\.PX>!V2,%4IKH(.4"24;_DT"(I4*F><.&E&\T_IA8)D@@4[?L M!4$DA4Z*<)URH2-#_(D@Q%*F^1W> >MGR,#H6=AAE,(F13A.N;"I2&&3!$*L M9IH]?J5GU_2O!H2NI)A)$7;3+6;\C:JJE#5)H,9&IMGQ9RLMF30AM;3E^B5Y MDYJHV"L79RP)!H#&WB1?I@BSI4@9U)(O!<)>)=/L VRI*]W^E*&U]&$9M2_\ M-MOP]VW7^>YTU^_RS;A56&SP"UYSB5\#BLDA>>"]E[,?;'_Y/+5PWUE!OEX;>O5\J3M-V^?M\;=,ACY]?6XTWW_E=RVWO\)WS,W?5Z?\?O_4%KT/F^ M>!GT1Y=6_^$YKCZ<[D*71_=%BXB?EF' 0.'1V2RQ>$S%'?'Q%^NUC'3'M6P4 MP&0(R(&F*G1.H4.-Z":\H3ODS]FEZC:;6+:;A2>JX?&;;A=ZLV?7WUJ>39X\ M!SIQ<.SY+0^X2SZ<':"#WWF,!^]$PR=J>* N2ZA#7AFL ?YB9Q,#8 $]/?W! M5.1!OR?V-H&O0=?04QSCV@Q[XI?W&L'EO?,EYLF_+(^H $0+V,8$%H1? >\? MO$*>IN35LC6'.)XZPO5D\/2.JD^@139#,D_,T-D+_XB0UTTO^.P9&GY@0%GC MH*V_8/RD [^8_/F83OD?1#Y^<$&8,O[),I\MF Q^1/CQOY:+,Z8&_V(S3?>[ MF]C6'T'/SB@<^54WC P!L&9>@Y\L)"%&3$ T/VP$] /?'4: .L8./@[H#+_F M9[<@KX&*;KY8!O3PT[1>_?.3GNE_MG7G)R#/ ^382(>S[ J_ZZ&?[)6=@1,G MI(\G\#-.!V04,5@T$QTHQ;*G MQ)F:ZA0!1%YTVX,W@&5< C &K'N8W@$49OLG/8%8D!8Q#\0 !!KPPR)A 3"H M.D+4^BMV+?+$"&(2N1MX2=.'0V;#,S*TK;&_CGG,$XD;!L*3\= 3+!"H1$-B MPG8?4>@'0,=E^)S+8/)C"SDUD N8HYM=9F;4=M#"M:[V4Z)+:KQ4#4T_'0_\ MNU0P/\FNP.](]5DL15=%S95 =!@ V13T%2J'0"B#+PV=!# M007MV1OH560?U1J# .)J9ZZ/LD1#B6%- O43-H&)@G!]1=QK'BCC4,O1H-=Y M#Y($SDD"RQCC!DJ(,6#4 +DC*FDI'-2 M$E@FR-(,Q/YP"%8A8M8&+(,5.#<+%BG&-P[ TEFBN@45@N2P5H=<2SR?56), MP.9[U=$B?7.#:V.>K1=FFV,?Z<^>06?51/"!@T.0)S#10O7_P]1G%3=]Y4"? M;(MJ$K5G1.T8G13DMG?*VF0N.'X_?2=)!XM\ EXT6G(:FS .2.+P?'(:N">^ MB >[P=:?/'1R_-YY]8:E1\LJYQH?2@(X'P$ (ER&[B?\C'ZY8< WSU?H8+!! M(QZXY/ZQKZ@QRD!5U>/>W1#=/AL&X9$3,W $/^IFZ+MM3CXNK)\2D_]D&$ Q M+:!I!Y,(R=3R?"_[@R *AB(0#B\L\*,1>J@W??,'NT"8 A\!$H"?-((#(&X, MJJ(!I($^!9=6]UUS\T,/NN6#W0X+.H$U_\)GP6,R@=^^Z,G/%'40IN+!F7G@ M:2E,M:];_Z]@B9Z-JT.- M^&GL&#:':5ZHK5N>@W)C5A)F M3#6&PWG.A]$]3LLMTT0X//)?$6BWECTF2B'W=S+4#9@%UV8XTKMS,)TW=43- M9X:7I(UUOXS6)VR7Z7?:F<_8%2]SZR?+U'F)V+)OQYI!1,*?BK,R4*?MTXKF M%^CB/_*(D1_B\X-#\Z -Y7;N4EPP3WKS6"C%0,>?GF[[2##H:Q;YDV^FN/0G M>&,6L9X,_=G7S !V;X(5"A%Y"'9T!,T/PW_H,+(ALC+W[!8B/-F0K* O5;=5 M;PRO 7G"#TC<*!$(C\[S1?JC#M>C++_9AE\,X!]U*^.L(?[UHJ84RP9*26Z@ MK-U \<[4?*^.-O] MWSG[MW? M=.[[G1N8Y7V_=]>] 33=D&^M.\!;A_1_ZW1VVQX\P]P__3"IIZ&[^%G4&79- M,AB!@0*:&XPF,!K8Q"7]$5HY-]2ELWGS%(2Y9K)!-^=@:@:=..PJ_' -%@&8 M7],KW>1#\9>NEW,-P'A_GV["0> _GHOG?,$7T4%&4C!R\#@/C[ZL_EZMYAN% MRMI'A;RR]O=-7:&;48S6U>;?*PCKN"95_;"K>.IS!P@.4 9-"2\+39 ,KS]( M)O(I^)AIX/6=LL##"QQ\JW:?BDWIA,L-4]GX":S9 #3+)X[7THY2W"6+[/0+ M7%^VJ]7O+ZJ#'8XT/%'UY[-M@;>1"V:FJHP-AQ^A\]AG'79#9AO\$[Z] 9ZL MZUSM0.5;U[J-_$_V?F2D#?E_[Y%&\&]-2.3A%4T\6H ?T/U]H89?87\9C5%6 M7"#"$NM?#UK7XGIX .[\"_JJOUV9EGF+9CV&)3Q3=Q\QY]-SM S/WX(I\Q_4 M'!"NQE1]3 T'_ 'X9M(QPY:Y9THG5T@++5/#/YTY(;3<-K7M*<#@=VIX+$/\ MH 4X(F_NE>F-+2K:*]_XLS[3I.SZ'X"/D MK)WQ$D$BO!MN4:)(5D@^*Y3/P I8+4_)%BH505@A)HM$7.7VR'"33,5M4E1O M&RV38K0UK^7I!/+ %G4PAQZR06#E1:7Y8J:I9!O5@Z7_!Z1W#.F_BSUYH52S M17+&0C4E3C4U4:@F]5Y ?V39;@XSM3$9&S X7N<"[$3YN]I ":3\+?*2 W$ M,.S.01B5\,M@+5>S2ED1Q$2(P5J^=*K9(B_CH!J\C;21+59$H9I3A[HV);M4 MXTI,VHTJ6JH*B^+G)50&/@/N5.2(:U,\8F$R?B:%&H;U&NSL#\E?8Q0_K;#G M6\N^L;PG=^@9X8P>9Q/:4R%742$KC57/A<>.(BUC"S\<=1EXVV"V5"NM+"/+ M#_Z$:=!;SC-?J.&WC?Y6D'3/W#WQ5,>CR-EB[6!/6;H-HE#/-K:/D7JPZDLY M6U5J@E!/ZMT'-%U,/#F,QRI!T4G'(9+D#,$W!9*/2.OE F@TI9BMUAN"V'[2 M8SBVJ#R$7!2\;KF2K2?%50@3>6"B;#-U';-5TB>8_"C^@\TF5/=3YTUGJ0" MNI1Z(./[D=1. ->.#]:6J?%<^!8'Y7Z6%];UJF0+E:H@AIQ!)C'Z1.IH6#MX5M#N%5 MW*XH +<6XTIIV TU"?!++HO&M@5W#J&Q"M!8L9HM-PZV*HY.8ZE-\7T(3QWS M(ZQ_>CHO.[)_K"?%!M-6H]N'Y(-!31?LI4X(S#V<^6JF6:Z#\#W8EY?FMBC4 ML]7()3_^(^2&G(W:Q2<[Q?NI#3ZVQ!3/X#]_) MQ\(NYK..'WU<2O477?W=ZEBUZ$Y_85IW!D_?/-Q#A-4SS5HA6ZJ+DB"Q M%6"\]-/(-*L-@=(,4K]1_*ME:5B^1VX01Y*:(=@BTG>ED&DVE&RY+LIFG]P; M/K9\W)=2E$RS7LI6&Z)D$:3>LO2=@A6;4IJ3$3-G-#;<;!)TWH*;"?9E"SR] M5,_6&M+ 3 U%;4VN.2Y%X2++9)V85__WC+5 MO;9R*N5,LYPMU,N"&!G2'#VV-(V%:G #,-LH'YP0(J!I*G*^A;40MC[$+-VX MW9K6S? -DO2GKCE7[WEA9D]LW-F)RBUX4JM>SM9*![MR4?&7 (/VXFAQ@WP^ M$2WB<;N:DBT6XMJA/BHM!H(]G$0(<_^*R1-OM>VTT'/M T:;7&J38GPUN5Y! M'NQ9B['$W4M$K5M7PF7G3HF3445B'5R@4BVKU$79EEN]=M_6M>]<==#M] MTKJ_(?U!K_WWWWIW-YW'_B^D\X\?W<&_#JOTFY1,MK#2KZ'[-Q[I3":T)6O; M<5:B9D*GB_5II/V:/I6^8[V6!Y\2]CN=4<7Z XULK92B(Y^2]I-/^SM6FSF, M]K&80C%;+<<5:95[N=NUE^TQ?FLRGC>>WY#ZQ$PVU.6F;D05T!E/#&O*V"-> M <>TN[E9MR='%#--4 :'UVV5&[RB4- 601H[!6%^C)(MQ7:@6![_3[K+$CJ= M>+=E<-VY89G/?K5BC3VY_HV@=#@$R@,BE"F4NV]'WP$@L?;L#8 Q@/-WZ@;7 MMP8\_8 W5:_AU#)FLAVY_M.%E $ M!W 3V]*\%H78/A*ZYR6V&B1"3\W)QU+9%%!].;0JO7U:M'KTL M9!S4EMHD^+M9*/[@I#!Y!_S9<8C;*;.KRM3E4**,$RX+N,H6 1>$S.\MESDM M4[NS8%I191S?3Z_41(G!R(#?P513/0'5E)!JBHV#2TR<)G*7_+#.W4?;T;&* MTQ2[[K6]&&.%]LN99D68>Z-E1.=@LJC'0Q:53+.JI#%@(Z1 ;'V\XRPM3&%V MHO>NRE*KXC4]567U*EUIFB:4W$ZP%[T_N=60W"I)N;8P^3;M#1LR0)0&\ENU MQHRX]$UN4T:,J(K7J&M^N+!:D<9L:^MD2(X^9?AI(/^7Z MP1I;6L%1LCV,=0%R:>D>E.^QMQE1Q^.JV;HBRND2:;6>.N5C?]+!TYY911'E M;-NEE*&,3WYNJR&72O;8/>EC?\XHXBV@V=KAUTQ$PE ";-;+(K7=,S[V)[42 M)[5";.?.CGX7:#@#44I-R6J2@B;2!-I.YH0?KLFB"I5RIEFM9JNQ5:E-F)9* M(['LKHNB$@O?2$/2\D)R@G*"29]@LDU9_NNI?X<60:( M7.<7PO[T='W[ZWSOPA. 4]4+MG]UVL+_([-3PV[W(7JZTPL]JJ'YN/ MFV9:/OU,:YEF(0]X6U,!:^4',J$V><'1KLG&Y3DX"^> E?%E."W/'5DVT(D6 M=47U#V"_?G(1".30R>&F:"$+\,;_[P!Q?\*$S@:,#/G(B^LZCA=Y88U"IEDL M92OE0K:\)O%QM@Y3.SKE[#=_A<^_5*MGRX75@B?A_'7>-Z$.IA-^I[8Z\KVP MDI(EQ4*QS!=XPU0V?F+VTJ-2ED '$P;]O3!C.E--(&;EONR.,9<%5'.9M^HN M-XK@+@NR8R8W6X\=5MF!'DKBT$/J<_A:,$^$+S7 4-"UG&X2E4YTEQHRMARM M5/H,D \ QZ[9]J$8,738P+,I]5*V4$]1L?1+IYQMA<;CH9P*4DXA.==&)S"P MDK3LPI:J>F./5]XD>&6YJKN7D%7XZ2"Q[L"DX=-[+GUD+H61M ZU30""LP#; M&Q^T41FVBGD*%7"_5AGVL[1[DT=)*V+^9)2$=1@;M6RMO)IX>')*2K_%O"!4 M_?NO\:H)FXV8Z>@OC!B61L@O Y5FY[470^F<<[@"^]\SM#0?T+2JC MU,&SS#:JJ[&NW=E$FM7"$-6N O?(1,7/S%2*JP[;R8GJ4JK\.6LV#F69O_AB M&8L;LQT.W8@\ 3/*-$NU0K92/S@+-RJ.$F#^7AR];8F Q$!O"M);+;MN2U1 M>DMM2L=*AC+?7-M%7N^8A>\O:=U]PP<4QX?%,;HAD7,FXQT[ CX=Q2\BX]6RMG +&Y1;$%Q<+YH0) M*0O)?PO]J Q ;@

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�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end XML 77 kids-20240331_htm.xml IDEA: XBRL DOCUMENT 0001425450 2024-01-01 2024-03-31 0001425450 2024-05-03 0001425450 2024-03-31 0001425450 2023-12-31 0001425450 us-gaap:NonrelatedPartyMember 2024-03-31 0001425450 us-gaap:NonrelatedPartyMember 2023-12-31 0001425450 us-gaap:RelatedPartyMember 2024-03-31 0001425450 us-gaap:RelatedPartyMember 2023-12-31 0001425450 2023-01-01 2023-03-31 0001425450 us-gaap:CommonStockMember 2023-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001425450 us-gaap:RetainedEarningsMember 2023-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001425450 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001425450 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001425450 us-gaap:CommonStockMember 2024-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001425450 us-gaap:RetainedEarningsMember 2024-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001425450 us-gaap:CommonStockMember 2022-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001425450 us-gaap:RetainedEarningsMember 2022-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001425450 2022-12-31 0001425450 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001425450 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001425450 us-gaap:CommonStockMember 2023-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001425450 us-gaap:RetainedEarningsMember 2023-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001425450 2023-03-31 0001425450 srt:ScenarioPreviouslyReportedMember 2023-01-01 2023-03-31 0001425450 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2023-01-01 2023-03-31 0001425450 kids:BostonBraceInternationalInc.Member 2024-01-05 2024-01-05 0001425450 us-gaap:RestrictedStockMember kids:BostonBraceInternationalInc.Member 2024-01-05 2024-01-05 0001425450 kids:BostonBraceInternationalInc.Member 2024-01-05 0001425450 us-gaap:RestrictedStockMember kids:BostonBraceInternationalInc.Member 2024-01-05 0001425450 kids:BostonBraceInternationalInc.Member us-gaap:TrademarksAndTradeNamesMember 2024-01-05 0001425450 kids:BostonBraceInternationalInc.Member us-gaap:CustomerRelationshipsMember 2024-01-05 0001425450 kids:BostonBraceInternationalInc.Member us-gaap:CustomerRelationshipsMember 2024-01-05 2024-01-05 0001425450 kids:RhinoPediatricOrthopedicDesignsIncMember 2023-07-01 2023-07-01 0001425450 kids:RhinoPediatricOrthopedicDesignsIncMember us-gaap:CommonStockMember 2023-07-01 2023-07-01 0001425450 kids:RhinoPediatricOrthopedicDesignsIncMember us-gaap:CommonStockMember 2023-07-01 0001425450 kids:MedtechConceptsLLCMember 2023-05-01 2023-05-01 0001425450 kids:MedtechConceptsLLCMember us-gaap:CommonStockMember 2023-05-01 2023-05-01 0001425450 kids:MedtechConceptsLLCMember us-gaap:CommonStockMember 2023-05-01 0001425450 kids:MedtechConceptsLLCMember 2023-05-01 0001425450 kids:MedtechConceptsLLCMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-05-01 2023-05-01 0001425450 kids:MedtechConceptsLLCMember us-gaap:TrademarksMember 2023-05-01 2023-05-01 0001425450 kids:MedtechConceptsLLCMember us-gaap:IntellectualPropertyMember 2023-05-01 2023-05-01 0001425450 kids:MedtechConceptsLLCMember us-gaap:IntellectualPropertyMember 2023-05-01 0001425450 us-gaap:PatentsMember 2024-03-31 0001425450 kids:IntellectualPropertyAndCapitalizedSoftwareMember 2024-03-31 0001425450 us-gaap:CustomerRelationshipsMember 2024-03-31 0001425450 us-gaap:LicensingAgreementsMember 2024-03-31 0001425450 us-gaap:PatentsMember 2023-12-31 0001425450 kids:IntellectualPropertyAndCapitalizedSoftwareMember 2023-12-31 0001425450 us-gaap:CustomerRelationshipsMember 2023-12-31 0001425450 us-gaap:LicensingAgreementsMember 2023-12-31 0001425450 us-gaap:TrademarksMember 2024-03-31 0001425450 us-gaap:TrademarksMember 2023-12-31 0001425450 kids:ApiFixLtdMember us-gaap:TrademarksMember 2023-01-01 2023-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2023-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:TermLoanMember 2024-03-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:TermLoanMember 2023-12-31 0001425450 us-gaap:MortgagesMember 2024-03-31 0001425450 us-gaap:MortgagesMember 2023-12-31 0001425450 kids:AcquisitionNotesMember us-gaap:NotesPayableOtherPayablesMember 2024-03-31 0001425450 kids:AcquisitionNotesMember us-gaap:NotesPayableOtherPayablesMember 2023-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:SecurityAndGuarantyAgreementMember 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:SecurityAndGuarantyAgreementMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:TermLoanMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember kids:OptionOneMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember kids:OptionOneMember 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember kids:OptionTwoMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember kids:OptionTwoMember 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember kids:OptionThreeMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember kids:OptionFourMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:RevolvingLoanMember kids:OptionFiveMember 2023-12-29 2023-12-29 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember 2024-03-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-06-13 2022-06-13 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember 2022-06-13 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember kids:ThreeMonthLIBORMember 2022-06-13 2022-06-13 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember 2022-06-13 2022-06-13 0001425450 us-gaap:MortgagesMember 2024-01-01 2024-03-31 0001425450 us-gaap:RestrictedStockMember 2023-12-31 0001425450 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0001425450 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001425450 us-gaap:RestrictedStockMember 2024-03-31 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001425450 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001425450 country:US 2024-01-01 2024-03-31 0001425450 country:US 2023-01-01 2023-03-31 0001425450 us-gaap:NonUsMember 2024-01-01 2024-03-31 0001425450 us-gaap:NonUsMember 2023-01-01 2023-03-31 0001425450 kids:TraumaAndDeformityMember 2024-01-01 2024-03-31 0001425450 kids:TraumaAndDeformityMember 2023-01-01 2023-03-31 0001425450 kids:SpineMember 2024-01-01 2024-03-31 0001425450 kids:SpineMember 2023-01-01 2023-03-31 0001425450 kids:SportsMedicineAndOtherMember 2024-01-01 2024-03-31 0001425450 kids:SportsMedicineAndOtherMember 2023-01-01 2023-03-31 0001425450 srt:AffiliatedEntityMember 2024-01-01 2024-03-31 0001425450 kids:StructureMedicalLLCMember kids:SupplierMember 2024-01-01 2024-03-31 0001425450 kids:StructureMedicalLLCMember kids:SupplierMember 2023-01-01 2023-03-31 0001425450 kids:MDOrthopaedicsMember 2024-01-01 2024-03-31 0001425450 kids:BostonOPMember 2024-03-31 0001425450 kids:VilexAndOrthexMember 2019-06-01 2019-06-30 0001425450 kids:SquadronCapitalLLCMember kids:TeamNoteBMember srt:AffiliatedEntityMember 2019-12-31 2019-12-31 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2021-07-20 2021-07-20 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-03-31 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0001425450 srt:MinimumMember 2024-01-01 2024-03-31 0001425450 srt:MaximumMember 2024-01-01 2024-03-31 0001425450 kids:ApiFixLtdMember us-gaap:SubsequentEventMember 2024-04-01 2024-04-01 0001425450 kids:ApiFixLtdMember us-gaap:SubsequentEventMember 2024-04-01 0001425450 kids:MedtechMember us-gaap:SubsequentEventMember 2024-04-01 2024-04-01 0001425450 kids:MedtechMember us-gaap:SubsequentEventMember 2024-04-01 shares iso4217:USD iso4217:USD shares kids:individual pure kids:tranche kids:segment kids:supplier 2024 Q1 false 0001425450 --12-31 http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://www.orthopediatrics.com/20240331#AssetsNoncurrentExcludingPropertyPlantAndEquipment http://www.orthopediatrics.com/20240331#AssetsNoncurrentExcludingPropertyPlantAndEquipment http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent 10-Q true 2024-03-31 false 001-38242 OrthoPediatrics Corp DE 26-1761833 2850 Frontier Drive Warsaw IN 46582 574 268-6379 Common Stock, $0.00025 par value per share KIDS NASDAQ Yes Yes Accelerated Filer false false false 23828882 21602000 31055000 1962000 1972000 26141000 49251000 1195000 1373000 36275000 34617000 112689000 105851000 5056000 3750000 203725000 226496000 48721000 41048000 70382000 69275000 91481000 83699000 18792000 15287000 4084000 2940000 184739000 171201000 437185000 438745000 19736000 12649000 9772000 11325000 154000 152000 10368000 10149000 5790000 7391000 45820000 41666000 9579000 9297000 572000 611000 3613000 3551000 5202000 5483000 1815000 1112000 20781000 20054000 66601000 61720000 0.00025 0.00025 50000000 50000000 23540411 23378408 6000 6000 583086000 580287000 -205547000 -197742000 -6961000 -5526000 370584000 377025000 437185000 438745000 44685000 31588000 12511000 8027000 32174000 23561000 14169000 12549000 24730000 17157000 2998000 2446000 41897000 32152000 -9723000 -8591000 -637000 210000 0 -670000 24000 331000 -613000 1211000 -10336000 -7380000 -2531000 -574000 -7805000 -6806000 22820779 22820779 22506024 22506024 -0.34 -0.34 -0.30 -0.30 -7805000 -6806000 -1426000 -962000 109000 617000 -118000 -301000 -1435000 -646000 -9240000 -7452000 23378408 6000 580287000 -197742000 -5526000 377025000 -7805000 -7805000 -1435000 -1435000 162003 2799000 2799000 23540411 6000 583086000 -205547000 -6961000 370584000 22877962 6000 560810000 -176768000 -5400000 378648000 -6806000 -6806000 -646000 -646000 264156 1959000 1959000 23142118 6000 562769000 -183574000 -6046000 373155000 -7805000 -6806000 5028000 3848000 2799000 2113000 0 -670000 281000 381000 -2445000 -574000 -1155000 2002000 6631000 5979000 953000 33000 6562000 5541000 -5049000 -1571000 -368000 709000 -6690000 -6461000 20693000 0 23474000 37250000 6460000 4940000 -3679000 32310000 538000 0 35000 36000 -573000 -36000 1479000 -138000 -9463000 25675000 33027000 10462000 23564000 36137000 223000 11000 117000 332000 BUSINESS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Spine, BandLoc Duo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Pediatric Nailing Platform | Femur, Devise Rail, Orthex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, The Fassier-Duval Telescopic Intramedullary System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SLIM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nail, The GAP Nail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, The Free Gliding SCFE Screw System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GIRO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Growth Modulation System, PNP Tibia System, ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mid-C System and Mitchell Ponseti</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> specialized bracing products to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation while our clubfoot orthopedic products are manufactured in-house. </span></div>We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants, instruments and specialized braces to meet the needs of pediatric surgeons or orthotists and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2023 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") o</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n March 8, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div><div style="padding-left:1pt;padding-right:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $205,547 and $197,742 as of March 31, 2024 and December 31, 2023, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short-term investments, at March 31, 2024 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in the Company's significant accounting polices as disclosed in Note 2 to the audited consolidated financial statements included in the 2023 Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the condensed consolidated financial statements, the Company has reclassified stock-based compensation to conform to the current period presentation. All stock-based compensation was previously recorded within general and administrative expenses, and such costs have now been allocated between general and administrative expenses, research and development expenses and sales and marketing expenses. The current presentation results in stock-based compensation expense being recorded in the same manner in which the award recipient's payroll costs are classified. This reclassification did not affect previously reported total operating expenses, loss before income taxes, or net loss in the condensed consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the impact of the reclassification on our condensed consolidated statements of operations: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing (prior presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing (new presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,549 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative (prior presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative (new presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development (prior presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development (new presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Concentration of Credit Risk </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, the FASB issued ASU No. 2023-06 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Disclosure Improvements - Codification Amendments in Response to SEC's Disclosure Update and Simplification Initiative". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This amendment modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. For entities subject to the SEC's existing disclosure requirements and entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. Amendments in this Update should be applied prospectively. The Company continues to analyze this ASU. The update is specific to disclosures and, therefore, is not expected to have a material impact to the condensed consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">." The standard requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. This authoritative guidance will be effective for us in fiscal 2024 for annual periods and in the first quarter of fiscal 2025 for interim periods, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>" ("ASU 2023-09), which enhances the transparency and decision usefulness of income tax disclosures. The ASU is effective for public companies for fiscal years beginning on or after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2023 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") o</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n March 8, 2024.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2023 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div>The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. -205547000 -197742000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div>In the condensed consolidated financial statements, the Company has reclassified stock-based compensation to conform to the current period presentation. All stock-based compensation was previously recorded within general and administrative expenses, and such costs have now been allocated between general and administrative expenses, research and development expenses and sales and marketing expenses. The current presentation results in stock-based compensation expense being recorded in the same manner in which the award recipient's payroll costs are classified. This reclassification did not affect previously reported total operating expenses, loss before income taxes, or net loss in the condensed consolidated statements of operations. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the impact of the reclassification on our condensed consolidated statements of operations: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing (prior presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing (new presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,549 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative (prior presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,666 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative (new presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,157 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development (prior presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development (new presentation)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12216000 333000 12549000 17666000 -509000 17157000 2270000 176000 2446000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Concentration of Credit Risk </span></div>Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments and Concentration of Credit Risk </span></div>Financial instruments that could subject the Company to credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents.The Company performs ongoing credit evaluations of customers and maintains a reserve for expected credit losses. The Company believes the risk of credit losses associated with accounts receivable is low given the history of collections and customer base. Additionally, the Company considers the risk for credit losses associated with short-term investments to be low given the types of investments which primarily include Certificates of Deposits and Treasury Bonds. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2023, the FASB issued ASU No. 2023-06 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Disclosure Improvements - Codification Amendments in Response to SEC's Disclosure Update and Simplification Initiative". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This amendment modifies the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. For entities subject to the SEC's existing disclosure requirements and entities required to file or furnish financial statements with or to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer, the effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all other entities, the amendments will be effective two years later. Amendments in this Update should be applied prospectively. The Company continues to analyze this ASU. The update is specific to disclosures and, therefore, is not expected to have a material impact to the condensed consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2023, the FASB issued ASU No. 2023-07, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">." The standard requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items to reconcile to segment profit or loss, and the title and position of the entity's CODM. The amendments in this update also expand the interim segment disclosure requirements. This authoritative guidance will be effective for us in fiscal 2024 for annual periods and in the first quarter of fiscal 2025 for interim periods, with early adoption permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>" ("ASU 2023-09), which enhances the transparency and decision usefulness of income tax disclosures. The ASU is effective for public companies for fiscal years beginning on or after December 15, 2024, with early adoption permitted. The amendments in ASU 2023-09 should be applied on a prospective basis. Retrospective application is permitted. We are currently evaluating the effect of this new guidance on our consolidated financial statements and disclosures. BUSINESS COMBINATIONS AND ASSET ACQUISITIONS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Boston Brace International, Inc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 5, 2024, the Company purchased all of the issued and outstanding share capital of Boston Brace International, Inc., a Massachusetts corporation ("Boston O&amp;P"). Boston O&amp;P has developed and manufactures pediatric orthotic and prosthetic devices, including non-surgical scoliosis treatment options, and provides related clinical services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the stock purchase agreement, the Company paid to the shareholders of Boston O&amp;P consideration of $22,000 in cash, subject to customary adjustments related to net working capital, transaction expenses, and funded indebtedness. Additionally, certain employees and executives of Boston O&amp;P also received awards of restricted stock of the Company which will vest in three years subject to continuous service. The Restricted Stock Award Agreements were to approximately 170 individuals for an aggregate of approximately 83,000 shares representing approximately $2,500 (based on a share price of $30.12, which was the average closing price during the four-month period ending on January 4, 2024) and were granted pursuant to the Company’s 2017 Plan. The restricted stock units are not considered part of the purchase consideration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration paid for Boston O&amp;P and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of estimated total acquisition consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable - trade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable-trade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,639 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: total net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,953 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,047 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of identifiable intangible assets and certain long-lived assets were based on valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Economic Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks / Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the pro forma net revenue and net loss assuming the acquisition of Boston O&amp;P occurred on January 1, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Rhino Pediatric Orthopedic Designs, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2023, the Company completed an acquisition of assets, including inventory and certain intangible assets, of Rhino Pediatric Orthopedic Designs, Inc. ("Rhino"). Rhino's product portfolio included several pediatric orthopedic products in the bracing and soft goods space, including the Cruiser </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Kicker </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Rhino Stomper </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company paid $1,024 in total consideration for the assets which was comprised of $546 of cash, including $46 of transactions costs, and 11,133 shares of the Company’s common stock, par value $0.00025 per share, representing approximately $478 (based on closing price of $42.91 on July 1, 2023). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Medtech Concepts LLC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2023, the Company purchased all of the issued and outstanding membership interest of Medtech Concepts LLC, a Delaware limited liability company (“MedTech”). MedTech has developed an early-stage, pre-commercial enabling technology platform designed to increase efficiency in the perioperative environment. The solution combines hardware, software, and data analytics to help streamline operative care and support better decision making in the operating room. In the future, the Company believes this enabling technology platform will provide valuable intraoperative resources for surgeons that will improve decision making, drive operating room efficiency, and ultimately improve healthcare for children. The Company also expects that the acquisition will further support future market share gains for its implant systems, similar to what the Company has experienced with the FIREFLY</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Technology and the 7D Surgical FLASH</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Navigation platform. No revenue was recorded from this platform in 2023, and the Company does not anticipate material revenue contributions from the platform in 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sellers of MedTech are being paid a purchase price of approximately $15,274 in the following manner: (i) cash in the aggregate amount of $3,000 was paid on May 1, 2023, the transaction closing date (the “Closing Date”); (ii) 43,751 unregistered shares of the Company’s common stock, par value $0.00025 per share, representing approximately $2,274 (based on a closing share price of $51.98 on May 1, 2023), were issued on the Closing Date; and (iii) an aggregate of $2,500 payable 50% in cash and 50% in shares of unregistered common stock, will be paid on each of the first four anniversaries of the Closing Date, all subject to the conditions set forth in the Membership Interest Purchase Agreement (the "Purchase Agreement"), as amended, relating to the transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the business acquired did not comprise an integrated set of activities that meet the definition of a business and therefore did not result in the acquisition of a business. Instead, the Company accounted for the transaction as an asset acquisition for accounting purposes. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Purchase Agreement, a number of future payments in the form of common stock are contingent on continued service through each applicable payment anniversary date. As such, these amounts have been excluded from measuring the cost of the acquisition. The result is $4,500 of stock compensation which is being recognized on a straight-line basis over the four year service period. Future cash payments and stock issuances that are not contingent on continuous service are included in the calculation of consideration. The total consideration is $10,043 after discounting the future guaranteed fixed payments to their present value. Additionally, since this was treated as an asset acquisition, the Company included $97 of transaction costs in the total consideration. The table below reconciles the payments and issuances to total consideration transferred after discounting the future payments to present value. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anniversary payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As result of this asset acquisition, the Company recorded a trademark asset in the amount of $520 with an indefinite useful life and an intellectual property asset relating to software acquired of $9,523 which is being amortized over a useful life of ten years. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin Unger, a member of the Company’s Board of Directors (the “Board”) through April 28, 2023, was one of the sellers in the transaction. As a result, the Board formed a special committee comprised of independent and disinterested directors (the “Special Committee”) with the exclusive authority to review, evaluate, and negotiate, or reject, the potential MedTech acquisition. The Purchase Agreement and the transactions contemplated thereby were approved by both the Special Committee and the full Board (with Mr. Unger abstaining).</span></div> 22000000 P3Y 170 83000 2500000 30.12 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration paid for Boston O&amp;P and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of estimated total acquisition consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable - trade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,093 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,592 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable-trade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,639 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: total net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,953 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,047 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 22000000 1307000 2876000 1093000 378000 4360000 3720000 3650000 2208000 19592000 581000 2063000 724000 2268000 1003000 6639000 12953000 9047000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of identifiable intangible assets and certain long-lived assets were based on valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Economic Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks / Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 3650000 3720000 P12Y 7370000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the pro forma net revenue and net loss assuming the acquisition of Boston O&amp;P occurred on January 1, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,435 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 45116000 38435000 -7786000 -6690000 1024000 546000 46000 11133 0.00025 478000 42.91 15274000 3000000 43751 0.00025 2274000 51.98 2500000 0.50 0.50 4500000 P4Y 10043000 97000 The table below reconciles the payments and issuances to total consideration transferred after discounting the future payments to present value. <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anniversary payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,871 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,043 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000000 3000000 2274000 2274000 5500000 4672000 97000 97000 10871000 10043000 520000 9523000 P10Y GOODWILL AND INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill for the three months ended March 31, 2024 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Boston O&amp;P acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,481 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the balances of amortizable intangible assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,619)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property &amp; Capitalized Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,764)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,382 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the balances of amortizable intangible assets were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property &amp; Capitalized Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,267 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,992)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses are tied to product launches and do not begin amortizing until the product is launched to the market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks are non-amortizing intangible assets which were $18,792 and $15,287 as of March 31, 2024 and December 31, 2023, respectively. Trademarks are recorded in Other intangible assets on the condensed consolidated balance sheets. The change in balance during the three months ended March 31, 2024 was driven by foreign currency translation adjustments and the Boston O&amp;P acquisition.</span></div>During 2023, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the Company completed a quantitative analysis whereby we determined the fair value of the ApiFix trademark asset was below the carrying value. We recorded an impairment charge of $985 for the year ended December 31, 2023 to reduce the carrying amount of the intangible asset to its estimated fair value. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill for the three months ended March 31, 2024 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Boston O&amp;P acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,481 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 83699000 9047000 -1265000 91481000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the balances of amortizable intangible assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,619)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property &amp; Capitalized Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,675)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,146 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,764)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,382 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the balances of amortizable intangible assets were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,646 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property &amp; Capitalized Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,862 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,267 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,992)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P11Y 44969000 11619000 33350000 P8Y10M24D 16027000 2911000 13116000 P12Y1M6D 22417000 3675000 18742000 P3Y7M6D 10733000 5559000 5174000 94146000 23764000 70382000 P11Y2M12D 45646000 11008000 34638000 P9Y1M6D 16026000 2524000 13502000 P12Y4M24D 18862000 3270000 15592000 P3Y9M18D 10733000 5190000 5543000 91267000 21992000 69275000 18792000 15287000 985000 FAIR VALUE OF FINANCIAL INSTRUMENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.</span></div><div style="padding-left:14pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange Trade Mutual Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 assets consist of short-term, liquid investments with original maturity of three months or less at inception and other short-term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 2 assets pertain to certain asset-backed securities, collateralized by non-mortgage-related consumer debt, or certificates of deposit. These securities are predominately priced by third parties, either by a pricing vendor or dealer with significant inputs observable in active markets. </span></div>The Company's Level 3 instruments consist of contingent consideration. The fair value of the contingent consideration liability assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as forecasted annual revenues, expected volatility and discount rates. The contingent consideration was zero as of both March 31, 2024 and December 31, 2023. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange Trade Mutual Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 26141000 0 26141000 0 25792000 0 25792000 5015000 0 0 5015000 18235000 0 0 18235000 207000 0 0 207000 DEBT AND CREDIT ARRANGEMENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of the dates indicated: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:57.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term loan and final payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage payable to affiliate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,063 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net of current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,908 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-right:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2023, the Company entered into an $80 million Credit, Security and Guaranty Agreement (the “Credit Agreement”) by and among (i) the Company and other borrowers party to the Credit Agreement (collectively, the “Borrowers”), (ii) MidCap Funding IV Trust, as Agent (“Agent”), (iii) MidCap Financial Trust, as Term Loan Servicer (“Servicer”), and (iv) the financial institutions or other entities from time to time party thereto as Lenders (collectively, “Lenders”). Under the terms of the Credit Agreement, the Lenders have provided to Borrowers a term loan in an aggregate principal amount that will not exceed $30 million available in three tranches of $10 million each subject to certain draw conditions (the “Term Loan”) and a revolving loan in an aggregate principal amount that will not exceed $50 million (the “Revolving Loan”). Borrowings are available subject to certain levels of working capital for the Revolving Loan. The second tranche of the Term Loan is eligible to be drawn between July 1, 2024 through June 30, 2025. The third tranche of the Term Loan is eligible to be drawn between January 1, 2025 through June 30, 2025. The Company must meet certain cash usage requirements at the time of each draw to be eligible to access these term loans. Interest on the Term Loan will accrue at the greater of (a) One Month Term SOFR plus 6.50% or (b) 9.0% and interest on the Revolving Loan will accrue at the greater of (a) One Month Term SOFR plus 4.0% or (b) 6.50% (the “Applicable Rate”) and </span></div><div style="padding-right:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be payable monthly by the Borrowers. The Term Loans may be prepaid in full through December 29, 2024 with payment of a 3.00% prepayment premium, after which they may be prepaid in full through December 29, 2025 with payment of a 2.00% prepayment premium, after which they may be prepaid in full through December 29, 2026 with payment of a 1.00% prepayment premium, after which they may be prepaid in full with no prepayment premium. An additional final payment of 3.00% ("Final Payment") of the amount of the Terms Loans advanced by the Lenders will be due upon prepayment or repayment of the Terms Loans in full, and is accounted for as debt discount. The first tranche of $10 million was issued under the Term Loan upon execution. Payments of principal and all accrued but unpaid interest will be due and payable upon the earlier of: (i) December 1, 2028; (ii) the occurrence of any transaction or series of transactions pursuant to which any person or entity in the aggregate acquire(s) 35% or more of the voting capital stock of the Company; (iii) a change in the majority of the Company’s Board of Directors over a 12-month period; (iv) the Company ceases to own directly or indirectly, 100% of the capital stock of any of its subsidiaries (with the exception of any subsidiaries permitted to be dissolved, merged or otherwise disposed of by the Credit Agreement), or (v) the occurrence of a change in control, fundamental change, deemed liquidation event or terms of similar import under any document or instrument governing or relating to debt of or equity interests of the Company. The loans under the Credit Agreement are secured by a security interest in the Company’s and other Borrowers' assets. The Credit Agreement provides for customary events of default. If an event of default is not cured within the time periods specified (if any), the Lenders and Agent have the right to accelerate the Company’s payment of principal and interest in addition to other rights and remedies.</span></div><div style="padding-right:7pt"><span><br/></span></div><div style="padding-right:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement includes certain customary non-financial covenants, and also include certain financial covenants related to the Company achieving minimum revenue targets over a trailing twelve month period. The Credit Agreement was amended on May 3, 2024 to clarify the inputs into the financial covenant calculations. No other changes were made to the Credit Agreement. The Company was in compliance with all covenants under the Credit Agreement, as amended, as of March 31, 2024 and December 31, 2023.</span></div><div style="padding-right:7pt"><span><br/></span></div><div style="padding-right:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt facilities available under the Credit Agreement replace the Fourth Amended and Restated Loan and Security Agreement with Squadron Capital, LLC ("Squadron"), (as amended, the “Squadron Loan Agreement”), which provided the Company with a $50 million revolving credit facility. During the year ended December 31, 2023, there was no indebtedness outstanding under the Squadron Loan Agreement and it was terminated in connection with the Credit Agreement.</span></div><div style="padding-right:7pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Squadron Loan Agreement accrued interest at an annual rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%, and the Company was permitted to make interest only payments on amounts outstanding. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company paid Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee was payable quarterly in arrears. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Squadron Loan Agreement were made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note matured at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024. </span></div><div><span><br/></span></div><div style="padding-right:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Squadron Loan Agreement were secured by substantially all of the Company's assets and were unconditionally guaranteed by each of its subsidiaries with the exception of Vilex in Tennessee, Inc. ("Vilex"). There were no traditional financial covenants associated with the Squadron Loan Agreement. However, there were negative covenants that prohibited us from, among other things, </span></div><div style="padding-right:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. At March 31, 2024, the mortgage balance was $726 of which current principal of $154 was included in the current portion of long-term debt. As of December 31, 2023, the mortgage balance was $763 of which current principal due of $152 was included in the current portion of long-term debt. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate interest expense relating to the notes payable to Squadron, the mortgage note payable to Tawani Enterprises Inc. and the term loan with MidCap was $339 and $11 for the three months ended March 31, 2024 and 2023, respectively.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of the dates indicated: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:57.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term loan and final payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage payable to affiliate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,063 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net of current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,151 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,908 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10300000 10300000 726000 763000 261000 0 11287000 11063000 982000 1003000 154000 152000 10151000 9908000 80000000 30000000 3 10000000 50000000 0.065 0.09 0.04 0.065 0.03 0.02 0.01 0.03 10000000 0.35 50000000 0.0869 0.10 0.0861 0.10 0.005 16000 0.05 726000 154000 763000 152000 339000 11000 INCOME TAXES <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the income tax benefit was $2,531 compared to $574 for the three months ended March 31, 2023. Our effective income tax rate was (24.5)% and (7.8)% for the three months ended March 31, 2024 and 2023, respectively. The higher effective rate compared to the prior period is from the remeasurement of the valuation allowance subsequent to recording the deferred tax liability as a result of the purchase accounting from the Boston O&amp;P acquisition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets were fully offset by a valuation allowance at March 31, 2024 and December 31, 2023, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix, Ltd. ("ApiFix") and Pega Medical. See Note 3 under Item 8 in the Company's Annual Report on Form 10-K for additional information regarding the ApiFix business combination. The Company has recorded a tax benefit during the period ended March 31, 2024 for losses generated in Canada and Israel, respectively.</span></div> -2531000 -574000 -0.245 -0.078 STOCKHOLDERS’ EQUITY<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,659)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">671,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, there was $16,757 of unrecognized compensation expense remaining related to our service-based restricted stock awards and restricted stock units. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.9 years or earlier upon an elimination of the restriction period as a result of a change in control event. </span></div>Stock-based compensation expense on restricted stock amounted to $2,799 and $1,959 for the three months ended March 31, 2024 and 2023, respectively. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.323%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,473 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,470)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82,659)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">671,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 592453 P1Y7M6D 13851 P1Y8M12D 165473 7900 3470 100 82659 0 671797 P1Y10M24D 21651 P1Y10M24D 16757000 P1Y10M24D 2799000 1959000 NET LOSS PER SHARE<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted net loss per share:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,805)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,820,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,506,024 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our basic and diluted net loss per share is computed using the two-class method.  For purposes of our equity disclosures and calculation of weighted average shares for basic earnings per share calculations, the two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. </span></div>The contingently issuable shares in the paragraph above do not include shares of our common stock associated with our obligation to issue a variable number of our common shares as a result of our recent acquisitions of Pega Medical, ApiFix or MedTech. See Note 3 for additional information regarding our commitment to issue future equity under the MedTech acquisition. Additionally, as a component of the acquisition of ApiFix, the Company is obligated to make anniversary installment payments on the second, third and fourth anniversary of the acquisition date. These payments included a minimum cash component with the remaining settled in common stock. See Note 3 under Item 8 in the Company's Annual Report on Form 10-K for additional information regarding this business combination. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted net loss per share:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,805)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,806)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,820,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,506,024 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -7805000 -6806000 22820779 22820779 22506024 22506024 -0.34 -0.34 -0.30 -0.30 BUSINESS SEGMENT <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reportable segment, which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No individual customer accounted for more than 10% of total product sales for the three months ended March 31, 2024 or 2023. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No individual customer accounted for more than 10% of consolidated accounts receivable as of March 31, 2024 and December 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by source were as follows: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by geographic location:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,685 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.025%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by category:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trauma and deformity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scoliosis</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,072 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sports medicine/other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,685 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,588 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1 1 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by source were as follows: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by geographic location:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,380 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,788 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,685 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 34305000 23800000 10380000 7788000 44685000 31588000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by category:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trauma and deformity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scoliosis</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,072 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sports medicine/other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,685 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,588 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 33302000 23395000 10203000 7072000 1180000 1121000 44685000 31588000 RELATED PARTY TRANSACTIONSIn addition to the expired debt and credit agreements and mortgage with Squadron (the Company's largest investor) and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $382 and $246 for the three months ended March 31, 2024 and 2023, respectively 1 382000 246000 EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. Additionally, employees of MD Ortho receive contribution matches up to 3% of their salary. 0.04 0.03 COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2024, the Company has recorded a lease liability of</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> $2,235</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and corresponding right-of-use asset of $2,529 on its <span style="-sec-ix-hidden:f-515"><span style="-sec-ix-hidden:f-516"><span style="-sec-ix-hidden:f-517"><span style="-sec-ix-hidden:f-518">condensed consolidated balance sheet</span></span></span></span>. We assumed $1,749 of operating right-of-use assets and $1,582 of total lease liabilities in connection with our acquisition of Boston O&amp;P.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">IMED Surgical - Software Ownership Dispute</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron, and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company ("IMED"), in Broward County, Florida Circuit Court. In the lawsuit, IMED claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point &amp; Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with IMED. IMED, among other things, requests that the defendants be ordered to convey and assign to IMED all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent IMED desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, IMED initiated an arbitration proceeding; however, IMED failed to pay the fees it was required to pay for the arbitration to continue, resulting in the arbitration panel terminating the arbitration proceedings in mid-October 2022. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to IMED before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, the Court partially lifted the stay in this case for the sole purpose of, as clarified by the Court's order on March 7, 2023, "permitting any party to argue any motion challenging the events that occurred which led to the arbitration panel's termination order." No filing was made in response to that order. No further filings were made in this case until October 30, 2023, when defendants filed a motion to dismiss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2023, the Court ordered IMED has until March 13, 2024, to appear before the Court and show cause why this case should not be dismissed for failure to pursue arbitration consistent with the Court’s orders. On March 13, 2024, a hearing took place to discuss the status of IMED’s effort to re-initiate arbitration. Thereafter, on March 25, 2024, the court ordered, if, by April 27, 2024, IMED has not begun arbitration, resolved this case, or substantiated (in the form of an attorney and client declaration) that it has executed an agreement with a litigation funder to pay for arbitration proceedings, to pay the balance due to the subject arbitration association and to re-instate the arbitration, the Court will dismiss this case without prejudice. On April 26, 2024, IMED informed the Court it has executed an agreement with a litigation funder to pay for arbitration proceedings, to pay the balance due to the subject arbitration association, and to reinstate the arbitration, and is in the final stages of resolving the balance due to the subject arbitration association.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the Company has strong defenses to the IMED lawsuit and we intend to vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Boston O&amp;P Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lawsuit arises from the alleged wrongful death of a patient following his January 2016, tracheal and laryngeal resection procedure at Boston Children’s Hospital, which was performed by two physicians named as defendants in the suit. The Plaintiffs allege that as a result of the patient’s post-operative care, which included placing his neck in a position of flexion in a modified brace provided by Boston O&amp;P, the patient was paralyzed, and years later, he died due to complications caused by his paralysis. The Company acquired all of the outstanding shares of Boston O&amp;P on January 5, 2024 as described more fully under Note 3 - Business Combinations and Asset Acquisitions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuit commenced in December 2018, in Suffolk Superior Court in Boston, Massachusetts. The Plaintiffs assert counts of negligence against each individual defendant, lack of informed consent against the physician defendants, failure to warn, breach of warranty and alleged improper use against Boston O&amp;P, and loss of consortium against all defendants. Trial is currently scheduled to begin in December 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe Boston O&amp;P has strong defenses to this lawsuit and we intend to vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchase Obligations and Performance Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASH</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Navigation platform during 2021, the Company agreed to a minimum purchase commitment for the first twelve months of that agreement. Additionally, the contract requires future purchase commitments based upon a percentage of historical purchases. As a result and as of March 31, 2024, the remaining purchase commitment under the agreement was $1,820 for the year ended December 31, 2024 and $1,456 for the year ended December 31, 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three months ended March 31, 2024, the Company recorded an expense of $542 based on current estimates. The Company recorded $300 of expense for the three months ended March 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales. </span></div>We have products in development that have royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of March 31, 2024, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results. 2235000 2529000 1749000 1582000 60000000 25000000 1820000 1456000 P5Y 542000 300000 0.005 0.20 SUBSEQUENT EVENT<div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ApiFix Acquisition Installment Payment</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2024, the fourth-year anniversary of the acquisition of ApiFix, the Company paid $2,250 in cash and issued 245,812 shares of the Company's common stock, representing $6,929 of fair value (based on the April 1, 2024 closing share price of $28.19), to fulfill its installment obligation to ApiFix. This was the third and final installment payment paid since the acquisition.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Anniversary Payment</span></div>On May 1, 2024, the first-year anniversary of the acquisition of MedTech, the Company paid $1,250 in cash and issued 42,882 shares of the Company's common stock, representing $1,331 of fair value (based on the May 1, 2024 closing share price of $31.04), to fulfill its installment obligation to MedTech. This was the first installment payment paid since the acquisition. 2250000 245812 6929000 28.19 1250000 42882 31.04 false false false false

6]CT 6(1N;(*J;,5TNK0;'=.5*&7(4AG
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